

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number  
**WO 2004/083249 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 16/28**,  
A61K 39/395, A61P 37/00, 37/06

(74) Agent: **GARRETT, Arthur, S.**; Finnegan, Henderson,  
Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W.,  
Washington, DC 20005-3315 (US).

(21) International Application Number:  
PCT/US2004/007444

(22) International Filing Date: 12 March 2004 (12.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/454,336 14 March 2003 (14.03.2003) US

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (*for all designated States except US*): **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US). **CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED** [GB/GB]; The Milstein Building, Granta Park, Cambridge CB1 6GH (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **YOUNG, Deborah, A.** [US/US]; 39 Nelson Road, Melrose, MA 02176 (US). **WHITTERS, Matthew, J.** [US/US]; 14 Brenton Wood Road, Hudson, MA 01749 (US). **VALGE-ARCHER, Vija** [US/GB]; 36 Westfield, Little Abington, Cambridge CB1 6BE (GB). **COLLINS, Mary** [US/US]; 54 Rathburn Road, Natick, MA 01760 (US). **WILLIAMS, Andrew, James** [GB/GB]; Larksmead, Long Lane, Fowlmere, Royston, Herts, SG8 7TG (GB). **WITEK, Joanne** [US/US]; 409 Arlington Street, Acton, MA 01720 (US).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR

(57) Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21 R). The antibodies can act as antagonists of IL-21 R activity, thereby modulating immune responses in general, and those mediated by IL-21 R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.



**WO 2004/083249 A2**

**ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR**  
**PRIORITY INFORMATION**

[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No. 60/454,336, filed March 14, 2003.

**TECHNICAL FIELD**

[0002] This invention relates to antibodies, e.g., human antibodies, and antigen-binding fragments thereof that bind the interleukin-21 (IL-21) receptor, in particular, the human IL-21 receptor, and their use in regulating immune responses mediated by the IL-21 receptor. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating immune disorders, e.g., autoimmune disorders.

**BACKGROUND OF THE INVENTION**

[0003] Antigens initiate immune responses and activate the two largest populations of lymphocytes: T cells and B cells. After encountering antigen, T cells proliferate and differentiate into effector cells, while B cells proliferate and differentiate into antibody-secreting plasma cells. Proliferation and differentiation of lymphocytes are regulated by extracellular proteins. Some of these proteins are called cytokines, which are small proteins (<30 kDa) secreted by lymphocytes and other cell types.

[0004] Interleukin-21 (IL-21) is a recently discovered cytokine, which is closely related to IL-2, IL-4 and IL-15 (Parrish-Novak et al. (2000) *Nature* 408:57-63). Human IL-21 has a molecular weight of about 15 kDa, consists of 131 amino acids, and shares about 57% identity with mouse IL-21. IL-21 is produced primarily by activated CD4<sup>+</sup> T cells.

[0005] IL-21 receptor (IL-21R) is a transmembrane, IL-21-binding protein that belongs to the class I cytokine receptor family. Both human and mouse IL-

21R have been described in WO 01/85792, herein incorporated by reference. The predicted size of human IL-21R is about 529 amino acids. IL-21R shows high sequence homology to IL-2 receptor  $\beta$  chain and IL-4 receptor  $\alpha$  chain (Ozaki et al. (2000) *Proc. Natl. Acad. Sci. USA* 97:11439-11444). The human and mouse IL-21R amino acid sequences share about 62% identity. Upon ligand binding, IL-21R associates with the common gamma cytokine receptor chain ( $\gamma_c$ ) that is shared by receptors for IL-2, IL-3, IL-4, IL-7, IL-9, IL-13 and IL-15 (Ozaki et al. (2000) *supra*; Asao et al. (2001) *J. Immunol.* 167:1-5).

[0006] IL-21R is expressed primarily in lymphoid tissues, such as B cells, T cells, and natural killer (NK) cells. The widespread lymphoid distribution of IL-21R suggests that IL-21 may play a role in immune regulation. Indeed, *in vitro* studies have shown that IL-21 significantly modulates the function of B cells, CD4+ and CD8+ T cells, and NK cells (Parrish-Novak et al. (2000) *supra*; Kasaian, M.T. et al. (2002) *Immunity.* 16:559-569). IL-21 and IL-21R have also been shown to be important for modulating the activity of macrophages, and synovial cells. For example, IL-21 augments the proliferation of B cells stimulated with anti-CD40 antibody, and suppresses the proliferation of B cells stimulated with anti-IgM and IL-4. IL-21 augments the proliferation and cytolytic activity of T cells and human NK cells. IL-21 also mediates the expression of cytokines, chemokines, or combination thereof, secreted by T cells, NK cells, macrophages, and synovial cells. Because of the dependence of B cells, T cells, NK cells, macrophages, and synovial cells on IL-21, altering IL-21 binding to IL-21R may affect certain immune responses. Such a manipulation provides a means for treating immune system disorders, such as autoimmune disease

disorders, inflammatory disorders, allergies, transplant rejection, cancer, immune deficiency, and other disorders.

### **SUMMARY OF THE INVENTION**

[0007] The present application provides antibodies that bind the IL-21 receptor ("IL-21R"), in particular, the human IL-21 receptor, with high affinity and specificity. In one embodiment, an antibody reduces, inhibits or antagonizes IL-21R activity. Such antibodies can be used to regulate immune responses or immune cell-associated disorders by antagonizing IL-21R activity. In other embodiments, an anti-IL-21R antibody can be used diagnostically, or as a targeting antibody to deliver a therapeutic or a cytotoxic agent to an IL-21R-expressing cell. Thus, anti-IL-21R antibodies of the invention are useful in diagnosing and treating immune cell-associated pathologies (e.g., pathologies associated with activity of at least one of: T cells (CD8+, CD4+ T cells), NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders).

[0008] Accordingly, in one aspect, the invention features an isolated antibody that binds to IL-21R, in particular, human IL-21R. An anti-IL-21R antibody may have at least one of the following characteristics: (1) it is a monoclonal or single specificity antibody; (2) it is a human or *in vitro* generated antibody; (3) it binds to IL-21R, in particular, the extracellular domain of human IL-21R, with an affinity constant ( $K_a$ ) of at least  $10^6 \text{ M}^{-1}$ ; and (4) it inhibits binding of IL-21 to IL-21R with an  $\text{IC}_{50}$  of 10 nM or less as an IgG, for example, as measured by a cell-based assay described in Example 9, or it inhibits the binding of an antibody to IL-21R with an  $\text{IC}_{50}$  of 10 nM or less, for example, as measured by an epitope binding assay described in Example 11.



[0009] Nonlimiting illustrative embodiments of the antibodies of the invention are referred to herein as “MUF”, “MUF-germline”, “MU11”, “18G4”, “18A5”, “19F5”, “CP5G2” and “R18.” The antibodies of the invention may specifically bind to the extracellular domain of an IL-21R, e.g., about amino acid 20 to 235 of SEQ ID NO:43 (human IL-21R), or a sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto. In other embodiments, antibodies specifically bind to a fragment of an IL-21R, e.g., a fragment of at least 10, 20, 50, 75, 100, 150, or 200 amino acids contiguous to the amino acid sequence set forth in SEQ ID NO:43, or a sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto. In other embodiments, an antibody binds to the extracellular domain of an IL-21R and competitively inhibits binding of “MUF”, “MUF-germline”, “MU11”, “18G4”, “18A5”, “19F5”, “CP5G2” or “R18” to its target epitope. In yet other embodiments, an antibody binds to the extracellular domain of an IL-21R and competitively inhibits binding of IL-21 to IL-21R. Such an inhibition of binding of IL-21 to its receptor by an antibody of the invention can be measured by one or more assays provided herein.

[0010] In one embodiment, an antibody of the present invention includes a  $V_H$  domain, a  $V_L$  domain, or a combination thereof, of the scFv fragment of “MUF”, “MUF-germline”, “MU11”, “18G4”, “18A5”, “19F5”, “CP5G2” or “R18”. For example, an antibody includes a  $V_H$  and/or a  $V_L$  domain having amino acid sequence as set forth in Tables 1A and 1B (SEQ ID NO:1, 19, 47, 65, 83, 101, 119 or 137 for  $V_H$  and SEQ ID NO:2, 20, 48, 66, 84, 102, 120 or 138 for  $V_L$ ), or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto, or which differs by no

more than 1, 2, 5, 10 or 15 amino acid residues from SEQ ID NO:1, 2, 19, 20, 47, 48, 65, 66, 83, 84, 101, 102, 119, 120, 137 or 138). In another embodiment, the antibody includes a V<sub>H</sub> and/or V<sub>L</sub> domain encoded by a nucleic acid having a nucleotide sequence as set forth in Tables 1A and 1B (SEQ ID NO:10, 28, 56, 74, 92, 110, 128, or 146 for V<sub>H</sub> and SEQ ID NO:11, 29, 57, 75, 93, 111, 129, or 147 for V<sub>L</sub>), or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30 or 45 nucleotides from SEQ ID NO:10, 11, 28, 29, 56, 57, 74, 75, 92, 93, 110, 111, 128, 129, 146 or 147). Typically, the V<sub>H</sub> and V<sub>L</sub> domains in a scFv fragment are linked by a linker sequence.

[0011] In other embodiments, the antibody includes an scFv domain having an amino acid sequence as set forth in Tables 1A and 1B (SEQ ID NO:3, 21, 49, 67, 85, 103, 121, or 139) or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto, or which differs by no more than 1, 2, 5, 10, 15, 20, 30 or 35 amino acid residues from SEQ ID NO:3, 21, 49, 67, 85, 103, 121, or 139). In another embodiment, the antibody include an scFv domain encoded by a nucleic acid having a nucleotide sequence as set forth in Tables 1A and 1B (SEQ ID NO:12, 30, 58, 76, 94, 112, 130, or 148), or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30, 45, 60, 90 or 105 nucleotides from SEQ ID NO:12, 30, 58, 76, 94, 112, 130, or 148). In yet other embodiments, the antibody comprises at least one complementarity determining region (CDR) of these V<sub>H</sub> and V<sub>L</sub> domains. For example, the antibody can include one, two, or three CDR's of the V<sub>H</sub> domain (i.e., H1, H2, and

H3) having an amino acid sequence as set forth in Tables 1A and 1B (SEQ ID NO:4, 5, 6, 22, 23, 24, 50, 51, 52, 68, 69, 70, 86, 87, 88, 104, 105, 106, 122, 123, 124, 140, 141, or 142), or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto). In some embodiments, a sequence that is substantially homologous to the H1, H2, or H3 amino acid sequences set forth in SEQ ID NO:4, 5, 6, 22, 23, 24, 50, 51, 52, 68, 69, 70, 86, 87, 88, 104, 105, 106, 122, 123, 124, 140, 141, or 142 includes one or more amino acid substitutions, for example, one or more conservative amino acid substitutions. In another embodiment, the antibody can include one, two, or three CDR's of the V<sub>L</sub> domain (i.e., L1, L2 and L3) having an amino acid sequence as set forth in Tables 1A and 1B (SEQ ID NO:7, 8, 9, 25, 26, 27, 53, 54, 55, 71, 72, 73, 89, 90, 91, 107, 108, 109, 125, 126, 127, 143, 144, or 145), or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto). In some embodiments, a sequence that is substantially homologous to the L1, L2, or L3 amino acid sequences set forth in SEQ ID NO:7, 8, 9, 25, 26, 27, 53, 54, 55, 71, 72, 73, 89, 90, 91, 107, 108, 109, 125, 126, 127, 143, 144 or 145 includes one or more amino acid substitutions, for example, one or more conservative amino acid substitutions.

[0012] In a still further embodiment, an antibody comprises a CDR of the V<sub>H</sub> domain of MUF, MU11, MUF-germline, 18G4, 18A5, 19F5, CP5G2, or R18, having the amino acid sequence set forth in Tables 1A and 1B (SEQ ID NO:6, 24, 52, 70, 88, 106, 124, or 142), or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto), which includes one or more amino acid substitutions, for example, one

or more conservative amino acid substitutions. An antibody according to the invention may either comprise a heavy chain variable region including a single CDR, such as H3, or any combinations of H1, H2 and H3. For example, in some embodiments, an antibody may include CDR (H3) in combination with CDR2 (H2). In other embodiments, an antibody may include a CDR3 (H3) in combination with a CDR1 (H1), or a combination of H1 and H2 CDRs. However, preferably, an antibody includes a heavy chain variable region comprising a CDR3 (H3), as set forth in any of SEQ ID NO:6, 24, 52, 70, 88, 106, 124, 142, and amino acid substitutions thereof, for example, one or more conservative amino acid substitutions, either alone or in combination with one or both of H1 and H2.

[0013] Similarly, in some embodiments, an antibody comprises a CDR of the V<sub>L</sub> domain of MUF, MU11, MUF-germline, 18G4, 18A5, 19F5, CP5G2, or R18, e.g., an L3 CDR having the amino acid sequence as set forth in Tables 1A and 1B (SEQ ID NO:9, 27, 55, 73, 91, 109, 127, or 145), or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical thereto), which includes one or more amino acid substitutions, for example, one or more conservative amino acid substitutions. An antibody according to the invention may either comprise a light chain variable region including a single CDR, such as L3, or any combinations of L1, L2 and L3. For example, in some embodiments, an antibody may include an L3 in combination with an L2. In other embodiments, an antibody may include an L3 in combination with an L1. In yet, another embodiment, an antibody may include a combination of L1 and L2 CDRs. However, preferably, an antibody includes a light chain variable region comprising an L3, as set forth in any of SEQ

ID NO:9, 27, 55, 73, 91, 109, 127, 145 and amino acid substitutions thereof, for example, one or more conservative amino acid substitutions thereof, either alone or in combination with one or both of L1 and L2.

[0014] In some embodiments, an antibody of the invention competes for IL-21R binding with an antibody which includes a V<sub>H</sub> domain which is at least 95%, 96%, 97%, 98%, 99%, or more than 99% identical to an amino acid sequence set forth in SEQ ID NO:1, 19, 47, 65, 83, 101, 119 or 137, and a V<sub>L</sub> domain which is at least 95%, 96%, 97%, 98%, 99%, or more than 99% identical to an amino acid sequence set forth in SEQ ID NO:2, 20, 48, 66, 84, 102, 120 or 138. In certain embodiments, an antibody competes for IL-21R binding with an antibody that includes a heavy chain variable region comprising at least one heavy chain CDR chosen from SEQ ID NO:6, 24, 52, 70, 88, 106, 124, 142 and amino acid substitutions thereof, for example, one or more conservative amino acid substitutions thereof. In certain embodiments, an antibody according to the invention competes for IL-21R binding, for example, human IL-21R binding, with an antibody that includes a light chain variable region comprising at least one light chain CDR chosen from SEQ ID NO:9, 27, 55, 73, 91, 109, 127, 145 and amino acid substitutions thereof, for example, one or more conservative amino acid substitutions thereof. An antibody with which an antibody of the invention competes for binding to IL-21R, for example, human IL-21R, may include both a heavy chain CDR chosen from SEQ ID NO:6, 24, 52, 70, 88, 106, 124, and 142, and a light chain CDR chosen from SEQ ID NO:9, 27, 55, 73, 91, 109, 127, and 145. In some embodiments, an antibody according to the invention includes more than one heavy chain CDR chosen from SEQ ID NO:4, 5, 6 for MUF; SEQ ID NO:22, 23, 24 for MU11; SEQ ID NO:50, 51, 52 for 18G4; SEQ ID NO:68, 69,

70 for 18A5; SEQ ID NO:86, 87, 88 for MUF-germline; SEQ ID NO:104, 105, 106 for 19F5; SEQ ID NO:122, 123, 124 for CP5G2; and SEQ ID NO:140, 141, 142 for R18, and/or one or more light chain variable region CDR chosen from SEQ ID NO:7, 8, 9 for MUF; SEQ ID NO:25, 26, 27 for MU11; SEQ ID NO:53, 54, 55 for 18G4; SEQ ID NO:71, 72, 73 for 18A5; SEQ ID NO:89, 90, 91 for MUF-germline; SEQ ID NO:107, 108, 109 for 19F5; SEQ ID NO:125, 126, 127 for CP5G2; and SEQ ID NO:143, 144, 145 for R18.

[0015] In yet other embodiments, an antibody according to the invention competes with IL-21, for example, human IL-21, for binding to IL-21R, for example, human IL-21R.

[0016] An antibody of the invention can be full-length (e.g., include at least one complete heavy chain and at least one complete light chain) or can include only an antigen-binding fragment (e.g., a Fab, F(ab')<sub>2</sub>, Fv or a single chain Fv fragment (scFv)). An antibody can include a constant region, or a portion thereof, chosen from any of: the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes. For example, heavy chain constant regions of the various isotypes can be used, including: IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, IgG<sub>4</sub>, IgM, IgA<sub>1</sub>, IgA<sub>2</sub>, IgD, and IgE. The light chain constant region can be chosen from kappa or lambda. An antibody may be an IgG, or it may also be IgG<sub>1κ</sub> or IgG<sub>1λ</sub>.

[0017] An anti-IL-21R antibody described herein can be derivatized or linked to another functional molecule (such as another peptide or protein (e.g., a Fab fragment)). For example, an antibody of the invention can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to at least one other molecular entity, such as another antibody (e.g.,

a bispecific or a multispecific antibody), toxin, radioisotope, cytotoxic or cytostatic agent, among others.

[0018] In another aspect, the invention features a pharmaceutical composition containing at least one anti-IL-21R antibody and a pharmaceutically acceptable carrier. The pharmaceutical composition can further include a combination of at least one anti-IL-21R antibody and at least one therapeutic agent (e.g., cytokine and growth factor inhibitors, immunosuppressants, anti-inflammatory agents, metabolic inhibitors, enzyme inhibitors, cytotoxic agents, cytostatic agents, or combinations thereof, as described in more detail herein). Combinations of the anti-IL-21R antibody and a therapeutic agent are also within the scope of the invention. The compositions and combinations of the invention can be used to regulate IL-21-dependent immune cells, such as B cells, T cells, NK cells, macrophages, and synovial cells.

[0019] In another aspect, the invention features a method of treating a subject with an immune cell-associated disease. The method includes administering to the subject an anti-IL-21R antibody in an amount sufficient to inhibit at least one IL-21R activity of immune cells, thereby treating the immune cell-associated disease.

[0020] The anti-IL-21R antibody can be administered to the subject, alone or in combination, with other therapeutic agents as described herein. The subject may be a mammal suffering from an immune cell-associated pathology (e.g., pathology associated with the aberrant activity of at least one of: T cells, NK cells, B cells, macrophages and megakaryocytes). The subject may be human. For example, the method can be used to treat a subject with an immune cell-associated disorder such as transplant rejection and autoimmune disease.

Autoimmune diseases may include diabetes mellitus (type I), arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis), multiple sclerosis, myasthenia gravis, vasculitis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, scleroderma, asthma, allergy, inflammatory bowel disease (IBD), and Crohn's disease. Treatment of an arthritic disorder (e.g., a disorder chosen from at least one of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis) using the anti-IL-21R antibodies of the present invention is an embodiment of the invention.

[0021] In another aspect, the invention provides a method for detecting the presence of IL-21R in a sample, *in vitro*. Samples may include biological samples such as serum, plasma, tissue and biopsy. The subject method can be used to diagnose a disorder, such as an immune cell-associated disorder as described herein. The method includes: (1) contacting the sample or a control sample with an anti-IL-21R antibody, and (2) detecting formation of a complex between the anti-IL-21R antibody and the sample or the control sample, wherein a statistically significant change in the formation of the complex in the sample relative to a control sample, is indicative of the presence of the IL-21R in the sample.

[0022] In another aspect, the invention provides a method for detecting the presence of IL-21R *in vivo* (e.g., *in vivo* imaging in a subject). The method can be used to diagnose a disorder, e.g., an immune cell-associated disorder as described herein. The method includes: (1) administering an anti-IL-21R antibody to a subject or a control subject under conditions that allow binding of



the antibody to IL-21R, and (2) detecting formation of a complex between the antibody and IL-21R, wherein a statistically significant change in the formation of the complex in the subject relative to a control, e.g., a control subject, is indicative of the presence of IL-21R.

[0023] An antibody according to the invention may be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials.

[0024] In another aspect, the invention provides a method for delivering or targeting an agent, e.g., a therapeutic or a cytotoxic agent, to an IL-21R-expressing cell *in vivo*. The method includes administering an anti-IL-21R antibody to a subject under conditions that allow binding of the antibody to IL-21R. The antibody may be coupled to a second therapeutic moiety, such as a toxin.

[0025] The disclosure provides nucleic acid sequences from the V<sub>H</sub> and V<sub>L</sub> domains of MUF, MUF-germline, MU11, 18G4, 18A5, 19F5, CP5G2 and R18. Also provided are nucleic acid sequences that comprise at least one CDR from MUF, MUF-germline, MU11, 18G4, 18A5, 19F5, CP5G2 and R18. The disclosure also provides vectors and host cells comprising such nucleic acids.

[0026] The disclosure further provides methods of producing new V<sub>H</sub> and V<sub>L</sub> domains and functional antibodies comprising all or a portion of such domains derived from the V<sub>H</sub> or V<sub>L</sub> domains of MUF, MUF-germline, MU11, 18G4, 18A5, 19F5, CP5G2 or R18.

[0027] Additional aspects of the disclosure will be set forth in part in the description, and in part will be obvious from the description, or may be learned by practicing the invention. The invention is set forth and particularly pointed out in the claims, and the disclosure should not be construed as limiting the scope of the claims. The following detailed description includes exemplary representations of various embodiments of the invention, which are not restrictive of the invention as claimed. The accompanying figures constitute a part of this specification and, together with the description, serve only to illustrate embodiments and not limit the invention.

#### **BRIEF DESCRIPTION OF THE FIGURES**

[0028] Figure 1A depicts the result of an ELISA which shows that MU11 specifically bind to human IL-21R.

[0029] Figure 1B depicts the result of a binding assay analyzed by FACS which shows that both MUF and MU11 bind on the surface of human IL-21R.

[0030] Figure 1C depicts the result of a binding assay analyzed by FACS which shows that MUF binds IL-21R on mouse B cells.

[0031] Figure 2 depicts the result of an ELISA which shows that MUF inhibits the binding of human IL-21 to human IL-21R.

[0032] Figure 3A depicts the result of a cell-proliferation assay which shows that addition of MUF blocked the ability of IL-21 to increase the proliferation of human CD4<sup>+</sup> T cells.

[0033] Figure 3B depicts the result of a cell-proliferation assay which shows that MU11 blocked the ability of IL-21 in COS cell culture media to increase the proliferation of mouse CD4<sup>+</sup> T cells.

[0034] Figure 3C depicts the result of a cell-proliferation assay which shows that MU11 blocked the ability of IL-21 in COS cell culture media to increase the proliferation of mouse CD8+ T cells, in a dose-dependent manner.

[0035] Figure 4 depicts the result of a cell-proliferation assay which shows that both MUF scFv and MUF IgG blocked the ability of IL-21 to increase the proliferation of Baf3Mu-1 cells which express an IL-21R.

[0036] Figures 5A depicts that addition of IL-21 to human fibroblast-like synoviocytes isolated from arthritis patients leads to an increase in the secretion of chemokines MCP-1 and GRO.

[0037] Figure 5B depicts that addition of IL-21 to human fibroblast-like synoviocytes isolated from arthritis patients leads to an increase in the secretion of chemokines 1-309, TARC, Eotaxin, MDC, Lymph, SDFIB, IP-10, I-TAC, MG and MP3B.

[0038] Figures 5C and 5D depict that addition of IL-21 to human fibroblast-like synoviocytes isolated from arthritis patients leads to an increase in the secretion of cytokines IFN-alpha and TNF-alpha (FIG. 5C) and IL-6 and IL8 (FIG. 5D).

[0039] Figure 5E shows that IL-21 exacerbates collagen induced arthritis (CIA) in a mouse model for arthritis, as measured by the indicia for CIA.

[0040] Figure 6 shows that IL-21 increases the proliferation of C57BL/6J cells in a mixed lymphocyte reaction, an *in vitro* model for transplant rejection.

## DETAILED DESCRIPTION

### Definitions

[0041] In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.

[0042] The “**antibody**” refers to an immunoglobulin or fragment thereof, and encompasses any polypeptide comprising an antigen-binding site. The term is not limited to polyclonal, monoclonal, monospecific, polyspecific, non-specific, humanized, human, single-chain, chimeric, synthetic, recombinant, hybrid, mutated, grafted, and *in vitro* generated antibodies. Unless preceded by the word “intact,” the term “antibody” includes antibody fragments such as Fab, F(ab')<sub>2</sub>, Fv, scFv, Fd, dAb, and other antibody fragments that retain antigen-binding function. Typically, such fragments would comprise an antigen-binding domain.

[0043] The terms “**antigen-binding domain**” and “**antigen-binding fragment**” refer to a part of an antibody molecule that comprises amino acids responsible for the specific binding between antibody and antigen. The part of the antigen that is specifically recognized and bound by the antibody is referred to as the “epitope.” An antigen-binding domain may comprise an antibody light chain variable region (V<sub>L</sub>) and an antibody heavy chain variable region (V<sub>H</sub>); however, it does not have to comprise both. Fd fragments, for example, have two V<sub>H</sub> regions and often retain some antigen-binding function of the intact antigen-binding domain. Examples of antigen-binding fragments of an antibody include (1) a Fab fragment, a monovalent fragment consisting of the V<sub>L</sub>, V<sub>H</sub>, C<sub>L</sub> and C<sub>H1</sub> domains; (2) a F(ab')<sub>2</sub> fragment, a bivalent fragment comprising two Fab

fragments linked by a disulfide bridge at the hinge region; (3) a Fd fragment consisting of the two V<sub>H</sub> and C<sub>H</sub>1 domains; (4) a Fv fragment consisting of the V<sub>L</sub> and V<sub>H</sub> domains of a single arm of an antibody, (5) a dAb fragment (Ward et al., (1989) *Nature* 341:544-546), which consists of a V<sub>H</sub> domain; and (6) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, V<sub>L</sub> and V<sub>H</sub>, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V<sub>L</sub> and V<sub>H</sub> regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) *Science* 242:423-426; and Huston et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies.

[0044] The term “**effective amount**” refers to a dosage or amount that is sufficient to regulate IL-21R activity to ameliorate clinical symptoms or achieve a desired biological outcome, e.g., decreased T cell and/or B cell activity, suppression of autoimmunity, suppression of transplant rejection, etc.

[0045] The term “**human antibody**” includes antibodies having variable and constant regions corresponding substantially to human germline immunoglobulin sequences as described by Kabat et al. (See Kabat, et al. (1991) *Sequences of Proteins of Immunological Interest*, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*), for

example in the CDRs, and in particular, CDR3. The human antibody can have at least one, two, three, four, five, or more positions replaced with an amino acid residue that is not encoded by the human germline immunoglobulin sequence.

[0046] The term “**IL-21R activity**” refers to at least one cellular process initiated or interrupted as a result of IL-21 binding to IL-21R on the cell. IL-21R activities include at least one of, but are not limited to: (1) binding IL-21 (e.g., human IL-21); (2) associating with signal transduction molecules (e.g.,  $\gamma c$  and/or JAK-1); (3) stimulating phosphorylation of STAT proteins (e.g., STAT5, STAT3, or combination thereof); (4) activating STAT proteins; and (5) modulating (e.g., increasing or decreasing) proliferation, differentiation, effector cell function, cytolytic activity, cytokine secretion, survival, or combinations thereof, of immune cells. Immune cells may include CD8<sup>+</sup> and CD4<sup>+</sup> T cells, NK cells, B cells, macrophages, and megakaryocytes. IL-21R activity can be determined *in vitro*, for example, using T cell proliferation assays as described in Examples 8 and 9. IL-21R activity can also be determined *in vivo*, for example, by scoring progression of an immune response or disorder as described in Example 12.

[0047] The phrase “**inhibit**” or “**antagonize**” IL-21R activity and its cognates refer to a reduction, inhibition, or otherwise diminution of at least one activity of IL-21R due to binding an anti-IL-21R antibody, wherein the reduction is relative to the activity of IL-21R in the absence of the same antibody. The activity can be measured as described in Examples 7, 8, 9 and 11. Inhibition or antagonism does not necessarily indicate a total elimination of the IL-21R polypeptide biological activity. A reduction in activity may be about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more.

[0048] The term “**interleukin-21 receptor**” or “**IL-21R**” refers to a class I cytokine receptor, also known as NILR (WO 01/85792; Parrish-Novak et al. (2000) *Nature* 408:57-63; Ozaki et al. (2000) *Proc. Natl. Acad. Sci. USA* 97:11439-114444). Upon ligand binding, IL-21R interacts with a common  $\gamma$  cytokine receptor chain ( $\gamma_c$ ) (Asao et al. (2001) *J. Immunol.* 167:1-5), and induces the phosphorylation of STAT1 and STAT3 (Asao et al. (2001) *supra* or STAT5 (Ozaki et al. (2000) *supra*). IL-21R shows widespread lymphoid tissue distribution. The term “IL-21R” refers to a receptor (which may be mammalian) which is capable of binding to IL-21, and has at least one of the following features: (1) an amino acid sequence of a naturally occurring mammalian IL-21R polypeptide or a fragment thereof, e.g., an amino acid sequence shown as SEQ ID NO:43 (human) or SEQ ID NO:45 (murine) or a fragment thereof; (2) an amino acid sequence substantially identical to, e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, an amino acid sequence shown as SEQ ID NO:43 (human) or SEQ ID NO:45 (murine) or a fragment thereof; (3) an amino acid sequence which is encoded by a naturally occurring mammalian IL-21R nucleotide sequence or a fragment thereof (e.g., SEQ ID NO:44 (human) or SEQ ID NO:46 (murine) or a fragment thereof); (4) an amino acid sequence encoded by a nucleotide sequence which is substantially identical to, e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, a nucleotide sequence shown as SEQ ID NO:44 (human) or SEQ ID NO:46 (murine) or a fragment thereof; (5) an amino acid sequence encoded by a nucleotide sequence degenerate to a naturally occurring IL-21R nucleotide sequence or a fragment thereof, e.g., SEQ ID NO:44 (human) or SEQ ID NO:46 (murine) or a fragment thereof; or (6) a nucleotide sequence that hybridizes to one of the foregoing nucleotide

sequences under stringent conditions, e.g., highly stringent conditions. The IL-21R may bind to IL-21 of mammalian origin, e.g., human or mouse. (Parrish-Novak et al. (2000) *supra*).

[0049] As used herein, “***in vitro* generated antibody**” refers to an antibody where all or part of the variable region (e.g., at least one CDR) is generated in a non-immune cell selection (e.g., an *in vitro* phage display, protein chip or any other method in which candidate sequences can be tested for their ability to bind to an antigen). This term excludes sequences generated by genomic rearrangement in an immune cell.

[0050] The term “**isolated**” refers to a molecule that is substantially free of its natural environment. For instance, an isolated protein is substantially free of cellular material or other proteins from the cell or tissue source from which it was derived. The term also refers to preparations where the isolated protein is sufficiently pure for pharmaceutical compositions; or at least 70-80% (w/w) pure; or at least 80-90% (w/w) pure; or at least 90-95% pure; or at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.

[0051] The nucleotide sequence and the predicted amino acid sequence of human IL-21R are shown in SEQ ID NO:44 and SEQ ID NO:43, respectively. Analysis of the human IL-21R amino acid sequence (SEQ ID NO:43) revealed the following structural features: a leader sequence (about amino acids 1-19 of SEQ ID NO:43); a WSXWS motif (about amino acids 213-217 of SEQ ID NO:43); a transmembrane domain (about amino acids 236-252 of SEQ ID NO:43); an extracellular domain (about amino acids 1-235 of SEQ ID NO:43 and about 20-235 of the mature IL-21R sequence); and an intracellular domain from about



amino acids 253-538 of SEQ ID NO:43. The mature human IL-21R is believed to have the sequence of amino acids 20-538 of SEQ ID NO:43.

[0052] The term “**repertoire**” refers to a genetically diverse collection of nucleotide sequences derived wholly or partially from sequences encoding immunoglobulins. The sequences may be generated by rearrangement *in vivo* of the V, D, and J segments of heavy chains, and the V and J segments of light chains. Alternatively, the sequences can be generated from a cell in response to which rearrangement occurs, e.g., *in vitro* stimulation. Alternatively, part or all of the sequences may be obtained by DNA splicing, nucleotide synthesis, mutagenesis, and other methods, see, e.g., U.S. Patent 5,565,332.

[0053] The terms “**specific binding**”, “**selective binding**” and “**selectively binds**” refer to two molecules forming a complex that is relatively stable under physiologic conditions. Selective binding is characterized by a high affinity and a low to moderate capacity as distinguished from nonspecific binding which usually has a low affinity with a moderate to high capacity. Typically, binding is considered specific or selective when the affinity constant  $K_a$  is higher than  $10^6 M^{-1}$ . If necessary, nonspecific binding can be reduced without substantially affecting selective binding by varying the binding conditions. The appropriate binding conditions, such as concentration of antibodies, ionic strength of the solution, temperature, time allowed for binding, concentration of a blocking agent (e.g., serum albumin, milk casein), etc., may be optimized by a skilled artisan using routine techniques. Illustrative conditions are set forth in Examples 1-11, but other conditions known to the person of ordinary skill in the art fall within the scope of this invention.

[0054] As used herein, the term “**stringent**” describes conditions for hybridization and washing. Stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. Aqueous and nonaqueous methods are described in that reference and either can be used. One example of stringent hybridization conditions is hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by at least one wash in 0.2X SSC, 0.1% SDS at 50°C. A second example of stringent hybridization conditions is hybridization in 6X SSC at about 45°C, followed by at least one wash in 0.2X SSC, 0.1% SDS at 55°C. Another example of stringent hybridization conditions is hybridization in 6X SSC at about 45°C, followed by at least one wash in 0.2X SSC, 0.1% SDS at 60°C. A further example of stringent hybridization conditions is hybridization in 6X SSC at about 45°C, followed by at least one wash in 0.2X SSC, 0.1% SDS at 65°C. High stringent conditions include hybridization in 0.5 M sodium phosphate, 7% SDS at 65°C, followed by at least one wash at 0.2X SSC, 1% SDS at 65°C.

[0055] The phrase “**substantially as set out**,” “**substantially identical**” or “**substantially homologous**” means that the relevant amino acid or nucleotide sequence (e.g., CDR(s), V<sub>H</sub>, or V<sub>L</sub> domain) will be identical to or have insubstantial differences (through conserved amino acid substitutions) in comparison to the sequences which are set out. Insubstantial differences include minor amino acid changes, such as 1 or 2 substitutions in a 5 amino acid sequence of a specified region. In the case of antibodies, the second antibody has the same specificity and has at least 50% of the affinity of the same.

[0056] Sequences substantially identical or homologous (e.g., at least about 85% sequence identity) to the sequences disclosed herein are also part of

this application. In some embodiment, the sequence identity can be about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher. Alternatively, substantial identity or homology exists when the nucleic acid segments will hybridize under selective hybridization conditions (e.g., highly stringent hybridization conditions), to the complement of the strand. The nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.

[0057] The percent identity can be determined by standard alignment algorithms, for example, the Basic Local Alignment Tool (BLAST) described by Altshul et al. ((1990) J. Mol. Biol., 215: 403-410); the algorithm of Needleman et al. ((1970) J. Mol. Biol., 48: 444-453); or the algorithm of Meyers et al. ((1988) Comput. Appl. Biosci., 4: 11-17). A set of parameters may be the Blosum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5. The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

[0058] The term “**therapeutic agent**” is a substance that treats or assists in treating a medical disorder. As used herein, a therapeutic agent refers to a substance, when administered to a subject with anti-IL-21R antibody, provides a better treatment compared to administration of the therapeutic agent or anti-IL-21R antibody alone. These therapeutic agents may include, but are not limited to, substances that modulate immune cells or immune responses in a manner

that complements the IL-21R activity of anti-IL-21R antibodies. Non-limiting examples and uses of therapeutic agents are described herein.

[0059] As used herein, a **"therapeutically effective amount"** of an anti-IL-21R antibody refers to an amount of an antibody which is effective, upon single or multiple dose administration to a subject (such as a human patient) at treating, preventing, curing, delaying, reducing the severity of, ameliorating at least one symptom of a disorder or recurring disorder, or prolonging the survival of the subject beyond that expected in the absence of such treatment.

[0060] The term **"treatment"** refers to a therapeutic or preventative measure. The treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.

### **Anti-IL-21R Antibodies**

[0061] The disclosure provides novel anti-IL-21R antibodies that comprise novel antigen-binding fragments.

[0062] In general, antibodies can be made, for example, using traditional hybridoma techniques (Kohler and Milstein (1975) *Nature*, 256: 495-499), recombinant DNA methods (U.S. Patent 4,816,567), or phage display using antibody libraries (Clackson et al. (1991) *Nature*, 352: 624-628; Marks et al. (1991) *J. Mol. Biol.*, 222: 581-597). For additional antibody production techniques, see *Antibodies: A Laboratory Manual*, eds. Harlow et al., Cold Spring Harbor Laboratory, 1988. The present invention is not limited to any particular source, method of production, or other special characteristics of an antibody.

[0063] Intact antibodies are immunoglobulins (Ig), and they typically are tetrameric glycosylated proteins composed of two light chains (~25 kDa each) and two heavy chains (~50 kDa each). Light chains are classified into two isotypes ( $\lambda$  and  $\kappa$ ), and heavy chains are classified into five isotypes (A, D, E, G, and M). Some heavy chain isotypes are further divided into isotype subclasses, e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, and IgG<sub>4</sub>.

[0064] The domain and three dimensional structures of different antibodies are known in the art (Harlow et al., supra). In brief, the light chain is composed of a constant domain (C<sub>L</sub>) and an N-terminal variable domain (V<sub>L</sub>). The heavy chain is composed of three or four constant domains (C<sub>H</sub>), a hinge region, and a N-terminal variable domain (V<sub>H</sub>). The C<sub>H</sub> adjacent to the V<sub>H</sub> domain is designated C<sub>H</sub>1. The V<sub>H</sub> and V<sub>L</sub> domains contain four regions of conserved sequence called framework (FR) regions (FR1, FR2, FR3, and FR4), which form a scaffold for three regions of hypervariable sequence called complementarity determining regions (CDR). The CDRs (CDR1, CDR2, and CDR3) contain most of the antibody amino acids that specifically binds antigen. Heavy chain CDRs are denoted H1, H2, and H3, while light chain CDRs are denoted L1, L2, and L3.

[0065] The Fab fragment (Fragment antigen-binding) consists of V<sub>H</sub>-C<sub>H</sub>1 and V<sub>L</sub>-C<sub>L</sub> domains covalently linked by a disulfide bond between the constant regions. The F<sub>v</sub> fragment is smaller and consists of V<sub>H</sub> and V<sub>L</sub> domains non-covalently linked. To overcome the tendency of non-covalently domains to dissociate, a single chain F<sub>v</sub> fragment (scF<sub>v</sub>) can be constructed. The scF<sub>v</sub> contains a flexible polypeptide that links the (1) C-terminus of V<sub>H</sub> to the N-terminus of V<sub>L</sub>, or the (2) C-terminus of V<sub>L</sub> to the N-terminus of V<sub>H</sub>. A 15-mer (Gly<sub>4</sub>Ser)<sub>3</sub> peptide may be used as a linker, but other linkers are known in the art.

[0066] Antibody diversity is created by use of multiple germline genes encoding variable regions and a variety of somatic events. The somatic events include recombination of variable gene segments and diversity (D) and joining (J) gene segments to make a complete  $V_H$  region and the recombination of variable and joining gene segments to make a complete  $V_L$  region. CDR3 (H3) is the greatest source of molecular diversity within an antibody sequence. H3, for example, can be as short as two amino acid residues or greater than 26. The smallest antigen-binding fragment is the Fv, which consists of the  $V_H$  and the  $V_L$  domains.

[0067] Antibodies and compositions having identical or similar CDR sequence to those disclosed herein are not likely to have been independently generated. The sequence of antibody genes after assembly and somatic mutation is highly varied, and these varied genes are estimated to encode  $10^{10}$  different antibody molecules (Immunoglobulin Genes, 2nd ed., eds. Jonio et al., Academic Press, San Diego, CA, 1995).

[0068] The present disclosure provides novel CDRs derived from human immunoglobulin gene libraries. The structure for carrying a CDR is generally an antibody heavy or light chain or portion thereof, where the CDR is located to a naturally occurring CDR region. The structures and locations of variable domains may be determined as described in Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, MD (1991).

[0069] DNA and amino acid (AA) sequences of illustrative embodiments of the anti-IL-21R antibodies of this invention, including their scFv fragments,  $V_H$  and  $V_L$  domains, and CDRs, are set forth in the Sequence Listing and enumerated in

Tables 1A and 1B. Specific embodiments of the antibodies are identified as MUF, MUF-germline, MU11, 18G4, 18A5, 19F5, CP5G2 and R18. The CDR positions in the  $V_H$  and  $V_L$  domains of the antibodies are listed in Table 2.

Table 1A: AA and DNA Sequences of V<sub>H</sub> and V<sub>L</sub> Domains, F<sub>V</sub>, and CDRs

REGION	TYPE	MUF	MU11	18G4	18A5
V <sub>H</sub>	AA	SEQ ID NO:1	SEQ ID NO:19	SEQ ID NO:47	SEQ D NO:65
V <sub>L</sub>	AA	SEQ ID NO:2	SEQ ID NO:20	SEQ ID NO:48	SEQ ID NO:66
scF <sub>v</sub>	AA	SEQ ID NO:3	SEQ ID NO:21	SEQ ID NO:49	SEQ ID NO:67
H1	AA	SEQ ID NO:4	SEQ ID NO:22	SEQ ID NO:50	SEQ ID NO:68
H2	AA	SEQ ID NO:5	SEQ ID NO:23	SEQ ID NO:51	SEQ ID NO:69
H3	AA	SEQ ID NO:6	SEQ ID NO:24	SEQ ID NO:52	SEQ ID NO:70
L1	AA	SEQ ID NO:7	SEQ ID NO:25	SEQ ID NO:53	SEQ ID NO:71
L2	AA	SEQ ID NO:8	SEQ ID NO:26	SEQ ID NO:54	SEQ ID NO:72
L3	AA	SEQ ID NO:9	SEQ ID NO:27	SEQ ID NO:55	SEQ ID NO:73
V <sub>H</sub>	DNA	SEQ ID NO:10	SEQ ID NO:28	SEQ ID NO:56	SEQ ID NO:74
V <sub>L</sub>	DNA	SEQ ID NO:11	SEQ ID NO:29	SEQ ID NO:57	SEQ ID NO:75
scF <sub>v</sub>	DNA	SEQ ID NO:12	SEQ ID NO:30	SEQ ID NO:58	SEQ ID NO:76
H1	DNA	SEQ ID NO:13	SEQ ID NO:31	SEQ ID NO:59	SEQ ID NO:77
H2	DNA	SEQ ID NO:14	SEQ ID NO:32	SEQ ID NO:60	SEQ ID NO:78
H3	DNA	SEQ ID NO:15	SEQ ID NO:33	SEQ ID NO:61	SEQ ID NO:79
L1	DNA	SEQ ID NO:16	SEQ ID NO:34	SEQ ID NO:62	SEQ ID NO:80
L2	DNA	SEQ ID NO:17	SEQ ID NO:35	SEQ ID NO:63	SEQ ID NO:81
L3	DNA	SEQ ID NO:18	SEQ ID NO:36	SEQ ID NO:64	SEQ ID NO:82



**Table 1B:** AA and DNA Sequences of V<sub>H</sub> and V<sub>L</sub> Domains, F<sub>V</sub>, and CDRs

<b>REGION</b>	<b>TYPE</b>	<b>MUF GERMLINE</b>	<b>19F5</b>	<b>CP5G2</b>	<b>R18</b>
<b>V<sub>H</sub></b>	<b>AA</b>	SEQ ID NO:83	SEQ ID NO:101	SEQ ID NO:119	SEQ ID NO:137
<b>V<sub>L</sub></b>	<b>AA</b>	SEQ ID NO:84	SEQ ID NO:102	SEQ ID NO:120	SEQ ID NO:138
<b>scF<sub>v</sub></b>	<b>AA</b>	SEQ ID NO:85	SEQ ID NO:103	SEQ ID NO:121	SEQ ID NO:139
<b>H1</b>	<b>AA</b>	SEQ ID NO:86	SEQ ID NO:104	SEQ ID NO:122	SEQ ID NO:140
<b>H2</b>	<b>AA</b>	SEQ ID NO:87	SEQ ID NO:105	SEQ ID NO:123	SEQ ID NO:141
<b>H3</b>	<b>AA</b>	SEQ ID NO:88	SEQ ID NO:106	SEQ ID NO:124	SEQ ID NO:142
<b>L1</b>	<b>AA</b>	SEQ ID NO:89	SEQ ID NO:107	SEQ ID NO:125	SEQ ID NO:143
<b>L2</b>	<b>AA</b>	SEQ ID NO:90	SEQ ID NO:108	SEQ ID NO:126	SEQ ID NO:144
<b>L3</b>	<b>AA</b>	SEQ ID NO:91	SEQ ID NO:109	SEQ ID NO:127	SEQ ID NO:145
<b>V<sub>H</sub></b>	<b>DNA</b>	SEQ ID NO:92	SEQ ID NO:110	SEQ ID NO:128	SEQ ID NO:146
<b>V<sub>L</sub></b>	<b>DNA</b>	SEQ ID NO:93	SEQ ID NO:111	SEQ ID NO:129	SEQ ID NO:147
<b>scF<sub>v</sub></b>	<b>DNA</b>	SEQ ID NO:94	SEQ ID NO:112	SEQ ID NO:130	SEQ ID NO:148
<b>H1</b>	<b>DNA</b>	SEQ ID NO:95	SEQ ID NO:113	SEQ ID NO:131	SEQ ID NO:149
<b>H2</b>	<b>DNA</b>	SEQ ID NO:96	SEQ ID NO:114	SEQ ID NO:132	SEQ ID NO:150
<b>H3</b>	<b>DNA</b>	SEQ ID NO:97	SEQ ID NO:115	SEQ ID NO:133	SEQ ID NO:151
<b>L1</b>	<b>DNA</b>	SEQ ID NO:98	SEQ ID NO:116	SEQ ID NO:134	SEQ ID NO:152
<b>L2</b>	<b>DNA</b>	SEQ ID NO:99	SEQ ID NO:117	SEQ ID NO:135	SEQ ID NO:153
<b>L3</b>	<b>DNA</b>	SEQ ID NO:100	SEQ ID NO:118	SEQ ID NO:136	SEQ ID NO:154

Table 2: Positions of CDRs within AA Sequences

<b>CDR</b>	<b>MUF</b> (SEQ ID NO:1)	<b>MUF</b> (SEQ ID NO:2)	<b>MU11</b> (SEQ ID NO:21)	<b>18G4</b> (SEQ ID NO:49)
H1	31-35		31-35	31-35
H2	50-66		50-66	50-66
H3	99-105		99-106	99-105
L1		23-33	156-166	156-166
L2		49-55	182-188	182-188
L3		88-100	221-229	221-231

<b>CDR</b>	<b>18A5</b> (SEQ ID NO:67)	<b>19F5</b> (SEQ ID NO:103)	<b>CP5G2</b> (SEQ ID NO:121)	<b>R18</b> (SEQ ID NO:139)
H1	31-36	31-35	31-35	31-35
H2	51-66	50-66	50-66	50-66
H3	99-107	99-109	99-107	99-110
L1	158-168	160-170	158-168	161-171
L2	184-190	186-192	184-190	187-193
L3	223-234	225-236	223-234	226-236

<b>CDR</b>	<b>MUF GERMLINE</b> (SEQ ID NO:85)
H1	31-35
H2	50-66
H3	99-105
L1	156-166
L2	182-188
L3	221-233

[0070] Anti-IL-21R antibodies of this invention may optionally comprise antibody constant regions or parts thereof. For example, a V<sub>L</sub> domain may be attached at its C-terminal end to a light chain constant domain like C<sub>κ</sub> or C<sub>λ</sub>. Similarly, a V<sub>H</sub> domain or portion thereof may be attached to all or part of a heavy chain like IgA, IgD, IgE, IgG, and IgM, and any isotype subclass. Constant regions are known in the art (see, for example, Kabat et al., Sequences of

Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, MD (1991).

[0071] In exemplary embodiments, MUF comprises heavy and light chain constant domains human IgG<sub>1λ</sub>, and MU11 comprises the heavy and light chain constant domains of human IgG<sub>1κ</sub>. In these antibodies, the sequences of the heavy chains outside of the V<sub>H</sub> domain are identical. The DNA and amino acid sequences for the C-terminal fragment of the λ light chain are set forth in SEQ ID NO:40 and SEQ ID NO:39, respectively. The DNA and amino acid sequences for the C-terminal fragment of the κ chain are set forth in SEQ ID NO:42 and SEQ ID NO:41, respectively. The DNA and amino acid sequences for the C-terminal fragment of IgG<sub>1</sub> heavy chain are set forth in SEQ ID NO:38 and SEQ ID NO:37, respectively.

[0072] Certain embodiments comprise a V<sub>H</sub> domain, a V<sub>L</sub> domain, or a combination thereof, of the F<sub>v</sub> fragment from MUF, MUF-germline, MU11, 18G4, 18A5, 19F5, CP5G2, or R18. Further embodiments comprise one, two, three, four, five or six complementarity determining regions (CDRs) from the V<sub>H</sub> and V<sub>L</sub> domains. Antibodies whose CDR sequences are set out in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20, 21, 22, 23, 24, 25, 26, 27, 47, 48, 49, 50, 51, 52, 53, 54, 55, 65, 66, 67, 68, 69, 70, 71, 72, 73, 83, 84, 85, 86, 87, 88, 89, 90, 91, 101, 102, 103, 104, 105, 106, 107, 108, 109, 119, 120, 121, 122, 123, 124, 125, 126, 127, 137, 138, 139, 140, 141, 142, 143, 144, or 145 are encompassed within the scope of this invention. For example, in one embodiment, an antibody comprises a CDR3 (H3) fragment of the V<sub>H</sub> domain of MUF, MUF-germline, MU11, 18G4, 18A5, 19F5, CP5G2, or R18.

[0073] In certain embodiments, the  $V_H$  and/or  $V_L$  domains may be germlined, i.e., the framework regions (FR) of these domains are mutated using conventional molecular biology techniques to match those produced by the germline cells. In other embodiments, the FR sequences remain diverged from the consensus germline sequences.

[0074] In one embodiment, the invention provides amino acid and nucleic acid sequences for the germlined MUF. Amino acid sequence for the  $V_H$  domain of the germlined MUF is depicted in SEQ ID NO:83 and 85. Amino acid sequence for the  $V_L$  domain of the germlined MUF is depicted in SEQ ID NO:84 and 85. Nucleic acid sequence for the germlined MUF  $V_H$  domain is depicted in SEQ ID NO:92 and 94 and that for the germlined  $V_L$  domain is depicted in SEQ ID NO:93 and 94. Germline sequences for the  $V_H$  and  $V_L$  domains can be identified by performing amino acid and nucleic acid sequence alignments against the VBASE database (MRC Center for Protein Engineering, UK). In some embodiments, the FR regions of the scFvs are mutated in conformity with the closest matches in the VBASE database and the CDR portions are kept intact.

[0075] In certain embodiments, antibodies of this invention specifically react with an epitope in the extracellular domain of human IL-21R. The predicted extracellular domain consists of a sequence from about amino acid 20 to about amino acid 235 of SEQ ID NO:43. In further embodiments, anti-IL-21R antibodies block the binding of IL-21 to IL-21R. In other embodiments, the anti-IL-21R antibodies specifically react with an epitope in the extracellular domain of mouse IL-21R. The extracellular domain of murine IL-21R consists of a sequence from about amino acid 20 to about amino acid 236 of SEQ ID NO:45.

The extracellular domain of mouse IL-21R is about 65% identical to the human counterpart.

[0076] It is contemplated that antibodies of this invention may bind other proteins, such as, for example, recombinant proteins comprising all or portion of the IL-21R extracellular domain.

[0077] One of ordinary skill in the art will recognize that the disclosed antibodies may be used to detect, measure, and/or inhibit proteins that differ somewhat from IL-21R. For example, these proteins may be homologs of IL-21R. Anti-IL-21R antibodies are expected to bind proteins that comprise a sequence which is at least about 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99% or more identical to any sequence of at least 100, 80, 60, 40, or 20 contiguous amino acids in the sequence set forth SEQ ID NO:43.

[0078] In addition to sequence homology analyses, epitope mapping (see, e.g., Epitope Mapping Protocols, ed. Morris, Humana Press, 1996), and secondary and tertiary structure analyses can be carried out to identified specific 3D structures assumed by the presently disclosed antibodies and their complexes with antigens. Such methods include, but are not limited to, X-ray crystallography (Engstrom (1974) Biochem. Exp. Biol., 11:7-13) and computer modeling of virtual representations of the present antibodies (Fletterick et al. (1986) Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0079] The disclosure provides a method for obtaining anti-IL-21R antibodies that comprises creating antibodies with altered Tables 1A and 1B V<sub>H</sub> and/or V<sub>L</sub> sequence(s). Such antibodies may be derived by a skilled artisan using techniques known in the art. For example, amino acid substitutions,

deletions, or additions can be introduced in FR and/or CDR regions. FR changes are usually designed to improve the stability and immunogenicity of the antibody, while CDR changes are typically designed to increase antibody affinity for its antigen. The changes that increase affinity may be tested by altering CDR sequence and measuring antibody affinity for its target (see Antibody Engineering, 2nd ed., Oxford University Press, ed. Borrebaeck, 1995).

[0080] Antibodies whose CDR sequences differ insubstantially from those set out in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 19, 20, 21, 22, 23, 24, 25, 26, 27, 47, 48, 49, 50, 51, 52, 53, 54, 55, 65, 66, 67, 68, 69, 70, 71, 72, 73, 83, 84, 85, 86, 87, 88, 89, 90, 91, 101, 102, 103, 104, 105, 106, 107, 108, 109, 119, 120, 121, 122, 123, 124, 125, 126, 127, 137, 138, 139, 140, 141, 142, 143, 144, or 145 are encompassed within the scope of this invention. Typically, this involves substitution of an amino acid with an amino acid having similar charge, hydrophobic, or stereochemical characteristics. More drastic substitutions in FR regions, in contrast to CDR regions, may also be made as long as they do not adversely affect the binding properties of the antibody. Substitutions may also be made to germline the antibody or stabilize the antigen binding site.

[0081] Conservative modifications will produce molecules having functional and chemical characteristics similar to those of the molecule from which such modifications are made. In contrast, substantial modifications in the functional and/or chemical characteristics of the molecules may be accomplished by selecting substitutions in the amino acid sequence that differ significantly in their effect on maintaining (1) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (2) the charge or hydrophobicity of the molecule at the target site, or (3) the size of the molecule.

[0082] For example, a "conservative amino acid substitution" may involve a substitution of a native amino acid residue with a nonnative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide may also be substituted with alanine, as has been previously described for "alanine scanning mutagenesis" (see, for example, MacLennan et al., 1998, *Acta Physiol. Scand. Suppl.* 643:55-67; Sasaki et al., 1998, *Adv. Biophys.* 35:1-24).

[0083] Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. For example, amino acid substitutions can be used to identify important residues of the molecule sequence, or to increase or decrease the affinity of the molecules described herein. Exemplary amino acid substitutions are set forth in Table 3.

Table 3: Amino Acid Substitutions

<b>Original Residues</b>	<b>Exemplary Substitutions</b>	<b>More Conservative Substitutions</b>
Ala (A)	Val, Leu, Ile	Val
Arg (R)	Lys, Gln, Asn	Lys
Asn (N)	Gln	Gln
Asp (D)	Glu	Glu
Cys (C)	Ser, Ala	Ser
Gln (Q)	Asn	Asn
Gly (G)	Pro, Ala	Ala
His (H)	Asn, Gln, Lys, Arg	Arg
Ile (I)	Leu, Val, Met, Ala, Phe, Norleucine	Leu
Leu (L)	Norleucine, Ile, Val, Met, Ala, Phe	Ile
Lys (K)	Arg, 1, 4 Diamino-butyric Acid, Gln, Asn	Arg
Met (M)	Leu, Phe, Ile	Leu
Phe (F)	Leu, Val, Ile, Ala, Tyr	Leu
Pro (P)	Ala	Gly
Ser (S)	Thr, Ala, Cys	Thr
Thr (T)	Ser	Ser
Trp (W)	Tyr, Phe	Tyr
Tyr (Y)	Trp, Phe, Thr, Ser	Phe
Val (V)	Ile, Met, Leu, Phe, Ala, Norleucine	Leu

[0084] In certain embodiments, conservative amino acid substitutions also encompass non-naturally occurring amino acid residues which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems.

[0085] In one embodiment, the method for making a variant V<sub>H</sub> domain comprises adding, deleting, or substituting at least one amino acid in the disclosed V<sub>H</sub> domains, or combining the disclosed V<sub>H</sub> domains with at least one V<sub>L</sub> domain, and testing the variant V<sub>H</sub> domain for IL-21R binding or modulation of IL-21R activity.

[0086] An analogous method for making a variant V<sub>L</sub> domain comprises adding, deleting, or substituting at least one amino acid in the disclosed V<sub>L</sub> domains, or combining the disclosed V<sub>L</sub> domains with at least one V<sub>H</sub> domain,



and testing the variant V<sub>L</sub> domain for IL-21R binding or modulation of IL-21R activity.

[0087] A further aspect of the disclosure provides a method for preparing antigen-binding fragments that bind IL-21R. The method comprises:

- (a) providing a starting repertoire of nucleic acids encoding a V<sub>H</sub> domain which lacks one or more of CDR1, 2 or 3 or contains a CDR1, 2 or 3 to be replaced;
- (b) inserting into or replacing the CDR1, 2 or 3 region of the starting repertoire with a nucleic acid encoding an amino acid sequence as substantially as set out herein for a V<sub>H</sub> CDR 1, 2 or 3, yielding a product repertoire;
- (c) expressing the nucleic acids of the product repertoire;
- (d) selecting a specific antigen-binding fragment that binds to IL-21R;  
and
- (e) recovering the specific antigen-binding fragment or nucleic acid encoding it.

[0088] An analogous method in which the V<sub>L</sub> CDR1, 2 or 3 of the invention is combined with a repertoire of nucleic acids encoding a V<sub>L</sub> domain which lacks a CDR1, 2 or 3 or contains a CDR1, 2 or 3 to be replaced.

[0089] Using recombinant DNA methodology, a disclosed CDR sequence may be introduced into a repertoire of V<sub>H</sub> or V<sub>L</sub> domains lacking the respective CDR (Marks et al. (BioTechnology (1992) 10: 779-783). For example, a primer adjacent to the 5' end of the variable domain and a primer to the third FR can be used to generate a repertoire of variable domain sequences lacking CDR3. This repertoire can be combined with a CDR3 of a disclosed antibody. Using analogous techniques, portions of a disclosed CDR sequence may be shuffled

with portions of CDR sequences from other antibodies to provide a repertoire of antigen-binding fragments that bind IL-21R. Either repertoire can be expressed in a host system such as phage display (described in WO 92/01047) so suitable antigen-binding fragments that bind to IL-21R can be selected.

[0090] A further alternative uses random mutagenesis of the disclosed  $V_H$  or  $V_L$  sequences to generate variant  $V_H$  or  $V_L$  domains still capable of binding IL-21R. A technique using error-prone PCR is described by Gram et al. (Proc. Nat. Acad. Sci. U.S.A. (1992) 89: 3576-3580).

[0091] Another method uses direct mutagenesis of the disclosed  $V_H$  or  $V_L$  sequences. Such techniques are disclosed by Barbas et al. (Proc. Nat. Acad. Sci. U.S.A. (1994) 91: 3809-3813) and Schier et al. (J. Mol. Biol. (1996) 263: 551-567).

[0092] A portion of a variable domain will comprise at least one CDR region substantially as set out herein and, optionally, intervening framework regions from the  $V_H$  or  $V_L$  domains as set out herein. The portion may include the C-terminal half of FR1 and/or the N-terminal half of FR4. Additional residues at the N-terminal or C-terminal end of the variable domain may not be same residues found in naturally occurring antibodies. For example, construction of antibodies by recombinant DNA techniques often introduces N- or C-terminal residues from its use of linkers. Some linkers may be used to join variable domains to other variable domains (e.g., diabodies), constant domains, or proteinaceous labels.

[0093] Although the embodiments illustrated in the Examples comprise a "matching" pair of  $V_H$  and  $V_L$  domains, a skilled artisan will recognize that alternative embodiments may comprise antigen-binding fragments containing

only a single CDR from either V<sub>L</sub> or V<sub>H</sub> domain. Either one of the single chain specific antigen-binding domains can be used to screen for complementary domains capable of forming a two-domain specific antigen-binding fragment capable of, for example, binding to IL-21R. The screening may be accomplished by phage display screening methods using the so-called hierarchical dual combinatorial approach disclosed in WO 92/01047. In this approach, an individual colony containing either a H or L chain clone is used to infect a complete library of clones encoding the other chain (L or H), and the resulting two-chain specific antigen-binding domain is selected in accordance with phage display techniques as described.

[0094] In some alternative embodiments, the anti-IL-21R antibodies can be linked to a protein (e.g., albumin) by chemical cross-linking or recombinant methods. The disclosed antibodies may also be linked to a variety of nonproteinaceous polymers (e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes) in manners set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337. The antibodies can be chemically modified by covalent conjugation to a polymer, for example, to increase their half-life in blood circulation. Exemplary polymers and attachment methods are shown in U.S. Pat. Nos. 4,766,106; 4,179,337; 4,495,285; and 4,609,546.

[0095] The disclosed antibodies can be modified to alter their glycosylation; that is, at least one carbohydrate moiety can be deleted or added to the antibody. Deletion or addition of glycosylation sites can be accomplished by changing amino acid sequence to delete or create glycosylation consensus sites, which are well known in the art. Another means of adding carbohydrate

moieties is the chemical or enzymatic coupling of glycosides to amino acid residues of the antibody (see WO 87/05330 and Aplin et al. (1981) *CRC Crit. Rev. Biochem.*, 22: 259-306). Removal of carbohydrate moieties can also be accomplished chemically or enzymatically (see Hakimuddin et al. (1987) *Arch. Biochem. Biophys.*, 259: 52; Edge et al. (1981) *Anal. Biochem.*, 118: 131; Thotakura et al. (1987) *Meth. Enzymol.*, 138: 350).

[0096] Methods for altering an antibody constant region are known in the art. Antibodies with altered function (e.g., altered affinity for an effector ligand such as FcR on a cell or the C1 component of complement) can be produced by replacing at least one amino acid residue in the constant portion of the antibody with a different residue (see e.g., EP 388,151 A1, US 5,624,821 and US 5,648,260, the contents of all of which are hereby incorporated by reference). Similar types of alterations could be described which if applied to a murine or other species antibody would reduce or eliminate similar functions.

[0097] For example, it is possible to alter the affinity of an Fc region of an antibody (e.g., an IgG, such as a human IgG) for FcR (e.g., Fc gamma R1) or C1q. The affinity may be altered by replacing at least one specified residue with at least one residue having an appropriate functionality on its side chain, or by introducing a charged functional group, such as glutamate or aspartate, or perhaps an aromatic non-polar residue such as phenylalanine, tyrosine, tryptophan or alanine (see e.g., US 5,624,821).

[0098] For example, replacing residue 297 (asparagine) with alanine in the IgG constant region significantly inhibits recruitment of effector cells, while only slightly reducing (about three fold weaker) affinity for C1q (see e.g., US 5,624,821). The numbering of the residues in the heavy chain is that of the EU

index (see Kabat et al., 1991 *supra*). This alteration destroys the glycosylation site and it is believed that the presence of carbohydrate is required for Fc receptor binding. Any other substitution at this site that destroys the glycosylation site is believed cause a similar decrease in lytic activity. Other amino acid substitutions, e.g., changing any one of residues 318 (Glu), 320 (Lys) and 322 (Lys), to Ala, are also known to abolish Clq binding to the Fc region of IgG antibodies (see e.g., US 5,624,821).

[0099] Modified antibodies can be produced which have a reduced interaction with an Fc receptor. For example, it has been shown that in human IgG<sub>3</sub>, which binds to the human Fc gamma R1 receptor, changing Leu 235 to Glu destroys its interaction with the receptor. Mutations on adjacent or close sites in the hinge link region of an antibody (e.g., replacing residues 234, 236 or 237 with Ala) can also be used to affect antibody affinity for the Fc gamma R1 receptor. The numbering of the residues in the heavy chain is based in the EU index (see Kabat et al., 1991 *supra*).

[0100] Additional methods for altering the lytic activity of an antibody, for example, by altering at least one amino acid in the N-terminal region of the CH2 domain, are described in WO 94/29351 by Morgan et al. and US 5,624,821, the contents of all of which are hereby expressly incorporated by reference.

[0101] The antibodies of this invention may be tagged with a detectable or functional label. These labels include radiolabels (e.g., <sup>131</sup>I or <sup>99</sup>Tc), enzymatic labels (e.g., horseradish peroxidase or alkaline phosphatase), and other chemical moieties (e.g., biotin).

[0102] One of skill in the art will appreciate that the modifications described above are not all-exhaustive, and that many other modifications are obvious to a skilled artisan in light of the teachings of the present disclosure.

### **Nucleic Acids, Cloning and Expression Systems**

[0103] The disclosure provides isolated nucleic acids encoding the disclosed antibodies. The nucleic acids may comprise DNA or RNA, and they may be synthetic (completely or partially) or recombinant (completely or partially). Reference to a nucleotide sequence as set out herein encompasses a DNA molecule with the specified sequence, and encompasses a RNA molecule with the specified sequence in which U is substituted for T.

[0104] Also provided are nucleic acids that comprise a coding sequence for one, two, or three CDR's, a  $V_H$  domain, a  $V_L$  domain, or combinations thereof, as disclosed herein, or a sequence substantially identical thereto (e.g., a sequence at least 85%, 90%, 95%, 96%, 97%, 98%, 99% or higher identical thereto, or which is capable of hybridizing under stringent conditions to the sequences disclosed).

[0105] In one embodiment, the isolated nucleic acids have nucleotide sequences encoding heavy chain and light chain variable regions of an anti-IL-21R antibody having at least one CDR chosen from the amino acid sequences of SEQ ID NO:4, 5, 6, 7, 8, 9, 22, 23, 24, 25, 26, 27, 50, 51, 52, 53, 54, 55, 68, 69, 70, 71, 72, 73, 86, 87, 88, 89, 90, 91, 104, 105, 106, 107, 108, 109, 122, 123, 124, 125, 126, 127, 140, 141, 142, 143, 144 and 145 or sequence encoding a CDR which differs by one or two amino acids from the sequences described herein. In some embodiments, the amino acid sequence of a CDR includes conservative amino acid substitutions of one or more amino acids in sequences

shown in SEQ ID NO:4, 5, 6, 7, 8, 9, 22, 23, 24, 25, 26, 27, 50, 51, 52, 53, 54, 55, 68, 69, 70, 71, 72, 73, 86, 87, 88, 89, 90, 91, 104, 105, 106, 107, 108, 109, 122, 123, 124, 125, 126, 127, 140, 141, 142, 143, 144 and 145.

[0106] A nucleic acid may encode only the light chain or the heavy chain variable region, or may also encode an antibody light or heavy chain constant region, operatively linked to the corresponding variable region. In one embodiment, a light chain variable region ( $V_L$ ) is linked to a constant region chosen from a kappa or a lambda constant region. The light chain constant region may also be a human kappa or lambda type. In another embodiment, a heavy chain variable region ( $V_H$ ) is linked to a heavy chain constant region of an antibody isotype chosen from IgG (e.g., IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, IgG<sub>4</sub>), IgM, IgA<sub>1</sub>, IgA<sub>2</sub>, IgD, and IgE. The heavy chain constant region may be an IgG (e.g., an IgG<sub>1</sub>) isotype.

[0107] Nucleic acid compositions of the present invention, while often in the native sequence (of cDNA or genomic DNA or mixtures thereof) except for modified restriction sites and the like, may be mutated in accordance with standard techniques to provide gene sequences. For coding sequences, these mutations, may affect amino acid sequence as desired. In particular, nucleotide sequences substantially identical to or derived from native V, D, J, constant, switches and other such sequences described herein are contemplated (where "derived" indicates that a sequence is identical or modified from another sequence).

[0108] In one embodiment, a nucleic acid differs (e.g., differs by substitution, insertion, or deletion) from that of the sequences provided (e.g., as follows: by at least one but less than 10, 20, 30, or 40 nucleotides; at least one

but less than 1%, 5%, 10% or 20% of the nucleotides in the subject nucleic acid). If necessary for this analysis the sequences should be aligned for maximum homology. "Looped" out sequences from deletions or insertions, or mismatches, are considered differences. The difference may be at a nucleotide(s) encoding a non-essential residue(s), or the difference may be a conservative substitution(s). The disclosure also provides nucleic acid constructs in the form of plasmids, vectors, transcription or expression cassettes, which comprise at least one nucleic acid as described herein.

[0109] The disclosure further provides a host cell that comprises at least one nucleic acid construct described herein. Also provided are the methods of making the encoded protein(s) from the nucleic acid(s) comprising sequence described herein. The method comprises culturing host cells under appropriate conditions so they express the protein from the nucleic acid. Following expression and production, the  $V_H$  or  $V_L$  domain, or specific binding member may be isolated and/or purified using any suitable technique, then used as appropriate.

[0110] Antigen-binding fragments,  $V_H$  and/or  $V_L$  domains, and encoding nucleic acid molecules and vectors may be isolated and/or purified from their natural environment, in substantially pure or homogenous form, or, in the case of nucleic acid, free or substantially free of nucleic acid or genes of origin other than the sequence encoding a polypeptide with the require function.

[0111] Systems for cloning and expressing polypeptides in a variety of host cells are known in the art. Cells suitable for producing antibodies are described in, for example, Fernandez et al. (1999) Gene Expression Systems, Academic Press, eds. In brief, suitable host cells include mammalian cells, insect cells,



plant cells, yeast cells, or prokaryotic cells, e.g., *E. coli*. Mammalian cells available in the art for heterologous polypeptide expression include lymphocytic cell lines (e.g., NSO), HEK293 cells, Chinese hamster ovary (CHO) cells, COS cells, HeLa cells, baby hamster kidney cells, oocyte cells, and cells from a transgenic animal, e.g., mammary epithelial cell. In one embodiment, the MUF and MU11 antibodies are expressed in HEK293 or CHO cells. In other embodiments, nucleic acids encoding the antibodies of the invention are placed under the control of a tissue-specific promoter (e.g., a mammary specific promoter) and the antibodies are produced in transgenic animals. For example, antibodies are secreted into the milk of the transgenic animal, such as a transgenic cow, pig, horse, sheep, goat or rodent. Suitable vectors may be chosen or constructed to contain appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes, and other sequences. The vectors may also contain a plasmid or viral backbone. For details, see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press (1989). Many established techniques used with vectors, including the manipulation, preparation, mutagenesis, sequencing, and transfection of DNA, are described in *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons (1992).

[0112] A further aspect of the disclosure provides a method of introducing the nucleic acid into a host cell. For eukaryotic cells, suitable transfection techniques may include calcium phosphate, DEAE-Dextran, electroporation, liposome-mediated transfection, and transduction using retrovirus or other viruses, e.g., vaccinia or baculovirus. For bacterial cells, suitable techniques may

include calcium chloride transformation, electroporation, and transfection using bacteriophage. DNA introduction may be followed by a selection method (e.g., drug resistance) to select cells that contain the nucleic acid.

### **Biological Deposits**

[0113] CHO cells transformed with vectors containing MUF heavy chain and light chain, and CHO cells transformed with vectors containing MU11 heavy and light chain, were deposited on March 5, 2003, at American Tissue Culture Collection (ATCC) under respective Deposit Designation Numbers PTA-5031 and PTA-5030. The address of the depository is 10801 University Blvd, Manassas, VA 20110, U.S.A.

### **Uses of Anti-IL-21R Antibodies**

[0114] Anti-IL-21R antibodies that act as antagonists to IL-21R can be used to regulate at least one IL-21R-mediated immune response, such as, one or more of cell proliferation, cytokine secretion, chemokine secretion, and cytolytic activity, of T cells, B cells, NK cells, macrophages, or synovial cells..

Accordingly, the antibodies of the invention can be used to inhibit the activity (e.g., proliferation, differentiation, and/or survival) of an immune or hematopoietic cell (e.g., a cell of myeloid, lymphoid, or erythroid lineage, or precursor cells thereof), and, thus, can be used to treat a variety of immune disorders and hyperproliferative disorders. Non-limiting examples of immune disorders that can be treated include, but are not limited to, transplant rejection, graft-versus-host disease, allergies (for example, atopic allergy) and autoimmune diseases.

Autoimmune diseases may include diabetes mellitus, arthritic disorders (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, and ankylosing spondylitis), spondyloarthropathy, multiple sclerosis,

encephalomyelitis, myasthenia gravis, systemic lupus erythematosus, cutaneous lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjögren's Syndrome, IBD (including Crohn's disease and ulcerative colitis), asthma (including intrinsic asthma and allergic asthma), scleroderma and vasculitis.

[0115] Multiple sclerosis is a central nervous system disease that is characterized by inflammation and loss of myelin sheaths - the fatty material that insulates nerves and is needed for proper nerve function. Inflammation that results from an immune response that is dependent on IL-21 can be treated with the antibodies and compositions of this invention. In the experimental autoimmune encephalitis (EAE) mouse model for multiple sclerosis (Tuohy et al. (J. Immunol. (1988) 141: 1126-1130), Sobel et al. (J. Immunol. (1984) 132: 2393-2401), and Traugott (Cell Immunol. (1989) 119: 114-129), treatment of mice with MU11 injections prior (and continuously) to EAE induction profoundly delays the onset of the disease. The antibodies of this invention may similarly be used to treat multiple sclerosis in humans.

[0116] Arthritis is a disease characterized by inflammation in the joints. Rheumatoid Arthritis (RA) is the most frequent form of arthritis, involving inflammation of connective tissue and the synovial membrane, a membrane that lines the joint. The inflamed synovial membrane often infiltrates the joint and damages joint cartilage and bone. Studies show that treatment of synovial cells and macrophages with IL-21 induces these cells to secrete cytokines and chemokines associated with inflammation. In the collagen induced arthritis (CIA) mouse model for rheumatoid arthritis (Courtenay et al. (Nature (1980) 283: 666-628) and Williams et al. (Immunol. (1995) 84: 433-439)), treatment of mice with

IL-21 subsequently (and continuously) to CIA induction exacerbates the disease. Increased secretion of inflammatory cytokines and chemokines, and more importantly, increased disease resulting from immune responses that are dependent on IL-21 may be treated with the antibodies of this invention. Similarly, the antibodies and compositions of this invention may be used to treat RA or other arthritic diseases in humans.

[0117] Transplant rejection is the immunological phenomenon where tissues from a donor are specifically “attacked” by immune cells of the host. The principle “attacking” cells are T cells, whose T cell receptors recognize the donor’s MHC molecules as “foreign.” This recognition activates the T cell, which proliferates and secretes a variety of cytokines and cytolytic proteins that ultimately destroy the transplant. T cells in a mixed lymphocyte reaction (MLR), an *in vitro* assay of transplant rejection, proliferate more strongly when supplemented with IL-21. MLR and transplantation models have been described by Current Protocols in Immunology, Second Edition, Coligan et al. eds., John Wiley & Sons, 1994; Kasaian et al. (Immunity (2002) 16: 559-569); Fulmer et al. (Am. J. Anat. (1963) 113: 273-285), and Lenschow et al. (Science (1992) 257: 789-792). The antibodies and compositions of this invention may be used to reduce the MLR and treat transplant rejection and related diseases (e.g., graft versus host disease) in humans that are dependent on IL-21.

[0118] Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the presence of autoantibodies, including antibodies to DNA, nuclear antigens, and ribonucleoproteins. These autoantibodies are associated with tissue and organ damage. The cause of SLE is unknown, but the occurrence of autoantibodies suggests inadequate inhibition of autoreactive

T cells or B cells. The antibodies and compositions of this invention can be used to inhibit the IL-21 mediated activities of autoreactive T cells and B cells, and treat SLE or related diseases in NZB X NZW mice (the mouse model for SLE) (Immunologic Defects in Laboratory Animals, Gershwin et al. eds., Plenum Press, 1981) or in humans.

[0119] Antibodies of this invention can also be used to treat hyperproliferative disorders associated with aberrant activity of IL-21-responsive cells and IL-21R-responsive cells. Examples of such cells include neoplastic cells of hematopoietic origin, e.g., cells arising from myeloid, lymphoid or erythroid lineages, or precursor cells thereof. Examples of such neoplastic disorders include leukemic cancers, and tumors of the blood, bone marrow (e.g., myeloma), and lymph tissue (e.g., lymphomas). In certain embodiments, the present invention is directed to the treatment of various leukemic cancers including, but not limited to, acute promyeloid leukemia (APML), acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) (reviewed in Vaickus, L. (1991) *Crit. Rev. in Oncol./Hematol.* 11:267-97). Examples of lymphoid malignancies that may be treated by the subject methods include, but are not limited to, acute lymphoblastic leukemia (ALL, which includes B-lineage ALL and T-lineage ALL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), hairy cell leukemia (HLL), and Waldenstrom's macroglobulinemia (WM). Additional forms of malignant lymphomas that can be treated by the present invention include, but not limited to, non-Hodgkin's lymphoma, peripheral T cell lymphomas, adult T cell leukemia/lymphoma (ATL), cutaneous T cell lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's lymphoma, and variants thereof.

## **Combination Therapy**

[0120] In one embodiment, a pharmaceutical composition comprising at least one anti-IL-21R antibody and at least one therapeutic agent is administered in combination therapy. The therapy is useful for treating pathological conditions or disorders, such as immune and inflammatory disorders. The term "in combination" in this context means that the antibody composition and the therapeutic agent are given substantially contemporaneously, either simultaneously or sequentially. If given sequentially, at the onset of administration of the second compound, the first of the two compounds may still be detectable at effective concentrations at the site of treatment.

[0121] For example, the combination therapy can include at least one anti-IL-21R antibody co-formulated with, and/or co-administered with, at least one additional therapeutic agent. The additional agents may include at least one cytokine inhibitor, growth factor inhibitor, immunosuppressant, anti-inflammatory agent, metabolic inhibitor, enzyme inhibitor, cytotoxic agent, and cytostatic agent, as described in more detail below. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies. Moreover, the therapeutic agents disclosed herein act on pathways that differ from the IL-21/IL-21R pathway, and thus are expected to enhance and/or synergize with the effects of the anti-IL-21R antibodies.

[0122] Therapeutic agents used in combination with anti-IL-21R antibodies may be those agents that interfere at different stages in the autoimmune and subsequent inflammatory response. In one embodiment, at least one anti-IL-21R antibody described herein may be co-formulated with, and/or co-administered

with, at least one cytokine and/or growth factor antagonist. The antagonists may include soluble receptors, peptide inhibitors, small molecules, ligand fusions, antibodies (that bind cytokines or growth factors or their receptors or other cell surface molecules), and "anti-inflammatory cytokines" and agonists thereof.

[0123] Non-limiting examples of the agents that can be used in combination with the anti-IL-21R antibodies described herein, include, but are not limited to, antagonists of at least one interleukin (e.g., IL-1, IL-2, IL-6, IL-7, IL-8, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, and IL-22); cytokine (e.g.,  $\text{TNF}\alpha$ , LT, EMAP-II, and GM-CSF); and growth factor (e.g., FGF and PDGF). The agents may also include, but not limited to, antagonists of at least one receptor for an interleukin, cytokine, and growth factor. Anti-IL-21R antibodies can also be combined with inhibitors (e.g., antibodies) to cell surface molecules such as CD2, CD3, CD4, CD8, CD25, CD28, CD30, CD40, CD45, CD69, CD80 (B7.1), CD86 (B7.2), CD90, or their ligands (e.g., CD154 (gp39, CD40L)), or LFA-1/ICAM-1 and VLA-4/VCAM-1 (Yusuf-Makagiansar et al. (2002) *Med Res Rev* 22(2):146-67)). Antagonists that can be used in combination with anti-IL-21R antibodies described herein may include antagonists of IL-1, IL-12,  $\text{TNF}\alpha$ , IL-15, IL-17, IL-18, IL-22, and their receptors.

[0124] Examples of those agents include IL-12 antagonists (such as antibodies that bind IL-12 (see e.g., WO 00/56772, Genetics Institute/BASF)); IL-12 receptor inhibitors (such as antibodies to the IL-12 receptor); and soluble IL-12 receptor and fragments thereof. Examples of IL-15 antagonists include antibodies against IL-15 or its receptor, soluble fragments of the IL-15 receptor, and IL-15-binding proteins. Examples of IL-18 antagonists include antibodies to IL-18, soluble fragments of the IL-18 receptor, and IL-18 binding proteins (IL-

18BP, Mallet et al. (2001) Circ. Res. 28). Examples of IL-1 antagonists include Interleukin-1-Converting Enzyme (ICE) inhibitors (such as Vx740), IL-1 antagonists (e.g., IL-1RA (ANIKINRA, AMGEN)), sIL-1RII (Immunex), and anti-IL-1 receptor antibodies.

[0125] Examples of TNF antagonists include antibodies to TNF (e.g., human TNF $\alpha$ ), such as D2E7 (human anti-TNF $\alpha$  antibody, U.S. 6,258,562, Humira<sup>TM</sup>, BASF); CDP-571/CDP-870/BAY-10-3356 (humanized anti-TNF $\alpha$  antibodies, Celltech/Pharmacia); cA2 (chimeric anti-TNF $\alpha$  antibody, Remicade<sup>TM</sup>, Centocor); and anti-TNF antibody fragments (e.g., CPD870). Other examples include soluble TNF receptor (e.g., human p55 or p75) fragments and derivatives, such as p55 kdTNFR-IgG (55 kD TNF receptor-IgG fusion protein, Lenercept<sup>TM</sup>) and 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel<sup>TM</sup>, Immunex, see, e.g., Arthritis & Rheumatism (1994) Vol. 37, S295; J. Invest. Med. (1996) Vol. 44, 235A). Further examples include enzyme antagonists (e.g., TNF $\alpha$  converting enzyme inhibitors (TACE) such as alpha-sulfonyl hydroxamic acid derivative (WO 01/55112) or N-hydroxyformamide inhibitor (GW 3333, -005, or -022)) and TNF-bp/s-TNFR (soluble TNF binding protein, see e.g., Arthritis & Rheumatism (1996) Vol. 39, No. 9 (supplement), S284; and Am. J. Physiol. Heart Circ. Physiol. (1995) Vol. 268, pp. 37-42). TNF antagonists may be soluble TNF receptor (e.g., human p55 or p75) fragments and derivatives, such as 75 kdTNFR-IgG; and TNF $\alpha$  converting enzyme (TACE) inhibitors.

[0126] In other embodiments, the anti-IL-21R antibodies described herein can be administered in combination with at least one of the following: IL-13 antagonists, such as soluble IL-13 receptors and/or anti-IL-13 antibodies; and IL-2 antagonists, such as IL-2 fusion proteins (e.g., DAB 486-IL-2 and/or DAB 389-



IL-2, Seragen, see e.g., *Arthritis & Rheumatism* (1993) Vol. 36, 1223) and anti-IL-2R antibodies (e.g., anti-Tac (humanized antibody, Protein Design Labs, see *Cancer Res.* 1990 Mar 1;50(5):1495-502)). Another combination includes anti-IL-21R antibodies in combination with non-depleting anti-CD4 inhibitors such as IDEC-CE9.1/SB 210396 (anti-CD4 antibody, IDEC/SmithKline). Yet other combinations include anti-IL-21R antibodies with CD80 (B7.1) and CD86 (B7.2) co-stimulatory pathway antagonists (such as antibodies, soluble receptors, or antagonistic ligands); P-selectin glycoprotein ligand (PSGL); and anti-inflammatory cytokines and agonists thereof (e.g., antibodies). The anti-inflammatory cytokines may include IL-4 (DNAX/Schering); IL-10 (SCH 52000, recombinant IL-10, DNAX/Schering); IL-13; and TGF.

[0127] In other embodiments, at least one anti-IL-21R antibody can be co-formulated with, and/or co-administered with, at least one anti-inflammatory drug, immunosuppressant, metabolic inhibitor, and enzymatic inhibitor. Non-limiting examples of the drugs or inhibitors that can be used in combination with the IL-21 antagonists described herein, include, but are not limited to, at least one of: non-steroidal anti-inflammatory drug (NSAID) (such as ibuprofen, Tenidap (see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S280)), Naproxen (see e.g., *Neuro Report* (1996) Vol. 7, pp. 1209-1213), Meloxicam, Piroxicam, Diclofenac, and Indomethacin); Sulfasalazine (see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S281); corticosteroid (such as prednisolone); cytokine suppressive anti-inflammatory drug (CSAID); and an inhibitor of nucleotide biosynthesis (such as an inhibitor of purine biosynthesis (e.g., folate antagonist such as methotrexate) and an inhibitor of pyrimidine biosynthesis (e.g., a dihydroorotate dehydrogenase (DHODH) inhibitor such as leflunomide

(see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S131; *Inflammation Research* (1996) Vol. 45, pp. 103-107)). Therapeutic agents for use in combination with IL-21/IL-21R antagonists may include NSAIDs, CSAIDs, DHODH inhibitors (such as leflunomide), and folate antagonists (such as methotrexate).

[0128] Examples of additional inhibitors include at least one of: corticosteroid (oral, inhaled and local injection); immunosuppressant (such as cyclosporin and tacrolimus (FK-506)); a mTOR inhibitor (such as sirolimus (rapamycin) or a rapamycin derivative (e.g., ester rapamycin derivative such as CCI-779 (Elit. L. (2002) *Current Opinion Investig. Drugs* 3(8):1249-53; Huang, S. et al. (2002) *Current Opinion Investig. Drugs* 3(2):295-304))); an agent which interferes with the signaling of proinflammatory cytokines such as  $\text{TNF}\alpha$  and IL-1 (e.g., IRAK, NIK, IKK, p38 or a MAP kinase inhibitor); a COX2 inhibitor (e.g., celecoxib and variants thereof (MK-966), see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S81); a phosphodiesterase inhibitor (such as R973401, see e.g., *Arthritis & Rheumatism* (1996) Vol. 39, No. 9 (supplement), S282)); a phospholipase inhibitor (e.g., an inhibitor of cytosolic phospholipase 2 (cPLA2) such as trifluoromethyl ketone analogs (U.S. 6,350,892)); an inhibitor of vascular endothelial cell growth factor (VEGF); an inhibitor of the VEGF receptor; and an inhibitor of angiogenesis. Therapeutic agents for use in combination with anti-IL-21R antibodies may include immunosuppressants (such as cyclosporine and tacrolimus (FK-506)); and mTOR inhibitors (such as sirolimus (rapamycin) or rapamycin derivatives (e.g., ester rapamycin derivatives such as CCI-779)); COX2 inhibitors (such as celecoxib and variants thereof); and phospholipase

inhibitors (such as inhibitors of cytosolic phospholipase 2 (cPLA2) (e.g., trifluoromethyl ketone analogs)).

[0129] Examples of therapeutic agents that can be co-administered and/or co-formulated with at least one anti-IL-21R antibody, include, but are not limited to, at least one of: TNF antagonists (such as anti-TNF antibodies); soluble fragments of TNF receptors (e.g., human p55 and p75) and derivatives thereof (such as p55 kdTNFR-IgG (55 kD TNF receptor-IgG fusion protein, Lenercept™) and 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™)); TNF enzyme antagonists (such as TACE inhibitors); antagonists of IL-12, IL-15, IL-17, IL-18, and IL-22; T cell and B cell depleting agents (such as anti-CD4 or anti-CD22 antibodies); small molecule inhibitors (such as methotrexate and leflunomide); sirolimus (rapamycin) and analogs thereof (such as CCI-779); Cox-2 and cPLA2 inhibitors; p38, TPL-2, Mk-2 and NFκB inhibitors; RAGE and soluble RAGE; P-selectin and PSGL-1 inhibitors (such as antibodies to and small molecule inhibitors); and estrogen receptor beta (ERB) agonists, and ERB-NFκB antagonists. Therapeutic agents that can be co-administered and/or co-formulated with at least one anti-IL-21R antibody may include at least one of: a soluble fragment of a TNF receptor (e.g., human p55 or p75) such as 75 kdTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel™); methotrexate; leflunomide; and sirolimus (rapamycin) and analogs thereof (such as CCI-779).

[0130] The anti-IL-21R antibodies disclosed herein can be used in combination with other therapeutic agents to treat specific immune disorders as discussed in further detail below.

[0131] Non-limiting examples of agents for treating arthritic disorders (e.g., rheumatoid arthritis, inflammatory arthritis, rheumatoid arthritis, juvenile

rheumatoid arthritis, osteoarthritis and psoriatic arthritis), with which an anti-IL-21R antibody can be combined include at least one of the following: TNF antagonists (such as anti-TNF antibodies); soluble fragments of TNF receptors (e.g., human p55 and p75) and derivatives thereof (such as p55 kDTNFR-IgG (55 kD TNF receptor-IgG fusion protein, Lenercept<sup>TM</sup>) and 75 kDTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel<sup>TM</sup>)); TNF enzyme antagonists (such as TACE inhibitors); antagonists of IL-12, IL-15, IL-17, IL-18, and IL-22; T cell and B cell depleting agents (such as anti-CD4 or anti-CD22 antibodies); small molecule inhibitors (such as methotrexate and leflunomide); sirolimus (rapamycin) and analogs thereof (e.g., CCI-779); Cox-2 and cPLA2 inhibitors; NSAIDs; p38, TPL-2, Mκ-2, and NFκB inhibitors; RAGE or soluble RAGE; P-selectin or PSGL-1 inhibitors (such as small molecule inhibitors and antibodies to); estrogen receptor beta (ERB) agonists, and ERB-NFκB antagonists. Therapeutic agents that can be co-administered and/or co-formulated with at least one IL-21/IL-21R antagonist may include at least one of: a soluble fragment of a TNF receptor (e.g., human p55 or p75) such as 75 kDTNFR-IgG (75 kD TNF receptor-IgG fusion protein, Enbrel<sup>TM</sup>); methotrexate; leflunomide; and sirolimus (rapamycin) or an analog thereof (e.g., CCI-779).

[0132] Non-limiting examples of agents for treating multiple sclerosis with which anti-IL-21R antibody can be combined include interferon-β (for example, IFNβ-1a and IFNβ-1b), copaxone, corticosteroids, IL-1 inhibitors, TNF inhibitors, antibodies to CD40 ligand, antibodies to CD80, and IL-12 antagonists.

[0133] Non-limiting examples of agents for treating inflammatory bowel disease or Crohn's disease with which an anti-IL-21R antibody can be combined include budenoside; epidermal growth factor; corticosteroids; cyclosporine;

sulfasalazine; aminosalicylates; 6-mercaptopurine; azathioprine; metronidazole; lipoxygenase inhibitors; mesalamine; olsalazine; balsalazide; antioxidants; thromboxane inhibitors; IL-1 receptor antagonists; anti-IL-1 monoclonal antibodies; anti-IL-6 monoclonal antibodies; growth factors; elastase inhibitors; pyridinyl-imidazole compounds; TNF antagonists as described herein; IL-4, IL-10, IL-13, and/or TGF $\beta$  or agonists thereof (e.g., agonist antibodies); IL-11; glucuronide- or dextran-conjugated prodrugs of prednisolone, dexamethasone or budesonide; ICAM-1 antisense phosphorothioate oligodeoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); slow-release mesalazine; methotrexate; antagonists of Platelet Activating Factor (PAF); ciprofloxacin; and lignocaine.

[0134] In other embodiments, an anti-IL-21R antibody can be used in combination with at least one antibody directed at other targets involved in regulating immune responses, e.g., transplant rejection or graft versus host disease. Non-limiting examples of agents for treating immune responses with which an IL-21/IL-21R antagonist of the invention can be combined include the following: antibodies against cell surface molecules, including but not limited to CD25 (IL-2 receptor  $\alpha$ ), CD11a (LFA-1), CD54 (ICAM-1), CD4, CD45, CD28/CTLA4, CD80 (B7-1), CD86 (B7-2), or combinations thereof. In another embodiment, an anti-IL-21R antibody is used in combination with at least one general immunosuppressive agent, such as cyclosporin A or FK506.

[0135] Another aspect of the present invention accordingly relates to kits for carrying out the combined administration of anti-IL-21R antibodies with other therapeutic agents. In one embodiment, the kit comprises at least one anti-IL-21R antibody formulated in a pharmaceutical carrier, and at least one therapeutic

agent, formulated as appropriate in one or more separate pharmaceutical preparations.

### **Diagnostic Uses**

[0136] Antibodies according to this invention may also be used to detect the presence of IL-21R in biological samples. By correlating the presence or level of these proteins with a medical condition, one of skill in the art can diagnose the associated medical condition. For example, stimulated T cells increase their expression of IL-21R, and an unusually high concentration of IL-21R expressing T cells in joints may indicate joint inflammation and possible arthritis. Illustrative medical conditions that may be diagnosed by the antibodies of this invention include multiple sclerosis, rheumatoid arthritis, and transplant rejection.

[0137] Antibody-based detection methods are well known in the art, and include ELISA, radioimmunoassays, immunoblots, Western blots, flow cytometry, immunofluorescence, immunoprecipitation, and other related techniques. The antibodies may be provided in a diagnostic kit that incorporates at least one of these procedures to detect IL-21R. The kit may contain other components, packaging, instructions, or other material to aid the detection of the protein and use of the kit.

[0138] Antibodies may be modified with detectable markers, including ligand groups (e.g., biotin), fluorophores and chromophores, radioisotopes, electron-dense reagents, or enzymes. Enzymes are detected by their activity. For example, horseradish peroxidase is detected by its ability to convert tetramethylbenzidine (TMB) to a blue pigment, quantifiable with a

spectrophotometer. Other suitable binding partners include biotin and avidin, IgG and protein A, and other receptor-ligand pairs known in the art.

[0139] Antibodies can also be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent association or otherwise) to at least one other molecular entity, such as another antibody (e.g., a bispecific or a multispecific antibody), toxins, radioisotopes, cytotoxic or cytostatic agents, among others. Other permutations and possibilities are apparent to those of ordinary skill in the art, and they are considered equivalents within the scope of this invention.

#### **Pharmaceutical Compositions and Methods of Administration**

[0140] Certain embodiments of the invention include compositions comprising the disclosed antibodies. The compositions may be suitable for pharmaceutical use and administration to patients. The compositions comprise an antibody of the present invention and a pharmaceutical excipient. As used herein, "pharmaceutical excipient" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., that are compatible with pharmaceutical administration. Use of these agents for pharmaceutically active substances is well known in the art. Compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions. The pharmaceutical compositions may also be included in a container, pack, or dispenser together with instructions for administration.

[0141] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Methods to accomplish the administration are known to those of ordinary skill in the art. It may also be

possible to create compositions which may be topically or orally administered, or which may be capable of transmission across mucous membranes. For example, the administration may be intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal.

[0142] Solutions or suspensions used for intradermal or subcutaneous application typically include at least one of the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycol, glycerine, propylene glycol, or other synthetic solvent; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate, or phosphate; and tonicity agents such as sodium chloride or dextrose. The pH can be adjusted with acids or bases. Such preparations may be enclosed in ampoules, disposable syringes, or multiple dose vials.

[0143] Solutions or suspensions used for intravenous administration include a carrier such as physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ), ethanol, or polyol. In all cases, the composition must be sterile and fluid for easy syringability. Proper fluidity can often be obtained using lecithin or surfactants. The composition must also be stable under the conditions of manufacture and storage. Prevention of microorganisms can be achieved with antibacterial and antifungal agents, e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, isotonic agents (sugar), polyalcohols (mannitol and sorbitol), or sodium chloride may be included in the composition. Prolonged absorption of the composition can be



accomplished by adding an agent which delays absorption, e.g., aluminum monostearate and gelatin.

[0144] Oral compositions include an inert diluent or edible carrier. The composition can be enclosed in gelatin or compressed into tablets. For the purpose of oral administration, the antibodies can be incorporated with excipients and placed in tablets, troches, or capsules. Pharmaceutically compatible binding agents or adjuvant materials can be included in the composition. The tablets, troches, and capsules, may contain (1) a binder such as microcrystalline cellulose, gum tragacanth or gelatin; (2) an excipient such as starch or lactose, (3) a disintegrating agent such as alginic acid, Primogel, or corn starch; (4) a lubricant such as magnesium stearate; (5) a glidant such as colloidal silicon dioxide; or (6) a sweetening agent or a flavoring agent.

[0145] Compositions may also be administered by a transmucosal or transdermal route. For example, antibodies that comprise a Fc portion may be capable of crossing mucous membranes in the intestine, mouth, or lungs (via Fc receptors). Transmucosal administration can be accomplished through the use of lozenges, nasal sprays, inhalers, or suppositories. Transdermal administration can also be accomplished through the use of composition containing ointments, salves, gels, or creams known in the art. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used. For administration by inhalation, antibodies are delivered in an aerosol spray from a pressured container or dispenser, which contains a propellant (e.g., liquid or gas) or a nebulizer.

[0146] In certain embodiments, antibodies of this invention are prepared with carriers to protect the antibodies against rapid elimination from the body.

Biodegradable polymers (e.g., ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polylactic acid) are often used. Methods for the preparation of such formulations are known by those skilled in the art. Liposomal suspensions can be used as pharmaceutically acceptable carriers too. The liposomes can be prepared according to established methods known in the art (U.S. Patent No. 4,522,811).

[0147] Antibodies or antibody compositions of the invention are administered in therapeutically effective amounts as described. Therapeutically effective amounts may vary with the subject's age, condition, sex, and severity of medical condition. Appropriate dosage may be determined by a physician based on clinical indications. Antibodies or compositions may be given as a bolus dose to maximize the circulating levels of antibodies for the greatest length of time. Continuous infusion may also be used after the bolus dose.

[0148] As used herein, the term "subject" is intended to include human and non-human animals. Subjects may include a human patient having a disorder characterized by cells that express IL-21R, e.g., a cancer cell or an immune cell. The term "non-human animals" of the invention includes all vertebrates, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.

[0149] Examples of dosage ranges that can be administered to a subject can be chosen from: 1  $\mu$ g/kg to 20 mg/kg, 1  $\mu$ g/kg to 10 mg/kg, 1  $\mu$ g/kg to 1 mg/kg, 10  $\mu$ g/kg to 1 mg/kg, 10  $\mu$ g/kg to 100  $\mu$ g/kg, 100  $\mu$ g to 1 mg/kg, 500  $\mu$ g/kg to 1 mg/kg.

[0150] It may be advantageous to formulate compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited for the patient. Each dosage

unit contains a predetermined quantity of antibody calculated to produce a therapeutic effect in association with the carrier. The dosage unit depends on the characteristics of the antibodies and the particular therapeutic effect to be achieved.

[0151] Toxicity and therapeutic efficacy of the composition can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Antibodies that exhibit large therapeutic indices may be less toxic and/or more therapeutically effective.

[0152] The data obtained from the cell culture assays and animal studies can be used to formulate a dosage range in humans. The dosage of these compounds may lie within the range of circulating antibody concentrations in the blood, that includes an ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage composition form employed and the route of administration. For any antibody used in the present invention, the therapeutically effective dose can be estimated initially using cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (i.e., the concentration of antibody which achieves a half-maximal inhibition of symptoms). The effects of any particular dosage can be monitored by a suitable bioassay. Examples of suitable bioassays include DNA replication assays, transcription-based assays, IL-21R/IL-21 binding assays, and other immunological assays.

[0153] The following examples do not in any way limit the scope of the invention. One of ordinary skill in the art will recognize the numerous modifications and variations that may be performed without altering the spirit or scope of the present invention. Such modifications and variations are encompassed within the scope of the invention. The entire contents of all references, patents and published patent applications cited throughout this application are incorporated by reference.

### **EXAMPLES**

#### **Example 1: Selection of MUF and MU11 Anti-IL-21R scF<sub>v</sub>'s**

[0154] An scF<sub>v</sub> phagemid library, which is an expanded version of the  $1.38 \times 10^{10}$  library described by Vaughan et al. ((1996) *Nature Biotech.*, 14: 309-314), was used to select antibodies specific for human IL-21R. Wells of microtiter plates were coated with soluble IL-21R fusion protein or control fusion protein (5-20 µg/ml in phosphate buffered saline (PBS)) and incubated overnight at 4°C. Wells were washed in PBS, then blocked for 1 hour at 37°C in MPBS (3% milk powder in PBS). Purified phage ( $10^{12}$  transducing units), blocked for 1 hour in MPBS, were added to the control fusion protein coated wells and incubated for 1 hour. The unbound phage was then transferred to IL-21R fusion protein wells and incubated for one hour. Wells were washed 5 times with PBST (0.1% v/v Tween 20 in PBS), then 5 times with PBS. Bound phage were eluted and used to infect exponentially growing *E.coli* TG1. Infected cells were grown in 2TY broth for 1 hour at 37°C, then streaked onto 2TYAG plates and incubated overnight at 30°C. The next day, colonies were transferred into 10 ml of 2TY broth plus 15% glycerol and stored at -70°C. Later, colonies from this first round

of selection were thawed and superinfected with helper phage to rescue (generate) scF<sub>v</sub> antibody-expressing phage for a second round of selection.

**Example 2: Selection of R18 and 19F5 Anti-IL-21R scFvs**

[0155] Anti-IL21R scFv (R18) was isolated using 200 nM of biotinylated human IL-21R fusion protein (bio.hIL21R) (Wyeth, Giralda Farms, NJ) in solution. Purified scFv phage ( $10^{12}$  tu) was blocked with MPBS and 125 µg/ml control fusion protein, as described above in Example 1. Biotinylated IL-21R fusion protein was added to the blocked phage to a final concentration of 200 nM and incubated for 1 hour at room temperature. Phage/antigen was added to 75 µl of Dynal M280 Streptavidin magnetic beads (Dynal Biotech Inc., Lake Success, NY) that had been blocked for 90 minutes at room temperature in 1 ml of 3% MPBS. The mixture was incubated for 15 minutes at room temperature with mixing. Beads were captured using a magnetic rack and washed 5 times in 1 ml PBST followed by three washes in PBS. Bound phage were eluted with 500 µl of 10 µg/ml trypsin in 0.2 M sodium phosphate buffer, pH 7.0 and incubated at 37°C for 30 minutes. Eluted phage were used to infect 10 ml exponentially growing *E. coli* TG-1 cells as described above. ScFv clones were isolated after three rounds of selection.

[0156] ScFv production was induced by addition of 1 mM IPTG to exponentially growing cultures and incubation overnight at 30°C. Crude scFv-containing periplasmic extracts (Griffiths et al.(1993) *EMBO J.*, 12:725-734) were screened for the ability to inhibit the binding of human IL-21R fusion protein to human IL-21-FLAG tagged protein. Briefly, anti-FLAG antibody was immobilized onto plastic and used to capture FLAG-tagged human IL-21 protein. Binding of human IL-21R fusion protein was detected with a Europium-labelled antibody to

the IL-21R fusion protein, and time resolved fluorescence was detected with the DELFIA reagent kit (PerkinElmer, Boston, MA). Purified scFv R18 clone exhibited an  $IC_{50}$  value of 770 nM for inhibition of IL-21R fusion protein binding to IL-21-FLAG tagged protein.

[0157] Anti-IL21R clone 19F5 was isolated by selection method as used for R18, except that 50 nM of human IL-21R fusion protein was used in the third round of selection.

**Example 3: Selection of 18A5 and 18G4 Anti-IL-21R scFvs**

[0158] Anti-IL21R scFvs, 18A5 and 18G4, were isolated by selecting on IL-21R expressing cell lines and IL-21R fusion protein in solution. Transfected hBaf3Mu-1 cells (Wyeth, Giralda Farms, NJ) expressing the human IL-21R on the cell surface were cultured using standard tissue culture methods. Purified scFv phage ( $10^{12}$  tu) were blocked with  $1 \times 10^8$  un-transfected Baf3 cells for 1 hour at room temperature in MPBS.

[0159] Blocked phage were added to  $1 \times 10^7$  hBaf3Mu-1 cells, which had been pre-incubated in MPBS for 1 hour. This was followed by incubation for one hour at room temperature with mixing. The hBaf3Mu-1 cells were subsequently washed 6 times in PBST. Specifically bound phage were eluted from the cells using 10  $\mu$ g/ml of trypsin in 0.2 M sodium phosphate buffer, pH 7.0, and incubated at 37°C for 30 minutes with shaking. The eluted phage supernatant was used to infect *E. coli* TG-1 cells as described above.

[0160] ScFv-expressing phage for the second round of selection were produced as described above. Phage were blocked with MPBS and 125  $\mu$ g/ml control fusion protein. Selection was carried out in solution with biotinylated human IL-21R fusion protein (Wyeth) following selection method described for

R18, except that beads were washed 5 times in 1 ml of MPBS / 0.1% (v/v) Tween 20 followed by three washes in PBS.

[0161] ScFv antibody-expressing phage particles were then further selected using selection method using hBaf3Mu-1 cells, as described above.

**Example 4: Selection of CP5G2 Anti-IL-21R scFv**

[0162] Clone CP5G2 was isolated by selection on murine IL-21R tagged with hexahistidine and a Flag affinity tag (hIL21R.His.Flag) (Wyeth, Giralda Farms, NJ). Purified scFv phage ( $10^{12}$  tu) were blocked with MPBS plus 30  $\mu$ l anti-Flag agarose beads for 1 hour at room temperature. hIL-21R.His.Flag, at a final concentration of 25 nM in MPBS, was added to blocked phage and incubated at room temperature for 1 hour. The library/antigen mixture was then added to 100  $\mu$ l of anti-Flag agarose beads that had been blocked in MPBS for 2 hours at room temperature, washed 3 times in PBS, and incubated a further 30 minutes with mixing. The beads were washed 4 times with PBST, followed by 4 times with PBS and the phage were eluted from the beads with 0.5  $\mu$ g/ml trypsin in 50 mM Tris, pH 8.0, 1 mM  $\text{CaCl}_2$ , as described above. Beads were collected using centrifugation. Eluted phage were used to infect 10 ml *E. coli* TG-1 cells, as described above. A second round of soluble selection was carried out, also as described above.

[0163] Colonies were picked into 96 well plates containing 100  $\mu$ l of 2TYAG. Crude scFv-containing periplasmic extracts were produced as described above, except the buffer used was 20% (w/v) sucrose, 50mM Tris-HCl, pH 7.5, 1 mM EDTA. Crude scFv-containing extracts were screened for the ability to inhibit the binding of 16 ng/ml biotinylated murine IL-21 (bio.mIL21) to murine IL-21R protein immobilized on plastic in a 96 well microtitre plate assay. Binding of

bio.mIL21 was detected with Europium-labelled streptavidin and TRF detected using the DELFIA reagent kit (PerkinElmer, Boston, MA).

[0164] Purified CP5G2 scFv exhibited an  $IC_{50}$  value of 590 nM in the above assay for inhibition of binding of IL-21 to IL-21R.

**Example 5: Identification of scFv's from MUF and MU11 phage clones**

[0165] To establish the specificity of the scFv's for IL-21R, a phage ELISA was performed against the IL-21R fusion protein. Individual TG1 cell colonies from the second selection were transferred to microtiter wells containing 100  $\mu$ l of 2TYAG medium. M13K07 helper phage (10 moi) was added to the exponentially growing TG1 culture, and the samples were incubated for one hour at 37°C. Plates were centrifuged and supernatant was removed, then the remaining pellets were suspended in 100  $\mu$ l of 2TYAG and incubated overnight at 30°C with shaking. The next day, plates were centrifuged and phage supernatant was transferred to new microtiter plate wells. Phage was blocked in MPBS prior to ELISA.

[0166] Wells of microtiter plates were coated with IL-21R fusion protein or control fusion protein (0.5-2.5  $\mu$ g/ml) and incubated overnight at 4°C. The next day, fusion protein solution was removed and wells were blocked for 1 hour in MPBS. Wells were washed with PBS, then 50  $\mu$ l of blocked phage was added. Plates were incubated for 1 hour, then washed 3 times with PBST and 3 times with PBS. Anti-M13-HRP conjugate (Pharmacia, Peapack, NJ) was added to wells, and the samples were incubated for one hour. Wells were washed 3 times with PBST and 3 times with PBS. TMB was added to wells, and the samples were incubated until color developed. The reaction was stopped with 25  $\mu$ l of 0.5 M  $H_2SO_4$ . The color signal was measured by reading absorbance at 450 nm



using a microtiter plate reader. Two phage clones showed specific binding to the IL-21R fusion protein and not the control fusion protein, and these clones are referred to in this application as MUF and MU11 phage clones.

[0167] Individual TG-1 colonies containing MUF and MU11 phage clones were streaked onto 2TYAG plates and incubated overnight at 30°C. Using pCANTAB6 vector specific oligos, the V<sub>H</sub> and V<sub>L</sub> regions of the phage were amplified by PCR and sequenced. Database searches revealed that the V<sub>L</sub> region of the MUF phage clone originated from lambda chain, and the V<sub>L</sub> region of the MU11 phage clone originated from kappa chain.

**Example 6: Conversion of scF<sub>v</sub> to IgG**

[0168] The V<sub>H</sub> and V<sub>L</sub> regions from the MUF and MU11 phage clones were amplified by PCR using clone-specific primers. The PCR products were digested with restriction enzymes and subcloned into appropriate vectors (see Example 2) containing the human IgG<sub>1</sub> heavy chain constant domain (Takahashi et al. (1982) Cell 29, 671) or the human lambda light chain constant domain or the human kappa light chain constant domain (Hieter et al. (1982) Nature 294: 536). The four constructs encode polypeptides referred to in this application as MUF heavy chain, MUF light chain, MU11 heavy chain, and MU11 light chain.

[0169] Vectors containing MUF heavy chain, MUF light chain, MU11 heavy chain, and MU11 light chain, were prepared, sequenced, and used to transfect HEK293 or CHO cells using standard techniques. Cells expressing MUF heavy and light chains produced MUF antibody, which is referred to in this application as "MUF", and cells expressing MU11 heavy and light chains produced MU11 antibody, which is referred to in this application as "MU11." Secreted antibodies were purified using protein A Sepharose (Pharmacia), then dialyzed with PBS.

[0170] Binding specificity of antibodies were determined as follows: ELISA plates were coated overnight with 2.5 µg/ml of IL-21R fusion protein. Plates were washed with PBSB (PBS + 1% bovine serum albumin), then incubated with various concentrations of MUF or MU11 for 2 hours at 25°C. The plates were washed, then a saturating amount of HRP-conjugated goat anti-human antibody was added. The plates were incubated for 1 hour at 25°C, then washed with PBSB, and developed with using TMB. An example of the results obtained by the ELISA is presented in Figure 1A.

[0171] Binding specificity of the antibodies was further confirmed by cell surface staining. Human IL-21R transduced TF-1 cells were bound with purified or biotinylated MUF or MU11 (1 mg/ml). Cells were incubated on ice for 30 minutes, washed with PBSB, then suspended in a solution containing PE-conjugated anti-human IgG antibody or PE-conjugated avidin. Cells were incubated on ice for 30 minutes, washed, then analyzed on a FACScan. The results are presented in Figure 1B. Purified mouse B cells were similarly stained with MUF, and the results are presented in Figure 1C.

#### **Example 7: MUF Blocks Binding of IL-21 to IL-21R**

[0172] Inhibition assays were performed to assess the ability of the antibodies to block binding of IL-21 to IL-21R. The ELISA was performed as described in Example 3 with the following modifications. After incubation with MUF or MU11 for 2 hours at 25°C, biotin-conjugated IL-21 (1 µg/ml) was added, and the samples were incubated for 1 hour at 25°C. After washing, saturating amount of avidin-HRP was added, and the samples were further incubated for 1 hour at 25°C. The wells were washed with PBSB, and the samples were developed using TMB. Results are presented in Figure 2. Under these

conditions, MUF blocked the binding of IL-21 to IL-21R, whereas MU11 did not. These data suggest that MUF and MU11 recognize different epitopes of IL-21R.

**Example 8: MUF and MU11 Decrease T Cell Responses**

[0173] Proliferation assays were performed to assess the antibody's ability to block the IL-21 mediated T cell proliferation. Human CD4<sup>+</sup> T cells ( $5 \times 10^4$  cells/well) were stimulated with PHA (phytohemagglutinin) and human IL-21. IL-21 in COS cell culture media (COS CM) was added to different samples at various concentrations. In indicated samples, MUF, MU11, or human IgG<sub>1</sub> isotype control were added. After 72 hours, <sup>3</sup>H-thymidine was added, and cell proliferation was measured by incorporated radioactivity using a LKB 1205 liquid scintillation counter. As shown in Figure 3A, IL-21 increased the proliferation of PHA-stimulated T cells. Addition of MUF blocked the ability of IL-21 to increase proliferation in the range between about 1:500 and 1:10,000. MUF blockage was overcome at higher doses of IL-21. Addition of MU11 or isotype control antibody did not significantly affect IL-21 augmented proliferation of human T cells.

[0174] In Figure 3B, a PLP-specific mouse CD4<sup>+</sup> T cell line was stimulated with PLP peptide (1 µg/ml) and SJL mouse spleen cells. IL-21 in COS cell culture media (COS IL-21) was titrated as shown on the X-axis. "Cos Mock" is COS culture medium without IL-21. In indicated samples, MU11 (1 µg/ml) was added. After 72 hours, <sup>3</sup>H-thymidine was added, and proliferation was measured by incorporated radioactivity. As shown in Figure 3B, IL-21 increased the proliferation of stimulated mouse T cells. Addition MU11 blocked the ability of IL-21 to increase proliferation of mouse CD4<sup>+</sup> T cells. These data suggest that MU11 acts as a non-competitive inhibitor: it blocks IL-21's ability to increase proliferation even though it does not block IL-21 binding to the receptor.

[0175] In Figure 3C, purified CD8<sup>+</sup> mouse T cells were stimulated with tosyl-beads (Dynal, Great Neck, NY) coated with anti-CD3 antibody. IL-21 in COS cell culture media (COS s/n) was titrated as indicated in the X-axis. The sample labeled "no antibody" was used as a control. In indicated samples, MU11 was added at the marked concentration. After 72 hours, <sup>3</sup>H-thymidine was added, and proliferation was measured by incorporated radioactivity. As shown in Figure 3C, the addition of MU11 blocked, in a dose dependent manner, the ability of IL-21 to increase the proliferation of CD8<sup>+</sup> T cells.

**Example 9: Inhibition of Cell Proliferation by scFvs and IgGs**

[0176] Antibodies of the invention were tested in a cell-based assay for IL-21R antagonism. In one such experiment, various scFv phage clones that were isolated as described in Examples 1-3, were tested in a cell-based assay for their potency to inhibit cell-proliferation by blocking IL-21 binding to IL-21R. A hBaf3Mu-1 cell suspension expressing human IL21R was used for such an assay. hBaf3Mu-1 cells (Wyeth) were washed to remove traces of murine IL-3 from their growth medium and incubated for 2 hours in growth RPMI Glutamax with 10% fetal bovine serum without IL-3 at 37°C in a 5% CO<sub>2</sub> incubator. About 10,000 to 20,000 Baf3Mu-1 cells were added to each well of a 96-well tissue culture plate and then incubated with an scFv or IgG for 30 minutes at 37°C. IL-21 (Wyeth, Giralda Farms, NJ) was then added to a concentration of 5 ng/ml and the cells were incubated for 24 hours. Cells were then pulse-labeled with 0.1 mCi/well <sup>3</sup>H thymidine overnight at 37°C and subsequently harvested to measure thymidine incorporation as an indication of proliferation of cells. An alternative protocol, IL-21 was added to a concentration of 0.3 ng/ml and the cells were incubated for 48 hours. Cells were then warmed to room temperature, and 15

ml/well CellTiter-Glo (Promega, WI) were added. After mixing and a 10 minute incubation period, luminescence was measured on a Wallac MicroBeta 1450 TriLux counter (PerkinElmer, Boston, MA) as an indication of cell proliferation or viability.

[0177] An  $IC_{50}$  value (i.e., concentration of an antibody required for 50% competition) for each scFv can be determined by plotting a measure of cell proliferation, e.g., thymidine incorporation, against the log concentration of IL-21. Typically, the lower an  $IC_{50}$ , the better affinity an antibody has for IL-21R. In one experiment depicted in FIG. 4, MUF inhibited cell response to IL-21 with an  $IC_{50}$  of 268nM as an scFv and 3nM as an IgG. The  $IC_{50}$  values of other scFv clones were subsequently compared with that of MUF, as summarized in Table 4 below.

Table 4:  $IC_{50}$  values of various scFvs

Clone	$IC_{50}$ Value (nM) ScFv
MUF	140
hIL21R18	473
18A5	213
18G4	522
19F5	91
CP5G2	329

#### **Example 10: MUF Germlining**

[0178] Sequence data for the scFv clones was used to identify the nearest germline sequence for the heavy and light chain of the MUF clone using VBASE. Mutations were made using standard site directed mutagenesis techniques with the appropriate mutagenic primers. Mutation of scFv sequences was confirmed by sequence analysis. Germlined scFv and  $V_H$  and  $V_L$  domain sequences for MUF are set forth in SEQ ID NO:85, 83 and 84, respectively.

[0179] The MUF scFv germlined sequence was subsequently assayed for its ability to block IL-21 induced hBaf3Mu-1 cell line proliferation in the assay

described herein. There was no significant difference in the potency of the germlined MUF to block Baf3Mu-1 cell proliferation when compared to the non-germlined MUF scFv.

#### **Example 11: Epitope Competition Assay**

[0180] The scFv clones 18A5, 19F5 and 18G4 were further tested in an epitope competition assay in order to determine whether they bound the same or a different epitope than MUF. ScFv-containing periplasmic extracts were prepared as described above for the various clones. Final buffer used was 50 mM MOPS, pH 7.4, 0.5 mM EDTA, 0.5 M sorbitol. The scFv-containing crude periplasmic extracts were screened for the ability to inhibit the binding of biotinylated human IL-21R fusion protein (bio.hIL21R) to MuF IgG protein immobilized on plastic in a 96 well microtitre plate assay. Binding of bio.hIL21R was detected with Europium-labelled streptavidin and TRF detected using the DELFIA reagent kit (PerkinElmer). Positive clones were used in an epitope competition assay described herein.

[0181] The IC<sub>50</sub> values obtained for the various clones in the epitope competition assay are summarized in Table 5.

**Table 5: Epitope Competition Assay**

<b>Clone</b>	<b>IC<sub>50</sub> (nM)</b>
MUF IgG	0.4
negative control	0.0
18A5	114
18G4	1.4
19F5	weak inhibition

#### **Example 12: Treatment of Arthritis**

[0182] IL-21 was used to study its effect on cells from the synovial membrane, the membrane that lines the joints. Human fibroblast-like

synoviocytes (HFLS) (Cell Applications (San Diego, CA)) were isolated from synovial tissues of rheumatoid arthritis patients undergoing joint surgery. HFLS cells were cultured with human IL-21 for 48 hours, and the supernatants were removed and tested for chemokines MCP-1 (monocyte chemoattractant protein or CCL11), GRO (growth-regulated oncogene or CXC ligand 1), I-309 (CCL1), TARC (thymus and activation-regulated chemokine), Eotaxin, MDC (macrophage-derived chemokine or CCL22), LYMPH (lymphotactin or XCL1), SDF-1B (stromal derived factor-1B or CXC ligand 12), IP-10 (CXC ligand 10), I-TAC (T-cell attracting chemokine or CXC ligand 11), MG (monokine induced by interferon or CXC ligand 9), MP3B (macrophage inhibitory protein) and cytokines IFN- $\alpha$ , TNF- $\alpha$ , IL-6, and IL-8 by ELISA. These chemokines and cytokines are known in the art to promote inflammation through a number of activities, and increased concentrations in the joints caused by IL-21 exacerbates inflammation and RA.

[0183] As shown in Figures 5A-5D, IL-21 repeatedly increased HFLS secretion of chemokines MCP-1, GRO, 1-309, TARC, Eotaxin, MDC, LYMPH, SDF-1B, IP-10, I-TAC, MG, MP3B and cytokines cytokines IFN- $\alpha$ , TNF- $\alpha$ , IL-6, and IL-8. IL-21 was used to regulate the clinical progression of CIA (Collagen Induced Arthritis). CIA is the standard mouse and rat model for studying rheumatoid arthritis, see e.g., Holmdahl et al., (2002) Ageing Res. Rev., 1:135. On day 0, mice were injected with 100  $\mu$ g of Collagen Type II in complete Freund's adjuvant, and on day 21, the mice were boosted with 100  $\mu$ g of Collagen Type II in incomplete Freund's adjuvant. On day 21, the mice were also injected daily with 1  $\mu$ g of IL-21, and each day, the mice were examined for disease. The clinical signs were scored as follows: 0 = no swelling, 1 = 1 to 2

swollen digits or swollen ankle, 2 = more than 2 swollen digits or mild paw swelling, 3 = extensive paw swelling, and 4 = ankylosis of paw. As shown in Figure 5E, mice injected with PBS after the collagen injections progressively developed disease. Mice injected with IL-21 after the collagen injections progressively developed more severe disease. Because treatment with IL-21 specifically exacerbates CIA, treatment with anti-IL-21R antibodies is expected to suppress or delay CIA. Thus, since this model predicts treatment efficacy for RA, treatment with anti-IL-21R antibodies would also be expected to suppress or delay RA in humans.

#### **Example 13: Treatment of Transplant Rejection**

[0184] Transplant rejection is the immunological phenomenon where tissues from a donor are specifically “attacked” by immune cells of the host. One assay to study transplant rejection *in vitro* is the mixed lymphocyte reaction (MLR). In the MLR assay, “donor” cells and “host” cells are mixed *in vitro*, and the host cells become activated and proliferate. Between day 3 and 5, <sup>3</sup>H-thymidine is added, and proliferation is measured by incorporated radioactivity using a liquid scintillation counter.

[0185] In Figure 6, C57BL/6J mouse spleen cells (500,000) and irradiated BDF1 mouse spleen cells (500,000) were suspended in 200 µl of culture media in a microtiter plate well. Three duplicate wells were supplemented with different amounts of mouse IL-21. On day 4, <sup>3</sup>H-thymidine was added, and day 5, incorporated radioactivity was measured using a LKB 1205 liquid scintillation counter. Samples “0” and “mock” indicate cultures without IL-21. In the absence of IL-21, C57BL/6J cells proliferated modestly (~6000 rads). In the presence of IL-21, C57BL/6J cells proliferated more strongly (~28,000-38,000 rads).



Treatment with IL-21 augments the proliferation of C57BL/6J cells (the "host" or alloreactive cells), suggesting that IL-21 mediates MLR. Addition or treatment with anti-IL-21R antibodies is, therefore, expected to suppress or delay MLR and transplant rejection and related diseases (e.g., graft versus host disease).

[0186] The specification is most thoroughly understood in light of the teachings of the references cited within the specification, all of which are hereby incorporated by reference in their entirety. The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to limit the scope of the invention. The skilled artisan recognizes that many other embodiments are encompassed by the claimed invention and that it is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

CLAIMS

We claim:

1. An isolated antibody comprising an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO:1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139, wherein the antibody selectively binds to an IL-21 receptor.
2. An isolated antibody encoded by a nucleotide sequence which is at least 95% identical to a nucleotide sequence chosen from SEQ ID NO:10, 11, 12, 28, 29, 30, 56, 57, 58, 74, 75, 76, 92, 93, 94, 110, 111, 112, 128, 129, 130, 146, 147, and 148, wherein the antibody selectively binds to an IL-21 receptor.
3. An isolated antibody comprising a V<sub>H</sub> domain having an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO:1, 19, 47, 65, 83, 101, 119 and 137, and a V<sub>L</sub> domain having an amino acid sequence which is at least 95% identical to an amino acid sequence chosen from SEQ ID NO:2, 20, 48, 66, 84, 102, 120 and 138, wherein the antibody selectively binds to an IL-21 receptor.
4. An isolated antibody comprising a V<sub>H</sub> domain which comprises one or more CDRs chosen from SEQ ID NO:4, 5, 6, 22, 23, 24; 50, 51, 52, 68, 69, 70, 86, 87, 88, 104, 105, 106, 122, 123, 124, 140, 141, 142 and conservative amino acid substitutions thereof, wherein the antibody selectively binds to an IL-21 receptor.

5. An isolated antibody comprising a V<sub>L</sub> domain which comprises one or more CDRs chosen from SEQ ID NO:7, 8, 9, 25, 26, 27, 53, 54, 55, 71, 72, 73, 89, 90, 91, 107, 108, 109, 125, 126, 127, 143, 144, 145 and conservative amino acid substitutions thereof, wherein the antibody selectively binds to an IL-21 receptor.
6. An isolated antibody that competes with an antibody comprising an amino acid sequence chosen from SEQ ID NO:1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139, for binding to an IL-21 receptor.
7. An isolated antibody which binds the same epitope on an IL-21 receptor as an antibody comprising an amino acid sequence chosen from SEQ ID NO:1, 2, 3, 19, 20, 21, 47, 48, 49, 65, 66, 67, 83, 84, 85, 101, 102, 103, 119, 120, 121, 137, 138 and 139.
8. The antibody of claim 1, 2, 3, 4, 5, 6 or 7, wherein the antibody selectively binds to an amino acid sequence that is at least 95% identical to a sequence comprising at least 100 contiguous amino acids set forth in SEQ ID NO:43.
9. The antibody of claim 1, 2, 3, 4, 5, 6 or 7, wherein the antibody selectively binds the extracellular domain of human IL-21 receptor.
10. The antibody of claim 1, 2, 3, 4, 5, 6 or 7, wherein the antibody inhibits the binding of IL-21 to an IL-21 receptor.
11. The antibody of claim 1, 2, 3, 4, 5, 6 or 7, wherein the antibody is human.


12. The antibody of claim 1, 2, 3, 4, 5, 6 or 7, wherein the antibody is an IgG<sub>1</sub> antibody.
13. The antibody of claim 12, wherein the antibody is IgG<sub>1λ</sub> or IgG<sub>1κ</sub>.
14. An isolated antibody expressed by a host cell having ATCC Deposit Designation No. PTA-5030 or PTA-5031.
15. A pharmaceutical composition comprising the antibody of claim 1, 2, 3, 4, 5, 6 or 7.
16. An isolated nucleic acid encoding the antibody of claim 1, 2, 3, 4, 5, 6 or 7.
17. An expression vector comprising the nucleic acid of claim 16.
18. A host cell transformed with the vector of claim 17.
19. The host cell of claim 18, wherein the host cell is a bacteria, mammalian cell, yeast cell, plant cell, or an insect cell.
20. A host cell having ATCC Deposit Designation No. PTA-5030 or PTA-5031.
21. A method of producing an antibody that binds to an IL-21 receptor, comprising culturing the host cell of claim 20 under conditions that allow expression of the antibody, and isolating the antibody from the cell culture.
22. A method of generating an antibody or antigen-binding fragment that selectively binds an IL-21 receptor comprising:
  - (a) providing a repertoire of nucleic acids encoding a variable domain that either includes a CDR 1, 2 or 3 to be replaced or lacks a CDR1, 2 or 3 encoding region;

- (b) combining the repertoire with a donor nucleic acid encoding an amino acid sequence substantially as set forth in SEQ ID NO:4, 5, 6, 7, 8, 9, 22, 23, 24, 25, 26, 27, 50, 51, 52, 53, 54, 55, 68, 69, 70, 71, 72, 73, 86, 87, 88, 89, 90, 91, 104, 105, 106, 107, 108, 109, 122, 123, 124, 125, 126, 127, 140, 141, 142, 143, 144 or 145, such that the donor nucleic acid is inserted into the CDR1, 2 or 3 region in the repertoire, so as to provide a product repertoire of nucleic acids encoding a variable domain;
  - (c) expressing the nucleic acids of said product repertoire;
  - (d) selecting an antigen-binding fragment specific for the IL-21 receptor; and
  - (e) recovering the antigen-binding fragment or nucleic acid encoding the antigen-binding fragment.
23. An antibody produced by the method of claim 22.
24. The method of claim 22, further comprising the step of germlining.
25. A method of regulating an immune response comprising contacting a cell with the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 23, thereby regulating the immune response.
26. The method of claim 25, wherein the cell is a leukocyte or a synovial cell.
27. The method of claim 26, wherein the leukocyte is a T cell, a B cell, a NK cell, or a macrophage.
28. The method of claim 25, wherein the immune response comprises cell proliferation, cytolytic activity, cytokine secretion, or chemokine secretion.


29. A method of treating or preventing an immune cell-associated disorder, in a subject, comprising, administering to the subject the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 23, in an amount sufficient to inhibit or reduce immune cell activity in the subject, thereby treating or preventing the disorder.
30. The method of claim 29, wherein the immune cell-associated disorder is chosen from multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, transplant rejection, inflammatory bowel disease, psoriasis and Crohn's disease.
31. The method of claim 30, wherein the immune cell-associated disorder is chosen from rheumatoid arthritis, inflammatory bowel disease, Crohn's disease and psoriasis.
32. The method of claim 29, further comprising administering to the subject another therapeutic agent chosen from a cytokine inhibitor, a growth factor inhibitor, an immunosuppressant, an anti-inflammatory agent, a metabolic inhibitor, an enzyme inhibitor, a cytotoxic agent, and a cytostatic agent.
33. The method of claim 32, wherein the therapeutic agent is chosen from a TNF antagonist, an IL-12 antagonist, an IL-15 antagonist, an IL-17 antagonist, an IL-18 antagonist, an IL-22 antagonist, a T cell depleting agent, a B cell depleting agent, methotrexate, leflunomide, rapamycin, or an analog thereof, a Cox-2 inhibitor, a cPLA2 inhibitor, an NSAID, and a p38 inhibitor.
34. A method of treating or preventing a hyperproliferative disorder, in a subject, comprising administering to the subject the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 23, in an amount sufficient to inhibit or reduce

hyperproliferation of IL-21- and/or IL-21<sub>α</sub>receptor-responsive cells in the subject, and allowing the antibody to treat or prevent the disorder.


35. The method of claim 34, wherein the subject is a mammal.
36. The method of claim 34, wherein the subject is a human.
37. The method of claims 29, 30 or 33, wherein the antibody is administered in a range chosen from 1 µg/kg to 20 mg/kg, 1 µg/kg to 10 mg/kg, 1 µg/kg to 1 mg/kg, 10 µg/kg to 1 mg/kg, 10 µg/kg to 100 µg/kg, 100 µg to 1 mg/kg, and 500 µg/kg to 1 mg/kg.
38. A diagnostic kit comprising the antibody of claim 1, 2, 3, 4, 5, 6, 7 or 23.

**FIG. 1A**






**FIG. 1B**




**FIG. 1C**


3/12




**FIG. 2**



**FIG. 3A**





**FIG. 3C**




FIG. 4

8/12

CHEMOKINES




FIG. 5A






FIG. 5B







**FIG. 5D**



**FIG. 5C**

**FIG. 5E**



**FIG. 6**

12/2

1/48

## SEQUENCE LISTING

<110> WYETH  
 CAMBRIDGE ANTIBODY TECHNOLOGY

<120> ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES  
 THEREFOR

<130> 08702.0137-00304

<140>  
 <141>

<150> 60/454,336  
 <151> 2003-03-14

<160> 154

<170> PatentIn Ver. 3.2

<210> 1  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 1  
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15  
 Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr  
 20 25 30  
 Ser Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 Gly Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe  
 50 55 60  
 Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Gly Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Arg Gly Leu Arg Ser Asp Asp Thr Ala Val Tyr Trp Cys  
 85 90 95  
 Ala Thr Leu Ala Gly Pro Leu Asp Ser Trp Gly Gln Gly Thr Leu Val  
 100 105 110  
 Thr

<210> 2  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Gly Leu Gly Gln  
 1 5 10 15

2/48

Thr Val Thr Ile Thr Cys Gln Gly Gly Ser Leu Arg Gln Tyr Tyr Ala  
                     20                    25                    30

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Val Val Ile Tyr  
                     35                    40                    45

Gly Lys Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Thr  
           50                    55                    60

Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu  
       65                    70                    75                    80

Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asn His  
                     85                    90                    95

Pro Leu Tyr Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu Gly Glu  
                     100                    105                    110

Ser

<210> 3  
 <211> 253  
 <212> PRT  
 <213> Homo sapiens

<400> 3  
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
       1                    5                    10                    15

Ser Val Arg Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr  
                     20                    25                    30

Ser Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
                     35                    40                    45

Gly Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe  
       50                    55                    60

Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Gly Thr Ala Tyr  
       65                    70                    75                    80

Met Glu Leu Arg Gly Leu Arg Ser Asp Asp Thr Ala Val Tyr Trp Cys  
                     85                    90                    95

Ala Thr Leu Ala Gly Pro Leu Asp Ser Trp Gly Gln Gly Thr Leu Val  
                     100                    105                    110

Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
                     115                    120                    125

Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser  
       130                    135                    140

Val Gly Leu Gly Gln Thr Val Thr Ile Thr Cys Gln Gly Gly Ser Leu  
       145                    150                    155                    160

3/48

```

Arg Gln Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
      165                      170                      175
Val Val Val Ile Tyr Gly Lys Asn Lys Arg Pro Ser Gly Ile Pro Asp
      180                      185                      190
Arg Phe Ser Gly Thr Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr
      195                      200                      205
Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp
      210                      215                      220
Ser Ser Gly Asn His Pro Leu Tyr Val Phe Gly Ala Gly Thr Lys Leu
      225                      230                      235                      240
Thr Val Leu Gly Ala Ala Ala His His His His His His
      245                      250

```

```

<210> 4
<211> 5
<212> PRT
<213> Homo sapiens

```

```

<400> 4
Ile Tyr Ser Val Ser
  1                      5

```

```

<210> 5
<211> 17
<212> PRT
<213> Homo sapiens

```

```

<400> 5
Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe Gln
  1                      5                      10                      15

```

Gly

```

<210> 6
<211> 7
<212> PRT
<213> Homo sapiens

```

```

<400> 6
Leu Ala Gly Pro Leu Asp Ser
  1                      5

```

```

<210> 7
<211> 11
<212> PRT
<213> Homo sapiens

```

4/48

<400> 7  
 Gln Gly Gly Ser Leu Arg Gln Tyr Tyr Ala Ser  
       1                              5                              10

<210> 8  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

<400> 8  
 Gly Lys Asn Lys Arg Pro Ser  
       1                              5

<210> 9  
 <211> 13  
 <212> PRT  
 <213> Homo sapiens

<400> 9  
 Lys Ser Arg Asp Ser Ser Gly Asn His Pro Leu Tyr Val  
       1                              5                              10

<210> 10  
 <211> 339  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 caggtccagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgagggtc 60  
 tcctgcaagg cttctggagg caccttcaac atctatagtg tcagctgggt gcgacaggcc 120  
 cctggacagg ggcttgagtg gatgggaagg atcatcccta tgcgtgatat tgcaaactac 180  
 gcgcagaggt tccagggcag ggtcacactt accgcggaaca agtcctcggg gacagcctac 240  
 atggagttgc gcggcctgag atctgacgac acggcgcgtct attggtgtgc gacattggct 300  
 ggccccttgg actcctgggg ccagggcacc ctggtcacc 339

<210> 11  
 <211> 339  
 <212> DNA  
 <213> Homo sapiens

<400> 11  
 tcgtctgagc tgactcagga cccagctgtg tctgtgggct tgggacagac agtcacgata 60  
 acatgtcaag gcggcagcct cagacaatat tatgcaagtt ggtaccaaca gaagccagga 120  
 caggcccctg tggttgtcat ctatggtaaa aataagcgac cctcagggat cccagaccga 180  
 ttctctggca ccacctcagg caacacagct tccttgacca tcaactggggc tcaggcggaa 240  
 gatgaggctg actactattg taagtcccgg gacagcagtg gtaaccatcc cctttatgtc 300  
 ttcggagcag ggaccaagct gaccgtccta ggtgagtca 339

<210> 12  
 <211> 759  
 <212> DNA  
 <213> Homo sapiens

5/48

```

<400> 12
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgagggtc 60
tcctgcaagg cttctggagg caccttcaac atctatagtg tcagctgggt gcgacaggcc 120
cctggacagg ggcttgagtg gatgggaagg atcatcccta tgcgtgatat tgcaaaactac 180
gcgacagagg tccaggggcag ggtcacactt accgcggaca agtcctcggg gacagcctac 240
atggagtgtg gcggcctgag atctgacgac acggccgtct attggtgtgc gacattggct 300
ggccccttgg actcctgggg ccaggggcacc ctggtcaccg tctcgagtgg aggcggcggg 360
tcaggcggag gtggctctgg cggcggcgga agtgcacttt cttctgagct gactcaggac 420
ccagctgtgt ctgtgggctt gggacagaca gtcacgatca catgtcaagg cggcagcctc 480
agacaatatt atgcaagttg gtaccaacag aagccaggac aggccctgt ggttgtcatc 540
tatggtaaaa ataagcgacc ctccagggatc ccagaccgat tctctggcac cacctcaggc 600
aacacagctt ccttgaccat cactggggct caggcgggaag atgaggctga ctactattgt 660
aagtcgccgg acagcagtgg taaccatccc ctttatgtct tcggagctgg gaccaagctg 720
accgtcctag gtgcggccgc acatcatcat caccatcac 759

```

```

<210> 13
<211> 15
<212> DNA
<213> Homo sapiens

```

```

<400> 13
atctatagtg tcagc 15

```

```

<210> 14
<211> 51
<212> DNA
<213> Homo sapiens

```

```

<400> 14
aggatcatcc ctatgcgtga tattgcaaac tacgcgcaga ggttcaggg c 51

```

```

<210> 15
<211> 21
<212> DNA
<213> Homo sapiens

```

```

<400> 15
ttggctggcc ccttggactc c 21

```

```

<210> 16
<211> 33
<212> DNA
<213> Homo sapiens

```

```

<400> 16
caaggcggca gcctcagaca atattatgca agt 33

```

```

<210> 17
<211> 21
<212> DNA
<213> Homo sapiens

```



6/48

<400> 17  
ggtaaaaaata agcgaccctc a 21

<210> 18  
<211> 39  
<212> DNA  
<213> Homo sapiens

<400> 18  
aagtcccggg acagcagtgg taaccatccc ctttatgtc 39

<210> 19  
<211> 118  
<212> PRT  
<213> Homo sapiens

<400> 19  
Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
1 5 10 15  
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
20 25 30  
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
35 40 45  
Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
50 55 60  
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
65 70 75 80  
Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95  
Ala Arg His Gly Gln Tyr Ala Leu Asp Ile Trp Gly Gln Gly Thr Met  
100 105 110  
Val Thr Val Ser Ser Gly  
115

<210> 20  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 20  
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly  
1 5 10 15  
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp  
20 25 30  
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Val Leu Ile  
35 40 45

7/48

Tyr Lys Ala Ser Thr Leu Glu Ser Gly Val pro Ser Arg Phe Ser Gly  
     50                    55                    60  
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
     65                    70                    75                    80  
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Trp  
                     85                    90                    95  
 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg  
                     100                    105

<210> 21  
 <211> 242  
 <212> PRT  
 <213> Homo sapiens

<400> 21  
 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg  
     1                    5                    10                    15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                     20                    25                    30  
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
                     35                    40                    45  
 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val  
                     50                    55                    60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
     65                    70                    75                    80  
 Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys  
                     85                    90                    95  
 Ala Arg His Gly Gln Tyr Ala Leu Asp Ile Trp Gly Gln Gly Thr Met  
                     100                    105                    110  
 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
                     115                    120                    125  
 Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Pro Ser Thr Leu Ser  
     130                    135                    140  
 Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly  
     145                    150                    155                    160  
 Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro  
                     165                    170                    175  
 Lys Val Leu Ile Tyr Lys Ala Ser Thr Leu Glu Ser Gly Val Pro Ser  
                     180                    185                    190  
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser  
                     195                    200                    205

8/48

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr  
 210 215 220

Ser Thr Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg  
 225 230 235 240

Ala Ala

<210> 22  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 22  
 Ser Tyr Gly Met His  
 1 5

<210> 23  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 23  
 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys  
 1 5 10 15

Gly

<210> 24  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 24  
 His Gly Gln Tyr Ala Leu Asp Ile Trp  
 1 5

<210> 25  
 <211> 11  
 <212> PRT  
 <213> Homo sapiens

<400> 25  
 Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala  
 1 5 10

<210> 26  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

9/48

&lt;400&gt; 26

Lys Ala Ser Thr Leu Glu Ser

1

5

&lt;210&gt; 27

&lt;211&gt; 9'

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

Gln Gln Ser Tyr Ser Thr Pro Trp Thr

1

5

&lt;210&gt; 28

&lt;211&gt; 417

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

atgaaattct	tagtcaacgt	tgcccttggt	tttatgggtcg	tgtacatttc	ttacatctat	60
gccaggtgc	agctgggtgga	gtctggggga	ggcgtgggtcc	agcctgggag	gtccctgaga	120
ctctcctgtg	cagcctctgg	attcaccttc	agtagctatg	gcatgcactg	ggcccgccag	180
gctccaggca	aggggctgga	gtgggtggca	gttatatcat	atgatggaag	taataaatac	240
tatgcagact	ccgtgaaggg	ccgattcacc	atctccagag	acaattccaa	gaacacgctg	300
tatctgcaaa	tgaacagcct	gagagacgag	gacacggctg	tgtattactg	tgcgaggcat	360
ggtcagtacg	ctcttgatat	ctggggggcaa	gggacaatgg	tcaccgtctc	ctcaggt	417

&lt;210&gt; 29

&lt;211&gt; 381

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

atgggatgga	gctgtatcat	cctcttcttg	gtagcaacag	ctacaggcgc	gcactccgac	60
atccagatga	cccagtctcc	ttccaccctg	tctgcatctg	taggagacag	agtcaccatc	120
acttgccggg	ccagtcaggg	tattagtagc	tggttggcct	ggtatcagca	gaaaccaggg	180
agagccccta	aggtcttgat	ctataaggca	tctacttttag	aaagtggggg	cccataaagg	240
ttcagcggca	gtggatctgg	gacagatttc	actctcacca	tcagcagtc	gcaacctgaa	300
gattttgcaa	cttactactg	tcaacagagt	tacagtaccc	cgtggacggt	cggccaaggg	360
accaagctcg	agatcaaacy	t				381

&lt;210&gt; 30

&lt;211&gt; 728

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

gaggtgcagc	tggtgcagtc	tggggggaggc	gtggtccagc	ctgggagggtc	cctgagactc	60
tcctgtgcag	cctctggatt	caccttcagt	agctatggca	tgcactgggt	ccgccaggct	120
ccaggcaagg	ggctggagtg	ggctggcagtt	atatcatatg	atggaagtaa	taaatactat	180
gcagactccg	tgaagggccg	attcaccatc	tccagagaca	attccaagaa	cacgctgtat	240
ctgcaaataa	acagcctgag	agacgaggac	acggctgtgt	attactgtgc	gaggcatggg	300
cagtacgctc	ttgatatctg	ggggcaaggg	acaatgggtca	ccgtctcttc	aggtggaggc	360
ggttcaggcg	gaggtggcag	cgccgggtggc	ggatcggaca	tcgtgatgac	ccagtctcct	420

10/48

```

tccaccctgt ctgcatctgt aggagacaga gtcaccatca cttgccgggc cagtcagggt 480
attagtagct ggttggcctg gtatcagcag aaaccaggga gagcccctaa ggtcttgatc 540
tataaggcat ctactttaga aagtgggggc ccatacaaggc tcagcggcag tggatctggg 600
acagatttca ctctcaccat cagcagctctg caacctgaag attttgcaac ttactactgt 660
caacagagtt acagtacccc gtggacgttc ggccaaggga ccaagctgga gatcaaactg 720
gcggccgc
728

```

<210> 31  
 <211> 18  
 <212> DNA  
 <213> Homo sapiens

<400> 31  
 agtagctatg gcatgcac 18

<210> 32  
 <211> 51  
 <212> DNA  
 <213> Homo sapiens

<400> 32  
 gttatatcat atgatggaag taataaatac tatgcagact ccgtgaaggg c 51

<210> 33  
 <211> 30  
 <212> DNA  
 <213> Homo sapiens

<400> 33  
 aggcatgggc agtacgctct tgatatctgg 30

<210> 34  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

<400> 34  
 cgggccagtc agggatttag tagctggttg gcc 33

<210> 35  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens

<400> 35  
 aaggcatcta ctttagaaag t 21

<210> 36  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

11/48

&lt;400&gt; 36

caacagagtt acagtacccc gtggacg

27

&lt;210&gt; 37

&lt;211&gt; 329

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Gly
1				5					10					15	

Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe
		20						25					30		

Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly
		35					40					45			

Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu
	50					55					60				

Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr
	65				70					75					80

Ile	Cys	Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys
				85					90					95	

Val	Glu	Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro
			100					105						110	

Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys
		115					120					125			

Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val
		130				135						140			

Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr
	145				150					155					160

Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu
				165					170					175	

Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His
			180					185					190		

Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys
		195					200						205		

Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln
		210				215					220				

Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu
		225			230					235					240

Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro
				245					250					255	

12/48

Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn  
 260 265 270

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu  
 275 280 285

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val  
 290 295 300

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln  
 305 310 315 320

Lys Ser Leu Ser Leu Ser Pro Gly Lys  
 325

<210> 38  
 <211> 1599  
 <212> DNA  
 <213> Homo sapiens

<400> 38  
 gcctccacca agggcccatc ggtcttcccc ctggcaacct cctccaagag cacctctggg 60  
 ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggg gacgggtgtcg 120  
 tggaactcag gcgccctgac cagcggcgtc cacaccttcc cggctgtcct acagtctctca 180  
 ggactctact ccctcagcag cgtagtgaac gtgccctcca gcagcttggg caccagacc 240  
 tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttggtgag 300  
 agggcagcac agggagggag ggtgtctgct ggaagccagg ctgagcgtc ctgcctggac 360  
 gcatcccggc tatgcagccc cagtccaggg cagcaaggca ggccccgtct gcctcttcac 420  
 ccggaggcct ctgcccggcc cactcatgct caggggagagg gtcttctggc tttttcccca 480  
 ggctctgggc aggcacaggc taggtgcccc taaccaggc cctgcacaca aaggggcagg 540  
 tgctgggctc agacctgcca agagccatat ccgggaggac cctgcccctg acctaagccc 600  
 accccaaagg ccaaactctc cactccctca gctcggacac cttctctcct ccagattcc 660  
 agtaactccc aatcttctct ctccagagcc caaatcttgt gacaaaactc acacatgccc 720  
 accgtgcccc ggtaagccag ccagggcctc gccctccagc tcaaggcggg acaggtgcc 780  
 tagggtagcc tgcattccagg gacaggcccc agccgggtgc tgacacgtcc acctccatct 840  
 ctctctcagc acctgaactc ctgggggggac cgtcagttct cctcttcccc ccaaaacca 900  
 aggacaccct catgatctcc cggaccctg aggtcacatg cgtgggtggg gacgtgagcc 960  
 acgaagacct tgaggtcaag ttcaactggt acgtggacgg cgtggagggt cataatgcca 1020  
 agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg 1080  
 tcctgcacca ggactggctg aatggcaagg agtacaagt caaggtctcc aacaaagccc 1140  
 tcccagcccc catcgagaaa accatctcca aagccaaagg tgggaccgt ggggtgcgag 1200  
 ggccacatgg acagaggccg gctcggccca ccctctgccc tgagagtgaac cgctgtacca 1260  
 acctctgtcc ctacagggca gccccgagaa ccacaggtgt acaccctgcc cccatcccgg 1320  
 gatgagctga ccaagaacca ggtcagcctg acctgcctgg tcaaaggctt ctatcccagc 1380  
 gacatcgccg tggagtggga gagcaatggg cagccggaga acaactacaa gaccacgcct 1440  
 cccgtgctgg actccgacgg ctcttctctc ctctacagca agctcaccgt ggacaagagc 1500  
 aggtggcagc aggggaacgt cttctcatgc tccgtgatgc atgaggctct gcacaaccac 1560  
 tacacgcaga agagcctctc cttaagtccg ggaaaataa 1599

<210> 39  
 <211> 106  
 <212> PRT  
 <213> Homo sapiens

13/48

&lt;400&gt; 39

```

Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
 1              5              10              15
Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp
              20              25              30
Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro
              35              40              45
Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn
              50              55              60
Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys
              65              70              75              80
Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val
              85              90              95
Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
              100              105

```

&lt;210&gt; 40

&lt;211&gt; 321

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

```

ggtcagccca aggtgcccc ctcggtcact ctgttcccgc cctcctctga ggagcttcaa 60
gccaacaagg ccacactggg gtgtctcata agtgacttct acccgggagc cgtgacagtg 120
gcctggaagg cagatagcag ccccgtaag gcgggagtgg agaccaccac accctccaaa 180
caaagcaaca acaagtacgc ggccagcagc tacctgagcc tgacgcctga gcagtggaag 240
tcccacagaa gctacagctg ccaggtcacg catgaaggga gcaccgtgga gaagacagtg 300
gccctacag aatgttcata g                                     321

```

&lt;210&gt; 41

&lt;211&gt; 105

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

```

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
 1              5              10              15
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
              20              25              30
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
              35              40              45
Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
              50              55              60
Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
              65              70              75              80

```



Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val  
85 90 95

```
<210> 42
<211> 324
<212> DNA
<213> Homo sapiens
```

```
<210> 43
<211> 538
<212> PRT
<213> Homo sapiens
```

<400> 43																
Met	Pro	Arg	Gly	Trp	Ala	Ala	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Gln	Gly	
1				5					10					15		
Gly	Trp	Gly	Cys	Pro	Asp	Leu	Val	Cys	Tyr	Thr	Asp	Tyr	Leu	Gln	Thr	
			20					25					30			
Val	Ile	Cys	Ile	Leu	Glu	Met	Trp	Asn	Leu	His	Pro	Ser	Thr	Leu	Thr	
		35					40					45				
Leu	Thr	Trp	Gln	Asp	Gln	Tyr	Glu	Glu	Leu	Lys	Asp	Glu	Ala	Thr	Ser	
	50					55					60					
Cys	Ser	Leu	His	Arg	Ser	Ala	His	Asn	Ala	Thr	His	Ala	Thr	Tyr	Thr	
65					70					75					80	
Cys	His	Met	Asp	Val	Phe	His	Phe	Met	Ala	Asp	Asp	Ile	Phe	Ser	Val	
				85					90					95		
Asn	Ile	Thr	Asp	Gln	Ser	Gly	Asn	Tyr	Ser	Gln	Glu	Cys	Gly	Ser	Phe	
			100					105					110			
Leu	Leu	Ala	Glu	Ser	Ile	Lys	Pro	Ala	Pro	Pro	Phe	Asn	Val	Thr	Val	
		115					120					125				
Thr	Phe	Ser	Gly	Gln	Tyr	Asn	Ile	Ser	Trp	Arg	Ser	Asp	Tyr	Glu	Asp	
	130					135					140					
Pro	Ala	Phe	Tyr	Met	Leu	Lys	Gly	Lys	Leu	Gln	Tyr	Glu	Leu	Gln	Tyr	
145					150					155					160	

15/48

Arg	Asn	Arg	Gly	Asp	Pro	Trp	Ala	Val	Ser	Pro	Arg	Arg	Lys	Leu	Ile
				165					170					175	
Ser	Val	Asp	Ser	Arg	Ser	Val	Ser	Leu	Leu	Pro	Leu	Glu	Phe	Arg	Lys
			180					185					190		
Asp	Ser	Ser	Tyr	Glu	Leu	Gln	Val	Arg	Ala	Gly	Pro	Met	Pro	Gly	Ser
		195					200					205			
Ser	Tyr	Gln	Gly	Thr	Trp	Ser	Glu	Trp	Ser	Asp	Pro	Val	Ile	Phe	Gln
	210					215					220				
Thr	Gln	Ser	Glu	Glu	Leu	Lys	Glu	Gly	Trp	Asn	Pro	His	Leu	Leu	Leu
225					230					235					240
Leu	Leu	Leu	Leu	Val	Ile	Val	Phe	Ile	Pro	Ala	Phe	Trp	Ser	Leu	Lys
				245					250					255	
Thr	His	Pro	Leu	Trp	Arg	Leu	Trp	Lys	Lys	Ile	Trp	Ala	Val	Pro	Ser
			260					265					270		
Pro	Glu	Arg	Phe	Phe	Met	Pro	Leu	Tyr	Lys	Gly	Cys	Ser	Gly	Asp	Phe
		275					280					285			
Lys	Lys	Trp	Val	Gly	Ala	Pro	Phe	Thr	Gly	Ser	Ser	Leu	Glu	Leu	Gly
	290					295					300				
Pro	Trp	Ser	Pro	Glu	Val	Pro	Ser	Thr	Leu	Glu	Val	Tyr	Ser	Cys	His
305					310					315					320
Pro	Pro	Arg	Ser	Pro	Ala	Lys	Arg	Leu	Gln	Leu	Thr	Glu	Leu	Gln	Glu
			325						330					335	
Pro	Ala	Glu	Leu	Val	Glu	Ser	Asp	Gly	Val	Pro	Lys	Pro	Ser	Phe	Trp
		340						345					350		
Pro	Thr	Ala	Gln	Asn	Ser	Gly	Gly	Ser	Ala	Tyr	Ser	Glu	Glu	Arg	Asp
		355					360					365			
Arg	Pro	Tyr	Gly	Leu	Val	Ser	Ile	Asp	Thr	Val	Thr	Val	Leu	Asp	Ala
	370					375					380				
Glu	Gly	Pro	Cys	Thr	Trp	Pro	Cys	Ser	Cys	Glu	Asp	Asp	Gly	Tyr	Pro
385					390					395					400
Ala	Leu	Asp	Leu	Asp	Ala	Gly	Leu	Glu	Pro	Ser	Pro	Gly	Leu	Glu	Asp
			405						410					415	
Pro	Leu	Leu	Asp	Ala	Gly	Thr	Thr	Val	Leu	Ser	Cys	Gly	Cys	Val	Ser
			420					425					430		
Ala	Gly	Ser	Pro	Gly	Leu	Gly	Gly	Pro	Leu	Gly	Ser	Leu	Leu	Asp	Arg
		435					440					445			
Leu	Lys	Pro	Pro	Leu	Ala	Asp	Gly	Glu	Asp	Trp	Ala	Gly	Gly	Leu	Pro
	450					455					460				

16/48

Trp Gly Gly Arg Ser Pro Gly Gly Val Ser Glu Ser Glu Ala Gly Ser  
465 470 475 480

Pro Leu Ala Gly Leu Asp Met Asp Thr Phe Asp Ser Gly Phe Val Gly  
485 490 495

Ser Asp Cys Ser Ser Pro Val Glu Cys Asp Phe Thr Ser Pro Gly Asp  
500 505 510

Glu Gly Pro Pro Arg Ser Tyr Leu Arg Gln Trp Val Val Ile Pro Pro  
515 520 525

Pro Leu Ser Ser Pro Gly Pro Gln Ala Ser  
530 535

&lt;210&gt; 44

&lt;211&gt; 2665

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

```

gtcgactgga ggcccagctg cccgtcatca gaggacagag tcttatgaca gcctgattgg 60
tgactcgggc tgggtgtgga ttctaccccc aggcctctgc ctgctttctc agaccctcat 120
ctgtcacccc cacgctgaac ccagctgcca cccccagaag cccatcagac tgcccccagc 180
acacggaatg gattttctgag aaagaagccg aaacagaagg cccgtgggag tcagcatgcc 240
gcgtaggctgg gccgccccct tgctcctgct gctgctccag ggaggctggg gctgccccga 300
cctcgtctgc tacaccgatt acctccagac ggtcatctgc atcctggaaa tgtggaacct 360
ccaccccagc acgctcacc cttacctggca agaccagtat gaagagctga aggacgaggc 420
cacctcctgc agcctccaca ggtcggccca caatgccacg catgccacct acacctgcca 480
catggatgta ttccacttca tggccgacga cattttcagt gtcaacatca cagaccagtc 540
tggcaactac tcccaggagt gtggcagctt tctcctggct gagagcatca agccggctcc 600
ccctttcaac gtgactgtga ccttctcagg acagtataat atctcctggc gctcagatta 660
cgaagaccct gccttctaca tgctgaaggg caagcttcag tatgagctgc agtacaggaa 720
ccggggagac ccctgggctg tgagtcogag gagaaagctg atctcagtg actcaagaag 780
tgtctccctc ctccccctgg agttccgcaa agactcgagc tatgagctgc aggtgcgggc 840
agggcccatg cctggctcct cctaccaggg gacctggagt gaatggagtg acccgggtcat 900
ctttcagacc cagtcagagg agttaaagga aggctggaac cctcacctgc tgcttctcct 960
cctgcttgct atagtcttca ttctgcctt ctggagcctg aagacccatc cattgtggag 1020
gctatggaag aagatatggg ccgtccccag ccctgagcgg ttcttcatgc ccctgtacaa 1080
gggctgcagc ggagacttca agaaatgggt ggggtgcacc ttactggct ccagcctgga 1140
cctgggacc tggagcccag aggtgccctc caccctggag gtgtacagct gccaccacc 1200
acggagcccg gccaaagagg tgcagctcac ggagctacaa gaaccagcag agctgggtgga 1260
gtctgacggg gtgcccagc ccagcttctg gccgacagcc cagaactcgg ggggctcagc 1320
ttacagttag gagaggatc ggccatacgg cctgggtgtcc attgacacag tgactgtgct 1380
agatgcagag gggccatgca cctggccctg cagctgtgag gatgacggct acccagccct 1440
ggacctggat gctggcctgg agcccagccc aggcctagag gaccactct tggatgcagg 1500
gaccacagtc ctgtcctgtg gctgtgtctc agctggcagc cctgggctag gagggccct 1560
gggaagcctc ctggacagac taaagccacc ccttgagat ggggaggact gggctggggg 1620
actgccctgg ggtggccggg cacttgaggg ggtctcagag agtgaggcgg gctcaccct 1680
ggccggcctg gatatggaca cgtttgacag tggctttgtg ggctctgact gcagcagccc 1740
tgtggagtgt gacttcacca gccccggggg cgaaggaccc ccccgagct acctccgcca 1800
gtgggtggtc attcctccgc cactttcgag ccctggaccc caggccagct aatgaggctg 1860
actggatgtc cagagctggc caggccactg ggccttgagc cagagacaag gtcacctggg 1920
ctgtgatgtg aagacacctg cagcctttgg tctcctggat gggcctttga gcctgatgtt 1980
tacagtgtct gtgtgtgtgt gtgcatatgt gtgtgtgtgc atatgcatgt gtgtgtgtgt 2040
gtgtgtctta ggtgcgcagt ggcagtgcca cgtgtgtgtg tgattgcacg tgctgtggg 2100
cctgggataa tgcccatggt actccatgca ttcacctgcc ctgtgcatgt ctggactcac 2160

```

17/48

```

ggagctcacc catgtgcaca agtgtgcaca gtaaactgtgt ttgtgggtcaa cagatgacaa 2220
cagccgtcct ccctcctagg gtcttgtgtt gcaagttgggt ccacagcatc tccgggggctt 2280
tgtgggatca gggcattgcc tgtgactgag gcgagagccca gccctccagc gtctgcctcc 2340
aggagctgca agaagtccat attgttcttt atcacctgcc aacaggaagc gaaaggggat 2400
ggagtgaacc catggtgacc tcgggaatgg caattttttg ggcgggcccct ggacgaaggt 2460
ctgaatcccg actctgatac cttctggctg tgctacctga gccaagtcgc ctcccctctc 2520
tggtgctagag tttccttata cagacagtgg ggaaggcatg acacacctgg gggaaattgg 2580
cgatgtcacc cgtgtacggg acgcagccca gagcagacc tcaataaacg tcagcttcct 2640
tcaaaaaaaaa aaaaaaaaaat ctaga 2665

```

&lt;210&gt; 45

&lt;211&gt; 529

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 45

```

Met Pro Arg Gly Pro Val Ala Ala Leu Leu Leu Leu Ile Leu His Gly
  1              5              10              15

Ala Trp Ser Cys Leu Asp Leu Thr Cys Tyr Thr Asp Tyr Leu Trp Thr
      20              25              30

Ile Thr Cys Val Leu Glu Thr Arg Ser Pro Asn Pro Ser Ile Leu Ser
      35              40              45

Leu Thr Trp Gln Asp Glu Tyr Glu Glu Leu Gln Asp Gln Glu Thr Phe
  50              55              60

Cys Ser Leu His Arg Ser Gly His Asn Thr Thr His Ile Trp Tyr Thr
  65              70              75              80

Cys His Met Arg Leu Ser Gln Phe Leu Ser Asp Glu Val Phe Ile Val
      85              90              95

Asn Val Thr Asp Gln Ser Gly Asn Asn Ser Gln Glu Cys Gly Ser Phe
    100              105              110

Val Leu Ala Glu Ser Ile Lys Pro Ala Pro Pro Leu Asn Val Thr Val
    115              120              125

Ala Phe Ser Gly Arg Tyr Asp Ile Ser Trp Asp Ser Ala Tyr Asp Glu
    130              135              140

Pro Ser Asn Tyr Val Leu Arg Gly Lys Leu Gln Tyr Glu Leu Gln Tyr
    145              150              155              160

Arg Asn Leu Arg Asp Pro Tyr Ala Val Arg Pro Val Thr Lys Leu Ile
    165              170              175

Ser Val Asp Ser Arg Asn Val Ser Leu Leu Pro Glu Glu Phe His Lys
    180              185              190

Asp Ser Ser Tyr Gln Leu Gln Val Arg Ala Ala Pro Gln Pro Gly Thr
    195              200              205

Ser Phe Arg Gly Thr Trp Ser Glu Trp Ser Asp Pro Val Ile Phe Gln
    210              215              220

```

18/48

Thr	Gln	Ala	Gly	Glu	Pro	Glu	Ala	Gly	Trp	Asp	Pro	His	Met	Leu	Leu	225	230	235	240
Leu	Leu	Ala	Val	Leu	Ile	Ile	Val	Leu	Val	Phe	Met	Gly	Leu	Lys	Ile	245	250	255	
His	Leu	Pro	Trp	Arg	Leu	Trp	Lys	Lys	Ile	Trp	Ala	Pro	Val	Pro	Thr	260	265	270	
Pro	Glu	Ser	Phe	Phe	Gln	Pro	Leu	Tyr	Arg	Glu	His	Ser	Gly	Asn	Phe	275	280	285	
Lys	Lys	Trp	Val	Asn	Thr	Pro	Phe	Thr	Ala	Ser	Ser	Ile	Glu	Leu	Val	290	295	300	
Pro	Gln	Ser	Ser	Thr	Thr	Thr	Ser	Ala	Leu	His	Leu	Ser	Leu	Tyr	Pro	305	310	315	320
Ala	Lys	Glu	Lys	Lys	Phe	Pro	Gly	Leu	Pro	Gly	Leu	Glu	Glu	Gln	Leu	325	330	335	
Glu	Cys	Asp	Gly	Met	Ser	Glu	Pro	Gly	His	Trp	Cys	Ile	Ile	Pro	Leu	340	345	350	
Ala	Ala	Gly	Gln	Ala	Val	Ser	Ala	Tyr	Ser	Glu	Glu	Arg	Asp	Arg	Pro	355	360	365	
Tyr	Gly	Leu	Val	Ser	Ile	Asp	Thr	Val	Thr	Val	Gly	Asp	Ala	Glu	Gly	370	375	380	
Leu	Cys	Val	Trp	Pro	Cys	Ser	Cys	Glu	Asp	Asp	Gly	Tyr	Pro	Ala	Met	385	390	395	400
Asn	Leu	Asp	Ala	Gly	Arg	Glu	Ser	Gly	Pro	Asn	Ser	Glu	Asp	Leu	Leu	405	410	415	
Leu	Val	Thr	Asp	Pro	Ala	Phe	Leu	Ser	Cys	Gly	Cys	Val	Ser	Gly	Ser	420	425	430	
Gly	Leu	Arg	Leu	Gly	Gly	Ser	Pro	Gly	Ser	Leu	Leu	Asp	Arg	Leu	Arg	435	440	445	
Leu	Ser	Phe	Ala	Lys	Glu	Gly	Asp	Trp	Thr	Ala	Asp	Pro	Thr	Trp	Arg	450	455	460	
Thr	Gly	Ser	Pro	Gly	Gly	Gly	Ser	Glu	Ser	Glu	Ala	Gly	Ser	Pro	Pro	465	470	475	480
Gly	Leu	Asp	Met	Asp	Thr	Phe	Asp	Ser	Gly	Phe	Ala	Gly	Ser	Asp	Cys	485	490	495	
Gly	Ser	Pro	Val	Glu	Thr	Asp	Glu	Gly	Pro	Pro	Arg	Ser	Tyr	Leu	Arg	500	505	510	

19/48

Gln Trp Val Val Arg Thr Pro Pro Pro Val Asp Ser Gly Ala Gln Ser  
 515 520 525

Ser

&lt;210&gt; 46

&lt;211&gt; 2628

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 46

```

gtcgacgcgg cgggtaccagc tgtctgcccc cttctcctgt ggtgtgcctc acggtcactt 60
gcttgtctga ccgcaagtct gcccatccct ggggcagcca actggcctca gcccgtgccc 120
caggcgtgcc ctgtctctgt ctggctgccc cagccctact gtcttcctct gtgtaggctc 180
tgcccagatg cccggctggg cctcagcctc aggactatct cagcagtgc tcccctgatt 240
ctggacttgc acctgactga actcctgccc acctcaaacc ttcacctccc accaccacca 300
ctccgagtcc cgctgtgact cccacgcccc ggagaccacc caagtgcccc agcctaaaga 360
atggctttct gagaaagacc ctgaaggagt aggtctggga cacagcatgc cccggggccc 420
actggctgcc ttactcctgc tgattctcca tggagcttgg agctgcctgg acctcacttg 480
ctacactgac tacctctgga ccatcacctg tgcctggag acacggagcc ccaaccccag 540
catactcagt ctcacctggc aagatgaata tgaggaactt caggaccaag agacctctct 600
cagcctacac aggtctggcc acaacaccac acatatatgg tacacgtgcc atatgcgctt 660
gtctcaattc ctgtccgatg aagttttcat tgtcaatgtg acggaccagt ctggcaacaa 720
ctcccaagag tgtggcagct ttgtcctggc tgagagcatc aaaccagctc cccccttgaa 780
cgtgactgtg gccttctcag gacgctatga tatctcctgg gactcagctt atgacgaacc 840
ctccaactac gtgctgaggg gcaagctaca atatgagctg cagtatcgga acctcagaga 900
cccctatgct gtgaggccgg tgaccaagct gatctcagtg gactcaagaa acgtctctct 960
tctccctgaa gagttccaca aagattctag ctaccagctc cagggtgcggg cagcgccctca 1020
gccaggcact tcattcaggg ggacctggag tgagtggagt gaccccgctc tctttcagac 1080
ccaggctggg gagcccagg caggctggga cctcacatg ctgctgctcc tggctgtctt 1140
gatcattgtc ctggttttca tgggtctgaa gatccacctg ccttggaggc tatggaaaaa 1200
gatatgggca ccagtgccca cccctgagag tttcttccag cccctgtaca gggagcacag 1260
cgggaaactc aagaaatggg ttaatacccc tttcacggcc tccagcatag agttgggtgc 1320
acagagttcc acaacaacat cagccttaca tctgtcattg tatccagcca aggagaagaa 1380
gttcccgggg ctgccgggtc tgggaagagca actggagtgt gatggaatgt ctgagcctgg 1440
tactgggtgc ataatccctc tggcagctgg ccaagcggtc tcagcctaca gtgaggagag 1500
agaccggcca tatggctctg tgtccattga cacagtgcgt gtgggagatg cagagggcct 1560
gtgtgtctgg cctgtagct gtgaggatga tggctatcca gccatgaacc tggatgctgg 1620
ccgagagtct ggccctaatt cagaggatct gctcttggtc acagaccctg cttttctgtc 1680
ttgcggtgtg gtctcaggta gtggctctcag gcttggaggc tcccaggca gcctactgga 1740
caggttgagg ctgtcatttg caaaggaagg ggactggaca gcagacccaa cctggagaac 1800
tgggtcccca ggagggggct ctgagagtga agcagggttc cccctgggtc tggacatgga 1860
cacatttgac agtggctttg caggttcaga ctgtggcagc cccgtggaga ctgatgaagg 1920
accccctcga agctatctcc gccagtgggt ggtcaggacc cctccacctg tggacagtgg 1980
agcccagagc agctagcata taataaccag ctatagttag aagaggcctc tgagcctggc 2040
atttacagtg tgaacatgta ggggtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg 2100
tgtgtgtgtg tgtgtgtgtg tgtcttgggt tgtgtgttag cacatccatg ttgggatttg 2160
gtctgttgct atgtattgta atgtctaaat ctctacccaa agttctaggc ctacgagtga 2220
attctcatgt ttacaaactt gctgtgtaaa ccttgttctc taatttaata ccattgggta 2280
aataaaattg gctgcaacca attactggag ggattagagg tagggggctt ttgagttacc 2340
tgttttggaga tggagaagga gagaggagag accaagagga gaaggaggaa ggagaggaga 2400
ggagaggaga ggagaggaga ggagaggaga ggagaggaga ggctgccgtg 2460
aggggagagg gaccatgagc ctgtggccag gagaaacagc aagtatctgg ggtacactgg 2520
tgaggaggtg gccaggccag cagttagaag agtagattag gggtgacctc cagtatttgt 2580
caaagccaat taaaataaca aaaaaaaaaa aaaagcggcc gctctaga 2628

```

20/48

<210> 47  
 <211> 116  
 <212> PRT  
 <213> Homo sapiens

<400> 47  
 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr  
 20 25 30  
 Ser Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 Gly Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe  
 50 55 60  
 Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Gly Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Trp Cys  
 85 90 95  
 Ala Thr Leu Ala Gly Pro Leu Asp Ser Trp Gly Arg Gly Thr Leu Val  
 100 105 110  
 Thr Val Ser Ser  
 115

<210> 48  
 <211> 109  
 <212> PRT  
 <213> Homo sapiens

<400> 48  
 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln  
 1 5 10 15  
 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala  
 20 25 30  
 Ser Trp Tyr Gln Lys Arg Pro Gly Gln Ala Pro Ile Leu Val Met Tyr  
 35 40 45  
 Gly Arg Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser  
 50 55 60  
 Phe Ser Gly Asn Arg Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu  
 65 70 75 80  
 Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Ala Tyr Ser Gly Asn Leu  
 85 90 95  
 Val Glu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 100 105

21/48

<210> 49  
 <211> 242  
 <212> PRT  
 <213> Homo sapiens

<400> 49

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
 1 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr  
 20 25 30  
 Ser Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 Gly Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe  
 50 55 60  
 Gln Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Ser Gly Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Trp Cys  
 85 90 95  
 Ala Thr Leu Ala Gly Pro Leu Asp Ser Trp Gly Arg Gly Thr Leu Val  
 100 105 110  
 Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
 115 120 125  
 Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser  
 130 135 140  
 Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu  
 145 150 155 160  
 Arg Thr Tyr Tyr Ala Ser Trp Tyr Gln Lys Arg Pro Gly Gln Ala Pro  
 165 170 175  
 Ile Leu Val Met Tyr Gly Arg Asn Lys Arg Pro Ser Gly Ile Pro Asp  
 180 185 190  
 Arg Phe Ser Gly Ser Phe Ser Gly Asn Arg Ala Ser Leu Thr Ile Thr  
 195 200 205  
 Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Ala  
 210 215 220  
 Tyr Ser Gly Asn Leu Val Glu Phe Gly Gly Gly Thr Lys Leu Thr Val  
 225 230 235 240  
 Leu Gly

<210> 50  
 <211> 5  
 <212> PRT



22/48

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

Ile Tyr Ser Val Ser  
1 5

&lt;210&gt; 51

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe Gln  
1 5 10 15

Gly

&lt;210&gt; 52

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

Leu Ala Gly Pro Leu Asp Ser  
1 5

&lt;210&gt; 53

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 53

Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala Ser  
1 5 10

&lt;210&gt; 54

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

Gly Arg Asn Lys Arg Pro Ser  
1 5

&lt;210&gt; 55

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 55

Lys Ser Arg Ala Tyr Ser Gly Asn Leu Val Glu  
1 5 10

23/48

<210> 56  
 <211> 348  
 <212> DNA  
 <213> Homo sapiens

<400> 56  
 gaggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60  
 tcctgcaagg cttctggagg caccttcaac atctatagtg tcagctgggt gcgacaggcc 120  
 cctggacagg ggcttgagtg gatgggaagg atcatcccta tgcgtgatat tgcaaaactac 180  
 gcgacagagg tccagggcag ggtcacactt accgcggaca agtcctcggg gacagcctac 240  
 atggagttgc gcagcctgag atctgacgac acggccgtct attggtgtgc gacattggct 300  
 ggccccttgg actcctgggg cagaggaacc ctggtcaccg tctcgagt 348

<210> 57  
 <211> 327  
 <212> DNA  
 <213> Homo sapiens

<400> 57  
 tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60  
 acatgccagg gagacagcct cagaacttat tatgcgagct ggtaccagaa gaggccagga 120  
 caggccccta tacttgtcat gtatggtaga aataagaggc cctcagggat ccagaccga 180  
 ttctctggct cttctcagg gaacagagct tccttgacca tcaactggggc tcaggcggaa 240  
 gatgaggctg actattactg taaatcccgg gcctacagtg gtaacctcgt agaattcggc 300  
 ggagggacca agctgaccgt cctaggt 327

<210> 58  
 <211> 726  
 <212> DNA  
 <213> Homo sapiens

<400> 58  
 gaggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60  
 tcctgcaagg cttctggagg caccttcaac atctatagtg tcagctgggt gcgacaggcc 120  
 cctggacagg ggcttgagtg gatgggaagg atcatcccta tgcgtgatat tgcaaaactac 180  
 gcgacagagg tccagggcag ggtcacactt accgcggaca agtcctcggg gacagcctac 240  
 atggagttgc gcagcctgag atctgacgac acggccgtct attggtgtgc gacattggct 300  
 ggccccttgg actcctgggg cagaggaacc ctggtcaccg tctcgagtgg aggcggcggg 360  
 tcaggcggag gtggctctgg cgggtggcggg agtgcacttt cttctgagct gactcaggac 420  
 cctgctgtgt ctgtggcctt gggacagaca gtcaggatca catgccaggg agacagcctc 480  
 agaacttatt atgcgagctg gtaccagaag aggccaggac agggccctat acttgtcatg 540  
 tatggtagaa ataagaggcc ctacagggat ccagaccgat tctctggctc cttctcaggg 600  
 aacagagctt ccttgaccat cactggggct caggcgggaag atgaggctga ctattactgt 660  
 aaatcccggg cctacagtgg taacctcgta gaattcggcg gagggaccaa gctgaccgtc 720  
 ctaggt 726

<210> 59  
 <211> 15  
 <212> DNA  
 <213> Homo sapiens

<400> 59  
 atctatagtg tcagc

15

24/48

<210> 60  
<211> 51  
<212> DNA  
<213> Homo sapiens

<400> 60  
aggatcatcc ctatgcgtga tattgcaaac tacgcgcaga gggtccaggg c 51

<210> 61  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 61  
ttggctggcc ccttggaactc c 21

<210> 62  
<211> 33  
<212> DNA  
<213> Homo sapiens

<400> 62  
caggagagaca gcctcagaac ttattatgcg agc 33

<210> 63  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 63  
ggtagaaata agaggccctc a 21

<210> 64  
<211> 33  
<212> DNA  
<213> Homo sapiens

<400> 64  
aaatcccggg cctacagtgg taacctcgta gaa 33

<210> 65  
<211> 118  
<212> PRT  
<213> Homo sapiens

<400> 65  
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Thr Ser Glu  
1 5 10 15  
Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly  
20 25 30

25/48

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp  
                   35                                  40                                  45  
 Ile Gly Ser Ile Ser His Thr Gly Asn Thr Tyr Tyr Asn Pro Pro Leu  
           50                                  55                                  60  
 Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser  
       65                                  70                                  75                                  80  
 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys  
                                   85                                  90                                  95  
 Ala Arg Gly Gly Gly Ile Ser Arg Pro Glu Tyr Trp Gly Lys Gly Thr  
                   100                                  105                                  110  
 Leu Val Thr Val Ser Ser  
           115

<210> 66  
 <211> 110  
 <212> PRT  
 <213> Homo sapiens

<400> 66  
 Ser Ser Glu Leu Thr Gln Asp Pro Pro Val Ser Val Ala Leu Gly Gln  
   1                  5                                  10                                  15  
 Thr Val Thr Leu Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala  
                   20                                  25                                  30  
 Ser Trp Tyr Gln Gln Lys Ser Gly Gln Ala Pro Ile Leu Leu Tyr  
           35                                  40                                  45  
 Gly Lys His Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser  
       50                                  55                                  60  
 Thr Ser Gly Asp Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu  
       65                                  70                                  75                                  80  
 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn Pro  
                   85                                  90                                  95  
 His Val Leu Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Ser  
           100                                  105                                  110

<210> 67  
 <211> 245  
 <212> PRT  
 <213> Homo sapiens

<400> 67  
 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Thr Ser Glu  
   1                  5                                  10                                  15  
 Thr Leu Ser Leu Thr Cys Ala Val Ser Gly Tyr Ser Ile Ser Ser Gly  
           20                                  25                                  30

26/48

Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp  
                   35                                  40                                  45  
 Ile Gly Ser Ile Ser His Thr Gly Asn Thr Tyr Tyr Asn Pro Pro Leu  
           50                                  55                                  60  
 Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser  
       65                                  70                                  75                                  80  
 Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys  
                                   85                                  90                                  95  
 Ala Arg Gly Gly Gly Ile Ser Arg Pro Glu Tyr Trp Gly Lys Gly Thr  
                   100                                  105                                  110  
 Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
           115                                  120                                  125  
 Gly Gly Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro Pro  
       130                                  135                                  140  
 Val Ser Val Ala Leu Gly Gln Thr Val Thr Leu Thr Cys Gln Gly Asp  
   145                                  150                                  155                                  160  
 Ser Leu Arg Thr Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Ser Gly Gln  
                   165                                  170                                  175  
 Ala Pro Ile Leu Leu Leu Tyr Gly Lys His Lys Arg Pro Ser Gly Ile  
                   180                                  185                                  190  
 Pro Asp Arg Phe Ser Gly Ser Thr Ser Gly Asp Thr Ala Ser Leu Thr  
       195                                  200                                  205  
 Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser  
       210                                  215                                  220  
 Arg Asp Ser Ser Gly Asn Pro His Val Leu Phe Gly Gly Gly Thr Gln  
   225                                  230                                  235                                  240  
 Leu Thr Val Leu Ser  
                   245

<210> 68  
 <211> 6  
 <212> PRT  
 <213> Homo sapiens

<400> 68  
 Ser Gly Tyr Tyr Trp Gly  
   1                                  5

<210> 69  
 <211> 16  
 <212> PRT  
 <213> Homo sapiens

27/48

&lt;400&gt; 69

Ser Ile Ser His Thr Gly Asn Thr Tyr Tyr Asn Pro Pro Leu Lys Ser  
 1 5 10 15

&lt;210&gt; 70

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 70

Gly Gly Gly Ile Ser Arg Pro Glu Tyr  
 1 5

&lt;210&gt; 71

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 71

Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala Ser  
 1 5 10

&lt;210&gt; 72

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 72

Gly Lys His Lys Arg Pro Ser  
 1 5

&lt;210&gt; 73

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 73

Asn Ser Arg Asp Ser Ser Gly Asn Pro His Val Leu  
 1 5 10

&lt;210&gt; 74

&lt;211&gt; 354

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 74

cagggtgcagc tgcaggagtc gggcccagga ctggtgaaga cttcggagac cctgtccctc 60  
 acctgcgctg tctctgggta ctccatcagc agtgggttact actggggctg gatccggcag 120  
 cccccaggga aggggttgga gtggattggg agtatctctc atactgggaa cacctactac 180  
 aaccgcgcc tcaagagtcg cgtcaccata tcagtagaca cgtccaagaa ccagttctcc 240  
 ctgaaaactga gctctgtgac cgccgcagac acggccgtgt attactgtgc gcgaggtggg 300  
 ggaattagca ggccggagta ctggggcaaa ggcaccctgg tcaccgtctc gagt 354

28/48

<210> 75  
 <211> 330  
 <212> DNA  
 <213> Homo sapiens

<400> 75  
 tcttctgagc tgactcagga ccctcctgtg tctgtggcct tgggacagac agtcacgctc 60  
 acatgccaaag gagacagcct cagaacctat tatgcaagct ggtaccagca gaagtcagga 120  
 caggccccta tactttctcct ctatggtaaa cacaacggc cctcagggat ccagaccgc 180  
 ttctctggct ccacctcagg agacacagct tccttgacca tcaactggggc tcaggcggaa 240  
 gacgaggctg actattactg taactcccg gactccagt gcaaccccca tgttctgttc 300  
 ggcggaggga ccagctcac cgttttaagt 330

<210> 76  
 <211> 735  
 <212> DNA  
 <213> Homo sapiens

<400> 76  
 caggtgcagc tgcaggagtc gggcccagga ctggtgaaga cttcggagac cctgtccctc 60  
 acctgcgctg tctctgggta ctccatcagc agtgggttact actggggctg gatccggcag 120  
 cccccaggga aggggttgga gtggattggg agtatctctc atactgggaa cacctactac 180  
 aaccgcgccc tcaagagtcg cgtcaccata tcagtagaca cgtccaagaa ccagttctcc 240  
 ctgaaactga gctctgtgac cgccgcagac acggccgtgt attactgtgc gcgagggtggg 300  
 ggaattagca ggccggagta ctggggcaaa ggcaccctgg tcaccgtctc gagtggaggc 360  
 ggcggttcag ggcgagggtg ctctggcggt ggcggaagt cactttcttc tgagctgact 420  
 caggaccctc ctgtgtctgt ggccttggga cagacagtca cgctcacatg ccaaggagac 480  
 agcctcagaa cctattatgc aagctggtac cagcagaagt caggacaggc ccctatactt 540  
 ctctctatg gtaaacacaa acggccctca gggatcccag accgcttctc tggtccacc 600  
 tcaggagaca cagcttcctt gaccatcact ggggctcagg cggaagacga ggctgactat 660  
 tactgtaact ccgaggactc cagtggcaac ccccatgttc tggtcggcgg agggaccag 720  
 ctcaccgttt taagt 735

<210> 77  
 <211> 18  
 <212> DNA  
 <213> Homo sapiens

<400> 77  
 agtgggttact actggggc 18

<210> 78  
 <211> 48  
 <212> DNA  
 <213> Homo sapiens

<400> 78  
 agtatctctc atactgggaa cacctactac aaccgcgccc tcaagagt 48

<210> 79  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

29/48

<400> 79  
ggtgggggaa ttagcaggcc ggagtac 27

<210> 80  
<211> 33  
<212> DNA  
<213> Homo sapiens

<400> 80  
caaggagaca gcctcagaac ctattatgca agc 33

<210> 81  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 81  
ggtaaacaca aacggccctc a 21

<210> 82  
<211> 36  
<212> DNA  
<213> Homo sapiens

<400> 82  
aactcccggg actccagtgg caacccccat gttctg 36

<210> 83  
<211> 116  
<212> PRT  
<213> Homo sapiens

<400> 83  
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
1 5 10 15  
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr  
20 25 30  
Ser Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45  
Gly Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe  
50 55 60  
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr  
65 70 75 80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95  
Ala Thr Leu Ala Gly Pro Leu Asp Ser Trp Gly Gln Gly Thr Leu Val  
100 105 110



30/48

Thr Val Ser Ser  
115

<210> 84  
<211> 111  
<212> PRT  
<213> Homo sapiens

<400> 84  
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln  
1 5 10 15  
Thr Val Arg Ile Thr Cys Gln Gly Gly Ser Leu Arg Gln Tyr Tyr Ala  
20 25 30  
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr  
35 40 45  
Gly Lys Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser  
50 55 60  
Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu  
65 70 75 80  
Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asn His  
85 90 95  
Pro Leu Tyr Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu Gly  
100 105 110

<210> 85  
<211> 244  
<212> PRT  
<213> Homo sapiens

<400> 85  
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser  
1 5 10 15  
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asn Ile Tyr  
20 25 30  
Ser Val Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45  
Gly Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe  
50 55 60  
Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr  
65 70 75 80  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

31/48

Ala Thr Leu Ala Gly Pro Leu Asp Ser Trp Gly Gln Gly Thr Leu Val  
                   100                                  105                                  110

Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly  
                   115                                  120                                  125

Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser  
                   130                                  135                                  140

Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Gly Ser Leu  
                   145                                  150                                  155                                  160

Arg Gln Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro  
                                   165                                  170                                  175

Val Leu Val Ile Tyr Gly Lys Asn Lys Arg Pro Ser Gly Ile Pro Asp  
                                   180                                  185                                  190

Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr  
                   195                                  200                                  205

Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp  
                   210                                  215                                  220

Ser Ser Gly Asn His Pro Leu Tyr Val Phe Gly Ala Gly Thr Lys Leu  
                   225                                  230                                  235                                  240

Thr Val Leu Gly

<210> 86  
 <211> 5  
 <212> PRT  
 <213> Homo sapiens

<400> 86  
 Ile Tyr Ser Val Ser  
   1                                  5

<210> 87  
 <211> 17  
 <212> PRT  
 <213> Homo sapiens

<400> 87  
 Arg Ile Ile Pro Met Arg Asp Ile Ala Asn Tyr Ala Gln Arg Phe Gln  
   1                                  5                                  10                                  15

Gly

<210> 88  
 <211> 7  
 <212> PRT  
 <213> Homo sapiens

32/48

&lt;400&gt; 88

Leu Ala Gly Pro Leu Asp Ser  
 1 5

&lt;210&gt; 89

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 89

Gln Gly Gly Ser Leu Arg Gln Tyr Tyr Ala Ser  
 1 5 10

&lt;210&gt; 90

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 90

Gly Lys Asn Lys Arg Pro Ser  
 1 5

&lt;210&gt; 91

&lt;211&gt; 13

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 91

Lys Ser Arg Asp Ser Ser Gly Asn His Pro Leu Tyr Val  
 1 5 10

&lt;210&gt; 92

&lt;211&gt; 348

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 92

caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60  
 tcttgcaagg cttctggagg caccttcaac atctatagtg tcagctgggt gcgacaggcc 120  
 cctggacagg ggcttgagtg gatgggaagg atcatcccta tgcgtgatat tgcaaactac 180  
 gcgcagaggt tccagggcag ggtcacaatt accgcggaca agtccacgag cacagcctac 240  
 atggagttga gcagcctgag atctgaagac acggccgtct attattgtgc gacattggct 300  
 ggcccccttg actcctgggg ccagggcacc ctggtcaccg tctcgagt 348

&lt;210&gt; 93

&lt;211&gt; 333

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 93

tcttctgagc tgactcagga cccagctgtg tctgtggcct tgggacagac agtcaggatc 60  
 acatgtcaag gcggcagcct cagacaatat tatgcaagtt ggtaccaaca gaagccagga 120  
 caggccccctg tgcttgatcat ctatggtaaa aataagcgac cctcagggat cccagaccga 180

33/48

```

ttctctggct cctcctcagg caacacagct tccttgacca tcaactggggc tcaggcggaa 240
gatgaggctg actactattg taagtcccgg gacagcagtg gtaaccatcc cctttatgtc 300
ttcggagctg ggaccaagct gaccgtccta ggt                                     333

```

<210> 94  
 <211> 732  
 <212> DNA  
 <213> Homo sapiens

```

<400> 94
caggtgcagc tgggtgcagtc tggggctgag gtgaagaagc ctgggtcctc ggtgaaggtc 60
tcctgcaagg cttctggagg caccttcaac atctatagtg tcagctgggt gcgacaggcc 120
cctggacagg ggcttgagtg gatgggaagg atcatcccta tgcgtgatat tgcaaaactac 180
gcgcagaggt tccagggcag ggtcacaatt accgcggaca agtccacgag cacagcctac 240
atggagttga gcagcctgag atctgaagac acggccgtct attattgtgc gacattggct 300
ggcccccttg actcctgggg ccagggcacc ctggtcaccg tctcgagtgg aggcggcggc 360
tcaggcggag gtggctctgg cgggtggcggg agtgcacttt cttctgagct gactcaggac 420
ccagctgtgt ctgtggcctt gggacagaca gtcaggatca catgtcaagg cggcagcctc 480
agacaatatt atgcaagttg gtaccaacag aagccaggac aggccctgt gcttgtcatc 540
tatggtaaaa ataagcgacc ctacagggatc ccagaccgat tctctggctc ctctcaggc 600
aacacagctt ccttgaccat cactggggct caggcggaag atgaggctga ctactattgt 660
aagtcccggg acagcagtggt taaccatccc ctttatgtct tcggagctgg gaccaagctg 720
accgtcctag gt                                     732

```

<210> 95  
 <211> 15  
 <212> DNA  
 <213> Homo sapiens

```

<400> 95
atctatagtg tcage                                     15

```

<210> 96  
 <211> 51  
 <212> DNA  
 <213> Homo sapiens

```

<400> 96
aggatcatcc ctatgcgtga tattgcaaac tacgcgcaga ggttccaggg c          51

```

<210> 97  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens

```

<400> 97
ttggctggcc ccttggaactc c                                     21

```

<210> 98  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

34/48

<400> 98  
caaggcggca gcctcagaca atattatgca agt 33

<210> 99  
<211> 21  
<212> DNA  
<213> Homo sapiens

<400> 99  
ggtaaaaata agcgaccctc a 21

<210> 100  
<211> 39  
<212> DNA  
<213> Homo sapiens

<400> 100  
aagtcgggg acagcagtg taaccatccc ctttatgtc 39

<210> 101  
<211> 120  
<212> PRT  
<213> Homo sapiens

<400> 101  
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15  
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asp Asn  
20 25 30  
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45  
Gly Trp Ile Asn Pro Lys Thr Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
50 55 60  
Gln Gly Arg Val Ser Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr  
65 70 75 80  
Met Asp Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
85 90 95  
Thr Arg Ser Leu Ser Pro Tyr Gly Gly Gln Leu Leu Tyr Trp Gly Arg  
100 105 110  
Gly Thr Met Val Thr Val Ser Ser  
115 120

<210> 102  
<211> 110  
<212> PRT  
<213> Homo sapiens

35/48

&lt;400&gt; 102

```

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
 1           5           10           15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Arg Tyr Tyr Ala
          20           25           30
Ser Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Phe
          35           40           45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Ala Ser
          50           55           60
Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
          65           70           75           80
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Thr Ser Ile Asn His
          85           90           95
Pro Val Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
          100           105           110

```

&lt;210&gt; 103

&lt;211&gt; 247

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 103

```

Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1           5           10           15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asp Asn
          20           25           30
Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
          35           40           45
Gly Trp Ile Asn Pro Lys Thr Gly Gly Thr Asn Tyr Ala Gln Lys Phe
          50           55           60
Gln Gly Arg Val Ser Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr
          65           70           75           80
Met Asp Leu Ser Arg Leu Thr Ser Asp Asp Thr Ala Val Tyr Tyr Cys
          85           90           95
Thr Arg Ser Leu Ser Pro Tyr Gly Gly Gln Leu Leu Tyr Trp Gly Arg
          100           105           110
Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
          115           120           125
Gly Ser Gly Gly Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp
          130           135           140
Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln
          145           150           155           160

```

Gly	Asp	Ser	Leu	Arg 165	Arg	Tyr	Tyr	Ala	Ser 170	Trp	Phe	Gln	Gln	Lys 175	Pro
Gly	Gln	Ala	Pro 180	Val	Leu	Val	Ile	Phe 185	Gly	Lys	Asn	Asn	Arg 190	Pro	Ser
Gly	Ile	Pro 195	Asp	Arg	Phe	Ser	Ala 200	Ser	Ser	Ser	Gly	Asn 205	Thr	Ala	Ser
Leu	Thr 210	Ile	Thr	Gly	Ala	Gln 215	Ala	Glu	Asp	Glu	Ala 220	Asp	Tyr	Tyr	Cys
Asn 225	Ser	Arg	Asp	Thr	Ser 230	Ile	Asn	His	Pro	Val 235	Ile	Phe	Gly	Gly	Gly 240
Thr	Lys	Leu	Thr	Val 245	Leu	Gly									

<400> 104  
Asp Asn Tyr Ile His  
1 5

```
<400> 105
Trp Ile Asn Pro Lys Thr Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln
   1                   5               10                  15
```

```
<210> 106
<211> 11
<212> PRT
<213> Homo sapiens
```

```
<210> 107
<211> 11
<212> PRT
<213> Homo sapiens
```

38/48

<400> 112  
 gaggtccagc tgggtgcagtc tggagctgag gtgaagaagc ctgggggcctc agtgaaggtc 60  
 tcctgtaagg cttccggata cgccttcacc gacaactata tacactgggt gcgacaggcc 120  
 cctggacaag ggcttgaatg gatgggatgg atcaacccta agactgggtg cacaactat 180  
 gcacaaaagt ttcagggcag ggtcagcatg accagggaca cgtccatcaa cacagcctac 240  
 atggacctaa gtaggctgac atctgacgac acggccgtct attactgtac gagaagcctt 300  
 tccccatatg gtggccaact cctctactgg ggccggggga caatgggtcac cgtctcgagt 360  
 ggaggcggcg gttcaggcgg aggtggctct ggccgtggcg gaagtgcact ttctctgag 420  
 ctgactcagg accctgctgt gtctgtggcc ttggggacaga cagtcaggat cacatgcaa 480  
 ggagacagcc tcagaagata ttatgcaagc tggttccagc agaagccagg acaggccct 540  
 gtacttgtca tctttggtaa aaacaaccgg ccctcaggga tcccagaccg attctctgcc 600  
 tccagttcag gaaacacagc ttccttgacc atcactgggg ctcaggcgga agatgaggct 660  
 gactattact gtaactcccg ggacaccagt attaaccatc ccgtgatatt cggcgggggg 720  
 accaagctga ccgtcctagg t 741

<210> 113  
 <211> 15  
 <212> DNA  
 <213> Homo sapiens

<400> 113  
 gacaactata tacac 15

<210> 114  
 <211> 54  
 <212> DNA  
 <213> Homo sapiens

<400> 114  
 tggatcaac ctaagactgg tggcacaaac tatgcacaaa agtttcaggg cagg 54

<210> 115  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

<400> 115  
 agcctttccc catatgggtgg ccaactcctc tac 33

<210> 116  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

<400> 116  
 caaggagaca gcctcagaag atattatgca agc 33

<210> 117  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens



37/48

&lt;400&gt; 107

Gln Gly Asp Ser Leu Arg Arg Tyr Tyr Ala Ser  
 1 5 10

&lt;210&gt; 108

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 108

Gly Lys Asn Asn Arg Pro Ser  
 1 5

&lt;210&gt; 109

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 109

Asn Ser Arg Asp Thr Ser Ile Asn His Pro Val Ile  
 1 5 10

&lt;210&gt; 110

&lt;211&gt; 360

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 110

gaggtccagc tgggtgcagtc tggagctgag gtgaagaagc ctgggggcctc agtgaaggctc 60  
 tctgtgaagg ctcccgata cgccttcacc gacaactata tacactgggt gcgacaggcc 120  
 cctggacaag ggcttgaatg gatgggatgg atcaacccta agactgggtg cacaaactat 180  
 gcacaaaagt ttcagggcag ggctcagcatg accaggggaca cgtccatcaa cacagcctac 240  
 atggacctaa gtaggctgac atctgacgac acggccgtct attactgtac gagaagcctt 300  
 tccccatatg gtggccaact cctctactgg ggccggggga caatgggtcac cgtctcgagt 360

&lt;210&gt; 111

&lt;211&gt; 330

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 111

tcttctgagc tgactcagga ccctgctgtg tctgtggcct tgggacagac agtcaggatc 60  
 acatgccaaag gagacagcct cagaagatat tatgcaagct gggtccagca gaagccagga 120  
 caggcccctg tacttgtcat ctttggtaaa aacaaccggc cctcagggat ccagaccga 180  
 ttctctgcct ccagttcagg aaacacagct tctttgacca tcaactggggc tcaggcggaa 240  
 gatgaggctg actattactg taactcccgg gacaccagta ttaaccatcc cgtgatattc 300  
 ggcgggggga ccaagctgac cgtcctaggt 330

&lt;210&gt; 112

&lt;211&gt; 741

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

39/48

<400> 117  
 ggtaaaaaca accggcctc a 21

<210> 118  
 <211> 36  
 <212> DNA  
 <213> Homo sapiens

<400> 118  
 aactcccgga acaccagtat taaccatccc gtgata 36

<210> 119  
 <211> 118  
 <212> PRT  
 <213> Homo sapiens

<400> 119  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Gly Gly Trp Lys Leu Pro Phe Phe Ala Tyr Trp Gly Arg Gly Thr  
 100 105 110  
 Leu Val Thr Val Ser Ser  
 115

<210> 120  
 <211> 110  
 <212> PRT  
 <213> Homo sapiens

<400> 120  
 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln  
 1 5 10 15  
 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Phe Tyr Ala  
 20 25 30  
 Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Ile Leu Val Ile Tyr  
 35 40 45

40/48

Gly Lys Ser Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser  
 50 55 60

Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu  
 65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser Arg Asp Arg Ser Gly Asn His  
 85 90 95

Leu Gly Met Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
 100 105 110

<210> 121  
 <211> 245  
 <212> PRT  
 <213> Homo sapiens

<400> 121  
 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

Ala Gly Gly Trp Lys Leu Pro Phe Phe Ala Tyr Trp Gly Arg Gly Thr  
 100 105 110

Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser  
 115 120 125

Gly Gly Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro Ala  
 130 135 140

Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp  
 145 150 155 160

Ser Leu Arg Thr Phe Tyr Ala Asn Trp Tyr Gln Gln Lys Pro Gly Gln  
 165 170 175

Ala Pro Ile Leu Val Ile Tyr Gly Lys Ser Asn Arg Pro Ser Gly Ile  
 180 185 190

Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr  
 195 200 205

41/48

Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Tyr Ser  
210 215 220

Arg Asp Arg Ser Gly Asn His Leu Gly Met Phe Gly Gly Gly Thr Lys  
225 230 235 240

Leu Thr Val Leu Gly  
245

&lt;210&gt; 122

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 122

Ser Tyr Ala Met Ser  
1 5

&lt;210&gt; 123

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 123

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

&lt;210&gt; 124

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 124

Gly Trp Lys Leu Pro Phe Phe Ala Tyr  
1 5

&lt;210&gt; 125

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 125

Gln Gly Asp Ser Leu Arg Thr Phe Tyr Ala Asn  
1 5 10

&lt;210&gt; 126

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

42/48

&lt;400&gt; 126

Gly Lys Ser Asn Arg Pro Ser  
 1 5

&lt;210&gt; 127

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 127

Tyr Ser Arg Asp Arg Ser Gly Asn His Leu Gly Met  
 1 5 10

&lt;210&gt; 128

&lt;211&gt; 354

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 128

gaggtgcagc	tgttggagtc	tgggggaggc	ttggtacagc	ctgggggggtc	cctgagactc	60
tcctgtgcag	cctctggatt	cacctttagc	agctatgcca	tgagctgggt	ccgccaggct	120
ccaggggaagg	ggctggagtg	ggtctcagct	attagtggta	gtgggtggtag	cacatactac	180
gcagactccg	tgaagggccg	gttcaccatc	tccagagaca	attccaagaa	cacgctgtat	240
ctgcaaatga	acagcctgag	agccgaggac	acggccgtgt	attactgtgc	gggggggtgg	300
aaacttccat	tttttgccta	ctgggggccg	ggcaccctgg	tcaccgtctc	gagt	354

&lt;210&gt; 129

&lt;211&gt; 330

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 129

tcttctgagc	tgactcagga	ccctgctgtg	tctgtggcct	tgggacagac	agtcaggatc	60
acatgccaaag	gagacagcct	cagaaccttt	tatgcaaact	ggtaccagca	gaagccagga	120
caggcccccta	tacttgtcat	ctatggtaaa	agcaaccgtc	cctcagggat	cccagaccga	180
ttctctgggt	ccagctcagg	aaacacagct	tccttgacca	tcactggggc	tcaggcggaa	240
gatgaggctg	actattactg	ttactcccgg	gacagaagtg	gtaaccatct	agggatgttc	300
ggcggaggga	ccaagctgac	cgtcctagg				330

&lt;210&gt; 130

&lt;211&gt; 735

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

gaggtgcagc	tgttggagtc	tgggggaggc	ttggtacagc	ctgggggggtc	cctgagactc	60
tcctgtgcag	cctctggatt	cacctttagc	agctatgcca	tgagctgggt	ccgccaggct	120
ccaggggaagg	ggctggagtg	ggtctcagct	attagtggta	gtgggtggtag	cacatactac	180
gcagactccg	tgaagggccg	gttcaccatc	tccagagaca	attccaagaa	caogctgtat	240
ctgcaaatga	acagcctgag	agccgaggac	acggccgtgt	attactgtgc	gggggggtgg	300
aaacttccat	tttttgccta	ctgggggccg	ggcaccctgg	tcaccgtctc	gagtggaggc	360
ggcgggttcag	gaggaggtgg	ctctggcggt	ggcggaaagt	cactttcttc	tgagctgact	420
caggaccctg	ctgtgtctgt	ggccttggga	cagacagtca	ggatcacatg	ccaaggagac	480
agcctcagaa	ccttttatgc	aaactggtac	cagcagaagc	caggacaggc	ccctatactt	540

43/48

gtcatctatg gtaaaagcaa ccgtccctca gggatcccag accgattctc tggctccagc 600  
 tcaggaaaca cagcttcctt gaccatcact ggggctcagg cggaagatga ggctgactat 660  
 tactgttact cccgggacag aagtggtaac catctaggga tggtcggcgg agggaccaag 720  
 ctgaccgtcc taggt 735

<210> 131  
 <211> 15  
 <212> DNA  
 <213> Homo sapiens

<400> 131  
 agctatgcca tgagc 15

<210> 132  
 <211> 54  
 <212> DNA  
 <213> Homo sapiens

<400> 132  
 gctattagtg gtagtggtgg tagcacatac tacgcagact ccgtgaaggg ccgg 54

<210> 133  
 <211> 27  
 <212> DNA  
 <213> Homo sapiens

<400> 133  
 ggggtggaaac ttccattttt tgccctac 27

<210> 134  
 <211> 33  
 <212> DNA  
 <213> Homo sapiens

<400> 134  
 caaggagaca gcctcagaac cttttatgca aac 33

<210> 135  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens

<400> 135  
 ggtaaaagca accgtccctc a 21

<210> 136  
 <211> 36  
 <212> DNA  
 <213> Homo sapiens

<400> 136  
 tactcccggg acagaagtgg taaccatcta gggatg 36

44/48

<210> 137  
 <211> 121  
 <212> PRT  
 <213> Homo sapiens

<400> 137

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
 1 5 10 15  
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
 20 25 30  
 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
 35 40 45  
 Ser Gly Ile Ser Gly Ser Gly Thr Ser Thr Tyr Tyr Ala Asp Ser Val  
 50 55 60  
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
 65 70 75 80  
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Thr His Ile Ser Glu Arg Pro Arg Gly Ala Phe Asp Ile Trp Gly  
 100 105 110  
 Arg Gly Thr Met Val Thr Val Ser Ser  
 115 120

<210> 138  
 <211> 109  
 <212> PRT  
 <213> Homo sapiens

<400> 138

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln  
 1 5 10 15  
 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Lys Tyr His Ala  
 20 25 30  
 Thr Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Val Tyr  
 35 40 45  
 Gly Lys Asn Arg Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser  
 50 55 60  
 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Gly  
 65 70 75 80  
 Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Thr Ser Gly Leu His  
 85 90 95

45/48

Tyr Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu Gly  
                   100                                  105

&lt;210&gt; 139

&lt;211&gt; 247

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 139

Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
       1                                  5                                  10                                  15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr  
                   20                                  25                                  30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val  
                   35                                  40                                  45

Ser Gly Ile Ser Gly Ser Gly Thr Ser Thr Tyr Tyr Ala Asp Ser Val  
       50                                  55                                  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr  
       65                                  70                                  75                                  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys  
                   85                                  90                                  95

Ala Thr His Ile Ser Glu Arg Pro Arg Gly Ala Phe Asp Ile Trp Gly  
                   100                                  105                                  110

Arg Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly  
                   115                                  120                                  125

Gly Gly Ser Gly Gly Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln  
       130                                  135                                  140

Asp Pro Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys  
       145                                  150                                  155                                  160

Gln Gly Asp Ser Leu Arg Lys Tyr His Ala Thr Trp Tyr Gln Gln Lys  
                   165                                  170                                  175

Pro Arg Gln Ala Pro Val Leu Val Val Tyr Gly Lys Asn Arg Arg Pro  
                   180                                  185                                  190

Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala  
       195                                  200                                  205

Ser Leu Thr Ile Thr Gly Ala Gln Ala Gly Asp Glu Ala Asp Tyr Tyr  
       210                                  215                                  220

Cys Asn Ser Arg Asp Thr Ser Gly Leu His Tyr Val Phe Gly Ala Gly  
       225                                  230                                  235                                  240

Thr Lys Leu Thr Val Leu Gly  
                   245



46/48

<210> 140  
<211> 5  
<212> PRT  
<213> Homo sapiens

<400> 140  
Ser Tyr Ala Met Ser  
1 5

<210> 141  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 141  
Gly Ile Ser Gly Ser Gly Thr Ser Thr Tyr Tyr Ala Asp Ser Val Lys  
1 5 10 15

Gly

<210> 142  
<211> 12  
<212> PRT  
<213> Homo sapiens

<400> 142  
His Ile Ser Glu Arg Pro Arg Gly Ala Phe Asp Ile  
1 5 10

<210> 143  
<211> 11  
<212> PRT  
<213> Homo sapiens

<400> 143  
Gln Gly Asp Ser Leu Arg Lys Tyr His Ala Thr  
1 5 10

<210> 144  
<211> 7  
<212> PRT  
<213> Homo sapiens

<400> 144  
Gly Lys Asn Arg Arg Pro Ser  
1 5

<210> 145  
<211> 11  
<212> PRT  
<213> Homo sapiens

47/48

&lt;400&gt; 145

Asn Ser Arg Asp Thr Ser Gly Leu His Tyr Val  
 1 5 10

&lt;210&gt; 146

&lt;211&gt; 363

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 146

```

caggtgcagc tgcaggagtc ggggggaggc ttggtacagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagc agctatgcc a tgagctgggt ccgccaggct 120
ccagggaagg ggctggagt ggtctcagg attagtggta gtggtactag cacatactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaagac acggccgtat attactgtgc gacacatatc 300
tcggaacgtc cacgtggtgc ttttgatatc tggggccggg ggacaatggt caccgtctcg 360
agt

```

&lt;210&gt; 147

&lt;211&gt; 327

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 147

```

tcttctgagc tgactcagga ccctgctgtg tctgtggccc tgggacagac agtcaggatc 60
acatgccaaag gagacagcct cagaaagtat catgcaactt ggtaccagca gaagccaagg 120
caggcccttg tacttgtcgt ctatggtaaa aacaggcgcc cctcagggat ccccgaccga 180
ttctctggct ccagctcagg aaacacagct tccctgacca tcaactggggc tcaggcggga 240
gatgaggctg actattactg taactcccgg gacaccagtg gtcttcatta tgtcttcgga 300
gctgggacca agctgaccgt cctaggt

```

&lt;210&gt; 148

&lt;211&gt; 741

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 148

```

caggtgcagc tgcaggagtc ggggggaggc ttggtacagc ctgggggggtc cctgagactc 60
tcctgtgcag cctctggatt cacctttagc agctatgcc a tgagctgggt ccgccaggct 120
ccagggaagg ggctggagt ggtctcagg attagtggta gtggtactag cacatactac 180
gcagactccg tgaagggccg gttcaccatc tccagagaca attccaagaa cacgctgtat 240
ctgcaaatga acagcctgag agccgaagac acggccgtat attactgtgc gacacatatc 300
tcggaacgtc cacgtggtgc ttttgatatc tggggccggg ggacaatggt caccgtctcg 360
agtggaggcg gcggttcagg cgaggggtgg tctggcggtg gcggaagtgc actttcttct 420
gagctgactc aggaccctgc tgtgtctgtg gccctgggac agacagtcag gatcacatgc 480
caaggagaca gcctcagaaa gtatcatgca acttggtacc agcagaagcc aaggcaggcc 540
cctgtacttg tcgtctatgg taaaaacagg cgccctcag ggatccccga ccgattctct 600
ggctccagct caggaaacac agcttccctg accatcactg gggctcaggc gggagatgag 660
gctgactatt actgtaactc ccgggacacc agtgggtcttc attatgtctt cggagctggg 720
accaagctga ccgtcctagg t

```

&lt;210&gt; 149

&lt;211&gt; 15

&lt;212&gt; DNA

48/48

&lt;213&gt; Homo sapiens

&lt;400&gt; 149

agctatgccca tgagc

15

&lt;210&gt; 150

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 150

ggattatgtg gtagtggtac tagcacatac tacgcagact ccgtgaaggg c

51

&lt;210&gt; 151

&lt;211&gt; 36

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

catatctcgg aacgtccacg tgggtgctttt gatatc

36

&lt;210&gt; 152

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 152

caaggagaca gcctcagaaa gtatcatgca act

33

&lt;210&gt; 153

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

ggtaaaaaca ggcgcccctc a

21

&lt;210&gt; 154

&lt;211&gt; 33

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

aactcccggg acaccagtgg tcttcattat gtc

33

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number  
**WO 2004/083249 A3**

- (51) International Patent Classification<sup>7</sup>: **C07K 16/28**,  
A61K 39/395, A61P 37/00, 37/06
- (21) International Application Number:  
PCT/US2004/007444
- (22) International Filing Date: 12 March 2004 (12.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/454,336 14 March 2003 (14.03.2003) US
- (71) Applicants (*for all designated States except US*): **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US). **CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED** [GB/GB]; The Milstein Building, Granta Park, Cambridge CB1 6GH (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **YOUNG, Deborah, A.** [US/US]; 39 Nelson Road, Melrose, MA 02176 (US). **WHITTERS, Matthew, J.** [US/US]; 14 Brenton Wood Road, Hudson, MA 01749 (US). **VALGE-ARCHER, Viia** [US/GB]; 36 Westfield, Little Abington, Cambridge CB1 6BE (GB). **COLLINS, Mary** [US/US]; 54 Rathburn Road, Natick, MA 01760 (US). **WILLIAMS, Andrew, James** [GB/GB]; Larksmead, Long Lane, Fowlmere, Royston, Herts, SG8 7TG (GB). **WITEK, Joanne** [US/US]; 409 Arlington Street, Acton, MA 01720 (US).
- (74) Agent: **GARRETT, Arthur, S.**; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *with international search report*  
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- (88) Date of publication of the international search report:  
9 December 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTIBODIES AGAINST HUMAN IL-21 RECEPTOR AND USES THEREFOR

(57) Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21 R). The antibodies can act as antagonists of IL-21 R activity, thereby modulating immune responses in general, and those mediated by IL-21 R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.



WO 2004/083249 A3

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/007444

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/28 A61K39/395 A61P37/00 A61P37/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ, Sequence Search

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 01/77171 A (ZYMOGENETICS INC) 18 October 2001 (2001-10-18)</p> <p>page 59, line 10 - line 18 page 68, line 22 - page 75, line 24 page 142, line 20 - page 144, line 14 example 10 example 24</p> <p style="text-align: center;">----- -/--</p>	<p>1-9, 11-13, 15-19, 22-38</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

10 September 2004

Date of mailing of the international search report

27/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Irion, A

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/007444

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 2002/128446 A1 (NOVAK JULIA E ET AL) 12 September 2002 (2002-09-12)</p> <p>paragraph '0436! - paragraph '0438! paragraph '0565! - paragraph '0566! paragraph '0567! - paragraph '0569! example 35 example 47</p> <p>-----</p>	<p>1-9, 11-13, 15-19, 23, 38</p>
A	<p>WO 01/85792 A (DONALDSON DEBRA D ; GENETICS INST (US); LOWE LESLIE (US); COLLINS MARY) 15 November 2001 (2001-11-15) the whole document page 21, line 27 - line 31 page 31, line 9 - line 23</p> <p>-----</p>	<p>1-38</p>
P,X	<p>WO 03/028630 A (DONALDSON DEBRA D ; LOWE LESLIE D (US); WITEK JOANN S (US); CARTER LAU) 10 April 2003 (2003-04-10) page 3, line 17 - line 29 example 7</p> <p>-----</p>	<p>1-38</p>
P,X	<p>US 2003/148447 A1 (CONKLIN DARRELL C ET AL) 7 August 2003 (2003-08-07) paragraph '0019! - paragraph '0020! paragraph '0091! paragraph '0156! - paragraph '0166! paragraph '0251! paragraph '0286! - paragraph '0287!</p> <p>-----</p>	<p>1-38</p>
P,A	<p>COLLINS MARY ET AL: "IL-21 and IL-21 receptor: A new cytokine pathway modulates innate and adaptive immunity." IMMUNOLOGIC RESEARCH, vol. 28, no. 2, 2003, pages 131-140, XP009036147 ISSN: 0257-277X the whole document</p> <p>-----</p>	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2004/007444

## Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. type of material
- ☒ a sequence listing
- ☐ table(s) related to the sequence listing
- b. format of material
- ☒ in written format
- ☒ in computer readable form
- c. time of filing/furnishing
- ☒ contained in the international application as filed
- ☒ filed together with the international application in computer readable form
- ☐ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/007444

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 25-37  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 25-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/007444

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0177171	A	18-10-2001	AU 5312701 A	23-10-2001
			CA 2420992 A1	18-10-2001
			EP 1303602 A2	23-04-2003
			WO 0177171 A2	18-10-2001
			US 2002137677 A1	26-09-2002
<hr/>				
US 2002128446	A1	12-09-2002	US 6307024 B1	23-10-2001
			US 2003125524 A1	03-07-2003
			US 2004110932 A1	10-06-2004
			AU 3731200 A	28-09-2000
			BR 0008772 A	07-05-2002
			CA 2366921 A1	14-09-2000
			CN 1378595 T	06-11-2002
			CZ 20013184 A3	17-04-2002
			EP 1165791 A2	02-01-2002
			HU 0200418 A2	29-05-2002
			JP 2002537839 A	12-11-2002
			NO 20014364 A	09-11-2001
			PL 351160 A1	24-03-2003
			WO 0053761 A2	14-09-2000
<hr/>				
WO 0185792	A	15-11-2001	AU 6308801 A	20-11-2001
			EP 1353953 A2	22-10-2003
			JP 2004500845 T	15-01-2004
			WO 0185792 A2	15-11-2001
			US 2003108549 A1	12-06-2003
			US 2003049798 A1	13-03-2003
<hr/>				
WO 03028630	A	10-04-2003	US 2003049798 A1	13-03-2003
			CA 2460916 A1	10-04-2003
			EP 1432431 A2	30-06-2004
			WO 03028630 A2	10-04-2003
			US 2003108549 A1	12-06-2003
			US 2004016010 A1	22-01-2004
<hr/>				
US 2003148447	A1	07-08-2003	NONE	